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11. Introduction 
The release of the human genome sequence with high accuracy and nearly complete 
coverage in 2004 (Human Genome Sequencing 2004) represented a milestone in 
genome research and launched the entry into the “post-genome era” (Davies and 
Wynshaw-Boris 2009). Nevertheless, the transfer of the genomic sequence into any 
information about the function of the corresponding genes, their allelic variations and 
the metabolic pathways involved, requires functional genome research using animal 
models. Applying forward and reverse genetics, a plenitude of murine disease 
models has already been generated and examined, providing the opportunity to 
elucidate the structure and function of genomes and the transformation of genome-
based knowledge into clinical research application (Collins et al. 2003a; Desaintes 
2008) (http://www.informatics.jax.org/). 
Major research efforts focussed on the investigation of important human diseases 
like diabetes mellitus (Collins et al. 2003b). The alarming dimensions of worldwide 
diabetes prevalence, the estimated increment of diabetic patients within the next 20 
years (Wild et al. 2004), the accompanying public health and economic burden, and 
the absence of translational strategies to combat this “epidemic disease” have 
triggered the interest in diabetes research (Garfield et al. 2003; Gary and Brancati 
2004). Since the pathogenesis of diabetes mellitus is not completely understood, 
experimental animal models represent a suitable tool to elucidate the genetic and 
pathogenic aspects of this disease. The power of ENU- (N-ethyl-N-nitrosourea) 
based random mutagenesis to generate mutant mouse models that recapitulate 
human disease phenotypes like diabetes mellitus has already been reported (Aigner 
et al. 2008). Integrated into the framework of the superordinated cluster “diabetes 
models” of the research training group “Functional Genome Research in Veterinary 
Medicine” supported by the DFG (Deutsche Forschungsgemeinschaft), the aim of the 
present study was the genetic, clinical and pathomorphological investigation of two 
novel diabetic mouse strains derived from the Munich ENU mouse mutagenesis 
project. 
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2. Literature review 
2.1 Genetically modified mice in biomedical research 
Due to ethical and technical limitations in human experimental research, animal 
models represent essential tools in biomedical research (Macchiarini et al. 2005; 
Moore 1999). Genetic predisposition and familiar heritability enact an important part 
in the pathogenesis of the most common human diseases, including e.g. obesity, 
cardiovascular diseases as well as diabetes mellitus. Therefore, genetically modified 
model systems have taken on great significance to contribute to basic biological 
research and its application in human medicine (Moore 1999; Spradling et al. 2006). 
However, in the majority of cases, the mouse, for a plethora of reasons, is still 
considered as the model organism of choice for the investigation of developmental 
and disease processes in the mammalian organism (Cox and Brown 2003; 
Rosenthal and Brown 2007). 
2.1.1 The murine model system 
2.1.1.1 Biological parameters 
From practical and biological viewpoints, the laboratory mouse represents a powerful 
model. Mice are small mammals and many metabolic pathways are analogues to 
those in human beings. Therefore, mutant mouse phenotypes often recapitulate 
human disease phenotypes (Bedell et al. 1997; Woychik et al. 1998). The short 
generation time of about 10 weeks, the high number of offspring, and the possibility 
to maintain mice under standardised conditions represent key features that 
emphasise the potential of the mouse as an ideal model system (Silver 1995). 
Additionally, with the advanced breeding technologies, including assisted 
reproductive technologies like intracytoplasmic sperm injection (ICSI) or in vitro 
fertilisation (IVF), the successful establishment of protocols for surgical 
manipulations, and the adaption and de novo development of clinical assay 
technologies, the laboratory mouse became a favoured disease model (Nagy et al. 
2003; Rossant and McKerlie 2001). 
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2.1.1.2 Genetic features 
During the last 100 years, a high number of genetically defined inbred mouse strains, 
relevant for human biology and disease have been established (Beck et al. 2000; 
Paigen 2003). With the recent release of the nearly complete mouse genome 
sequence, comparative analysis of the human and the murine genome revealed 
remarkable similarities between both species. Ninety-nine percent of the murine 
genes possess homologues in the human genome and 96% of them are located 
within a similar conserved syntenic interval. Additionally, 40% of the mouse genome 
can be aligned confidentially to the human genome and 80% of the proteins, 
identified in the mouse have strict orthologues in human beings (Mouse Genome 
Sequencing 2009). Functional genome analysis of aberrant phenotypes comprises 
two complementary approaches: forward and reverse genetics (Brown et al. 2006; 
Nguyen and Xu 2008; Rosenthal and Brown 2007). The gene-driven approach 
involves the direct genetic manipulation of specific genes to control gene activity 
temporally, spatially, and reversibly by using reverse genetics techniques. The most 
common genetic manipulations in reverse genetics imply additive gene transfer, gene 
targeting by homologous recombination, and gene trapping. The phenotype-driven 
approach, based on forward genetics techniques starts with the observation of an 
abnormal phenotype as a result of spontaneous or induced genetic alterations and 
aims to proceed towards the identification and molecular understanding of the 
underlying genetic aberrations (Argmann et al. 2006; Russ et al. 2002). 
2.1.2 Random mutagenesis in mice 
Different approaches have been established for random mutagenesis in mice: 
Table 2.1: Comparison of random mutagenesis strategies (adapted from Hrabé de 
Angelis et al.  2007 and Stanford et al.  2001). 
Mutagenesis strategy  Mutation frequency Type of mutation induced 
Spontaneous 5 x 10-6 per locus Point mutations, small deletions, chromosomal rearrangements 
X-rays 13-50 x 10-5 per locus Chromosomal rearrangements 
Chemical mutagens 11-150 x 10
-5 per 
locusa 
Chromosomal rearrangements, point 
mutations, translocations, small deletionsa 
Insertional 
mutagenesis 
5-100 % of all 
transgenic animalsa 
Insertions, deletions, disruption of 
endogenous gene expression or coding 
sequencea 
a Depending on the respective agent/strategy that is applied 
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With the description of the alkylating effect of some chemical mutagens and the 
discovery of the high mutagenic potential of nitroso-compounds (a category of 
alkylating agents), this group of chemical mutagens has reached predominant 
importance until today (van Harten 1998). According to the sensitivity of the targeted 
germ cell stage, alkylating agents can be divided into agents that affect: 
• stem cell spermatogenesis and induce predominantly intragenic lesions (small 
deletions, base pair substitutions) like Procarbazine, Triethylenemelamine, N-
ethyl-N-nitrosourea, and Methylnitrosourea, agents that affect 
• early spermatids, like Chlorambucil and Melphalan, and agents that affect 
• late spermatids or spermatozoa and predominantly cause large lesions 
(chromosome aberrations, deletions) such as Ethylmethanesulfate, 
Methylethanesulfate, Cyclophosphamide, and Diethylsulfate (Hrabé de Angelis et 
al. 2007). 
 
2.2 N-ethyl-N-nitrosourea (ENU)-induced mutagenesis 
Alkylating agents can also be differentiated into mono- (including N-ethyl-N-
nitrosourea), bi-, or poly-functional alkylating agents. Monofunctional agents are most 
suitable because they act at a higher concentration level than polyfunctional agents 
before cell death arises and are therefore less cytotoxic. Furthermore, 
monofunctional agents induce higher mutation rates and are reported to induce a 
higher proportion of point mutations than polyfunctional alkylating agents (Sanderson 
and Shield 1996; van Harten 1998). In 1979, N-ethyl-N-nitrosourea (ENU) was 
discovered to be the most potent chemical mutagen in the mouse that has been 
investigated so far (Russell et al. 1979). Since that time, ENU has emerged as the 
most favourable alkylating agent for application in chemical mutagenesis and has 
been used in many different laboratories and mutagenesis experiments as an in vivo 
germline mutagen (Balling et al. 1998; O'Brien and Frankel 2004; Smits et al. 2008). 
2.2.1 Biochemical features of ENU 
ENU is a monofunctional alkylating agent (Fig. 2.1A) that needs no metabolic 
processing for its activation. ENU acts by transferring its ethyl group to oxygen or 
nitrogen residues at various reactive nucleophilic sites of the DNA. Mispairing of the 
DNA double strand and, finally base pair substitution, or base-pair loss represent the 
consequences from ENU-mediated DNA alkylation (Guenet 2004; Hrabé de Angelis 
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et al. 2004; Shibuya and Morimoto 1993) (Fig. 2.1B, C). Further, a dose-dependent 
linear relationship between the administered ENU dose and the resulting mutation 
rate has been reported (Favor et al. 1997; Favor et al. 1990).  
  
Reactive sites that are susceptible 
for alkylation 
Base Reactive sites 
Adenine N1-, N3-, N7- 
Guanine O6-, N3-, N7- 
Thymine O2-, O4-, N3- 
Cytosine O2-, N3- 
  
 
Figure 2.1: Biochemical structure of ENU (A), reactive sites that are susceptible for 
ENU induced alkylation (B), and example of ENU-induced base pair substitutions (C, 
D). Alkylation of thymine results in formation of O4-Ethylthymine (C) which is, by mistake, 
recognised as cytosine, leading to the corresponding base exchange during replication 
Modified according to Hrabé de Angelis et al. 2004 and Noveroske et al. 2000. 
 
ENU predominantly induces point mutations, thereby leading to allelic series for 
functional gene analysis (Schimenti and Bucan 1998; Stanford et al. 2001). A/T→T/A 
transversions (27-30%) and A/T→G/C transitions (30-37%) represent the most 
common ENU-induced modifications. If a coding sequence is affected, missense 
mutations are reported to represent the most frequent consequences. Most of the 
mutations sequenced yet, bear these types of mutations (Noveroske et al. 2000; 
Papathanasiou and Goodnow 2005), whereas nonsense, splice-site, and frameshift 
mutations as well as in-frame deletions occur less frequently (Barbaric et al. 2007). 
The respective point mutation can lead to complete loss-of-function (null mutation), 
D C 
B A 
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partial loss-of-function (hypomorphs), gain-of-function (hypermorphs) or altered 
function (neomorphs) of the affected proteins (O'Brien and Frankel 2004). The 
predominance of A/T→T/A transversions limits the spectrum of ENU-induced 
mutations. Evaluation of data from both phenotype- and genotype-driven screens 
showed that genes with a long coding sequence length (>1000 bases), high numbers 
of exons (>10 exons), and high G and C contents (>58%), are more susceptible for 
ENU-induced mutations. Additionally, many mutations are often neighboured by G 
and C nucleotides. Consequentially, about 50% of the mouse genes are supposed to 
be underrepresented in ENU mutagenesis projects (Barbaric et al. 2007). However, 
the mutation efficacy of ENU and the possibility to produce a large number of mutant 
offspring from one treated mouse (Balling et al. 1998) represent appreciable 
advantages of ENU-driven mutagenesis. Mutation frequency of ENU-induced 
mutations varies, depending on the applied dose and the administration protocol 
(Coghill et al. 2002; Favor et al. 1990; Hitotsumachi et al. 1985). In current ENU-
driven screens, mutation rates of 1 mutation in 0.1-2.5 Mb were observable (Beier 
2000; Concepcion et al. 2004; Sakuraba et al. 2005). Assuming a mutation frequency 
of 1 in every 1 Mb together with total length of the haploid mouse genome of 2.5x109 
bp and 20,200 coding sequences with an average length of 1000 bp (Barbaric et al. 
2007; Mouse Genome Sequencing 2009), ENU mutagenesis would result in about 
2500 mutations per genome (including mutations in non-coding regions) and in 20 
mutated coding nucleotides per genome. Due the redundancy within the genetic 
code, many of the base exchanges within coding regions are predicted to be silent 
mutations (i.e. change in a base pair without altering the protein coding amino acid). 
Additionally, the mean distance of 1-2.5 Mb between two mutations allows 
segregation of most silent and non-causative mutations by phenotype-selective 
breeding strategies (Griffiths et al. 1999; Russ et al. 2002). 
2.2.2 Contribution of ENU mutagenesis to biomedical research 
Disease-associated alleles in human beings are usually characterised by subtle 
genetic modifications (Korf 1995). ENU induces preferably point mutations that 
involve a broad range of mutant phenotypes (Justice et al. 1999). 
Screening for mutations in ENU mutagenesis projects imply two complementary 
strategies, e.g. phenotype- (forward genetics) and genotype-driven screens (reverse 
genetics). In phenotype-driven screens mutant models are selected according to 
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defined phenotypes of interest, observable in human diseases. This strategy aims to 
identify the causative mutation and subsequently, the disease-associated gene of the 
selected phenotypes. In genotype-driven strategies, mutations in specific genes of 
interest are identified by DNA analysis from sperm archives, embryonic stem cells or 
ENU-mutagenised mice without previous phenotypic screening (Acevedo-Arozena et 
al. 2008; Kennedy and O'Bryan 2006). The aim in both approaches is the 
identification of disease-associated genes/alleles and the dissection of the structure-
to-function relationships of the affected protein. This attempt is not limited to 
monogenic Mendelian traits but can also focus on the investigation of diseases, 
resulting from interactions of multiple loci. Since ENU-generated models usually are 
monogenic, a practical approach towards multigenic alterations is the application of 
sensitised/modifier screens (Acevedo-Arozena et al. 2008; Nolan et al. 2002). An 
additional important aspect is the potential of ENU to induce various types of alleles 
(allelic series). 
2.2.3 ENU mutagenesis project strategies 
ENU-driven projects can be classified into genome-wide and region-specific screens. 
The choice of the project type depends on the aim of the study. Genome-wide 
screens provide the opportunity to investigate the genetic regulation of a specific 
biological process, whereas region-specific screens are usually applied to obtain 
allelic series, or are performed for functional analysis of a particular genomic interval 
(Kile and Hilton 2005). Up to now, several genome-wide and region-specific ENU 
screens have been accomplished, with emphasis on different research focuses. The 
Munich ENU mouse mutagenesis project was one of the first established large-scale 
ENU programs (Cordes 2005; Kennedy and O'Bryan 2006). 
2.3 The Munich ENU mouse mutagenesis project 
In the phenotype-driven large-scale Munich ENU mouse mutagenesis project, a high 
number of mutant mice has been generated and tested for a multitude of phenotypic 
abnormalities by high-throughput screening (Hrabé de Angelis et al. 2000). 
2.3.1 Research focus 
In order to extend the quantity and quality of mouse mutant resources, the Munich 
ENU project aimed to produce a plethora of mouse mutants, recapitulating 
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phenotypes of relevant inherited human diseases. The large-scale screening strategy 
allows addressing the “phenotype gap” between the available spectrum of mutant 
mice and human disease phenotypes. For this purpose, the production of a broad 
range of various phenotypes was expected (Brown and Balling 2001; Brown and 
Peters 1996; Hrabé de Angelis and Balling 1998). Representing a prerequisite for the 
practicability of the phenotype–driven strategy, standardised feasible procedures to 
evaluate phenotypes of interest were established. The screening and phenotyping 
protocol was mainly focused on the identification of postnatal aberrant phenotypes 
with major screens for dysmorphology, behaviour, immunology, clinical chemistry, 
and additional associated screens (DNA repair, deafness, nociceptive and 
mitochondrial disease) (Balling 2001; Soewarto et al. 2000). Screening strategies 
were primarily established to discover aberrant phenotypes that result from dominant 
or recessive mutations (Hrabé de Angelis et al. 2000). 
2.3.2 Mutagenesis and screening protocol 
The Munich ENU mouse mutagenesis project was carried out on the inbred 
C3HeB/FeJ (C3H) genetic background. At an age of 10-14 weeks, male mice were 
injected intraperitoneally with weekly doses of 90 mg/kg ENU for a period of three 
weeks. After a time period of transient sterility (10-15 days, depending on the dosage 
and application protocol) (Hitotsumachi et al. 1985; Russell et al. 1979), mutagenised 
G0 males were mated with C3H females to produce G1 offspring, which were 
subsequently screened for abnormal phenotypes (screen for dominant mutations). 
Inheritance of the abnormal phenotype on the C3H genetic background was tested in 
G2 progenies, derived from mating G1 animals, exhibiting an aberrant phenotypic 
trait, with healthy C3H mice. Screening for recessive mutations was carried out on 
G3 animals, generated by mating G1 males, which did not show an abnormal 
phenotype in the screen for dominant mutations, with female C3H mice to produce 
G2 female mice which were then again mated with their fathers. Inheritance of the 
abnormal phenotype was tested in G4 intercross mice or in progenies resulting from 
G4xG3 backcrosses (Aigner et al. 2008; Hrabé de Angelis et al. 2000) (Fig. 2.2). In 
the clinical chemical screen, blood samples from fasted mice were analysed for more 
than 20 parameters, including basic haematology, plasma enzyme activities, 
electrolyte concentrations, and substrates like glucose concentrations, serum 
cholesterol, and urea (Rathkolb et al. 2000). Established mutant strains were bred on 
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the C3H inbred genetic background to allow phenotypic studies without interfering 
influences of variations in the genetic background (Hrabé de Angelis et al. 2000). 
More than 15,000 G1 offspring and 500 G3 pedigrees were screened for clinically 
relevant parameters, resulting in more than 100 phenotypic mutant strains. Further, a 
large number of phenotypic mutant mice, which were not yet tested for inheritance of 
the abnormal phenotype, were conserved by sperm freezing (Aigner et al. 2008; 
Hrabé de Angelis et al. 2000). 
 
 
 
 
 
 
 
 
Figure 2.2: Generation of ENU-induced mutant mouse models. After intraperitoneal ENU 
administration, male G0 mice were mated to female wild-type mice to produce G1 mice. The 
screen for dominant mutations was carried out in the G1 offspring. The inheritance of the 
abnormal phenotype for dominant mutations was tested in the G2 offspring, and the screen 
for recessive mutations was accomplished with G3 progeny. Modified according to Aigner et 
al. 2008. 
2.3.3 Linkage analysis of dominant mutations 
The identification of the causative mutation starts with the determination of the 
affected chromosomal region. Genetic linkage is the logical consequence of physical 
linkage, and is appropriable for linkage analysis of loci that are polymorphic (with two 
or more distinguishable alleles) (Silver 1995). In the Munich ENU mouse 
mutagenesis project, linkage analysis was performed using an outcross-backcross 
breeding panel. Heterozygous phenotypic mutants on the C3H inbred genetic 
background were mated to wild-type mice of a second inbred strain (C57BL/6J). Male 
G1 hybrid offspring, displaying the abnormal phenotype, were again backcrossed to 
wild-type females of the second inbred strain. The resulting G2 progenies were 
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classified into phenotypic mutants and phenotypic wild-type mice. Using a panel of 
genome-wide DNA markers (single-nucleotide polymorphisms (SNPs) or 
microsatellites1 (Lindblad-Toh et al. 2000; Xing et al. 2005)), which are polymorphic 
for the two inbred strains used, DNA analysis of phenotypic mutant G2 mice and 
phenotypic wild-type littermates was carried out. High throughput genotyping of the 
outcross-backcross panel was performed by matrix-assisted laser desorption 
ionisation time-of-flight mass spectrometry (Buetow et al. 2001; Hrabé de Angelis et 
al. 2000). Genotypic discrimination resulted in determination of the affected 
chromosomal region, which is heterozygous in phenotypic mutant G2 animals and 
homozygous for the C57BL/6J genotype in phenotypic wild-type G2 mice. 
Genotyping of only 50 G2 phenotypic mutants provides the opportunity to map the 
causative mutation to a specific chromosomal region. With the assignment of the 
number of meioses scored and the number of loci that display recombinant allelic 
combination, testing of the hypothesis that two loci are linked is now feasible by chi2-
test. Linkage analysis, together with the available mouse genome sequence provides 
therefore the basis for positional candidate gene selection and sequencing (Balling 
2001; Reeves and D’Eustachio 1999; Silver 1995). 
 
Figure 2.3: Schematic illustration of the breeding strategy for linkage analysis. The 
position of the causative mutation is marked by a red triangle. Modified according to Aigner 
et al. 2008. 
2.3.4 Phenotype screening for diabetic mouse models 
The clinical chemical screen in the Munich ENU mouse mutagenesis project was 
accomplished with blood samples from 90-day-old G1 and G3 offspring which were 
                                            
1 Microsatellite markers represent short but surpassing polymorphic, high density spread tandem 
repeats of mono-, di-, tri- or tetrameric sequences. Allelic variation manifests in differences in the 
number of repeats, present in a tandem array (Silver 1995). 
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fasted overnight. The required blood volume was yielded by puncture of the 
retroorbital sinus under short-term general anaesthesia. Plasma glucose 
concentrations from Li-heparinised blood samples were quantified by an enzymatic 
hexokinase assay using the reagent OSR6121 (Olympus, Germany) in the linear 
measurement range of 10-800 mg/dl (0.6-45 mmol/l) (Rathkolb et al. 2000). Since 
genetic and environmental influences are known to affect phenotypic characteristics 
(Cox and Brown 2003; Klempt et al. 2006), the physiological range of plasma glucose 
was determined in wild-type control mice. Based on the upper value of the 90% 
range (208 mg/dl in male mice, 201 mg/dl in female animals), mice exhibiting plasma 
glucose concentrations of more than 200 mg/dl in two measurements within an 
interval of three weeks were considered hyperglycaemic. Four hyperglycaemic 
mouse strains, harbouring dominant mutations have been established so far and 
further strains are currently tested for inheritance of the diabetic phenotype (Aigner et 
al. 2008). The successful identification of the causative mutation and the clinical and 
pathomorphological consequences has already been described for the strain 
GLS004 (Herbach et al. 2007). Two other hyperglycaemic mouse strains, GLS001 
and GLS006, were subsequently chosen for the present study. 
2.3.5 Initial characterisation of the ENU strains GLS001 and GLS006 
After the confirmation of a dominant mutation being causative for the abnormal 
phenotype in both strains, genome-wide linkage analysis was carried out, using DNA 
samples of 75 G2 backcross mutants and 15 wild-type littermates for the ENU strain 
GLS001, and DNA samples from 70 G2 backcross mutants and 22 wild-type 
littermates of the ENU strain GLS006. Single nucleotide polymorphism (SNP)-based 
strategies were performed using a genome-wide mapping panel consisting of a total 
number of 136 (GLS001) and 141 (GLS006) polymorphic markers (performed in 
cooperation with the Institute of Experimental Genetics (Prof. Dr. M. Hrabé de 
Angelis, Helmholtz Zentrum München, Neuherberg). SNP analyses revealed a strong 
linkage (χ2=64.7; p<0.0001 for GLS001 mice and χ2=80.2; p<0.0001 for the ENU 
strain GLS006) of the diabetic phenotype of both strains to polymorphic markers on 
chromosome 11. The diabetic phenotype of GLS001 mice mapped to a marker at 
14.3 Mb (reference SNP: rs13480881), that of GLS006 mice to a marker at 7.1 Mb 
(reference SNP: rs13480851) (chapter 9.2). Scanning the mouse genome data base 
(Mouse Genome Informatics, MGI; http://www.informatics.jax.org/) for potential 
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diabetes-associated candidate genes indicated the glucokinase (Gck) gene, which is 
situated within the mapping region, as a potential candidate gene for both strains. 
Murine Gck, which is located on chromosome 11 at 5.8-5.9 Mb, is comprised of 11 
exons including liver- and β-cell specific variants of exon 1, and spans a total number 
of ~48.8 kb2. Since the glucokinase enzyme is known to play an important role in 
regulation of glucose metabolism, the positional Gck was chosen as candidate gene 
for both ENU strains to undergo further sequence analysis. 
2.4 Diabetes mellitus in human beings  
2.4.1 Definition and description of diabetes mellitus 
Diabetes mellitus is defined as a heterogeneous group of metabolic disorders 
characterised by hyperglycaemia resulting from defects in insulin secretion, insulin 
action or both. Long-term consequences of prolonged hyperglycaemia represent 
damage, dysfunction, and failure of various organs, especially the eyes, kidneys, 
nerves, heart, and blood vessels (American Diabetes Association 2009). The 
pathogenesis of diabetes mellitus involves various complex determinants influencing 
the development of this disease. At least three factors are involved in the 
pathogenesis of diabetes mellitus (Leahy 2005; Lehmann and Spinas 2000). 
• Genetic predisposition: i.e. mutations/polymorphisms in genes, encoding for 
transcription factors (Weedon et al. 2006), mutations in genes involved in 
glucose metabolism (glucokinase) 
• Beta cell dysfunction and failure resulting in inadequate insulin secretion 
• Peripheral insulin resistance: decreased response of liver, muscle, and 
adipose tissue to insulin stimulus 
A fourth pathogenic factor is discussed to contribute to the development of diabetes 
mellitus: environmental conditions like lifestyle, nutrition or infectious agents are 
supposed to strongly influence the development of diabetes mellitus (Leahy 2005; 
Lehmann and Spinas 2000). 
The pathognomonic sign of diabetes mellitus represents hyperglycaemia, 
occasionally accompanied by polyuria, polydipsia, weight loss, sometimes with 
polyphagia and blurred vision. Other concomitant symptoms including impairment of 
                                            
2 http://www.ensembl.org/Mus_musculus/Gene/Summary?g=ENSMUSG00000041798 
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growth and susceptibility to certain infections can also appear. Hyperglycaemia with 
ketoacidosis or the nonketotic hyperosmolar syndrome represent possible life 
threatening consequences of uncontrolled diabetes mellitus. Further, chronic 
hyperglycaemia is known to be associated with long-term complications resulting 
from macro- and microvascular lesions. Organ-specific microvascular pathology 
includes retinopathy accompanied by potential loss of vision; nephropathy leading to 
renal failure; peripheral neuropathy; risk of foot ulcers, amputations, and Charcot 
joints; and autonomic neuropathy causing gastrointestinal, genitourinary, and 
cardiovascular symptoms, and sexual dysfunction. Atherosclerotic macrovascular 
lesions increase the risk of cardiovascular, peripheral arterial, and cerebrovascular 
disease in diabetic patients. An increase in the polyol pathway flux, enhanced 
formation of advanced glycation end-products (AGEs), the activation of protein 
kinase C (PKC), sorbitol accumulation, and myo-inositol depletion, and an 
accelerated hexosamine pathway are the mechanisms that are hypothesised to 
major account for macro- and microvascular complications in diabetes mellitus 
(American Diabetes Association 2009; Brownlee 2001; Kikkawa 2000). 
2.4.2 Diagnostic criteria for diabetes mellitus 
Diagnosis of diabetes mellitus in patients with severe hyperglycaemia or in 
asymptomatic persons with only slightly elevated blood glucose values requires 
feasible diagnostic tests (Alberti and Zimmet 1998). 
According to the expert committee on the diagnosis and classification of diabetes 
mellitus, subjects, meeting one of the criteria stated in Table 2.2, are classified 
diabetic.  
Table 2.2: Criteria for the diagnosis of diabetes 
1. Fasting plasma glucose (FPG) ≥126 mg/dl (7.0 mmol/l). Fasting is defined as no caloric 
intake for at east 8 h.* 
2. Symptoms of hyperglycaemia and a casual plasma glucose ≥200 mg/dl (11.1 mmol/l). 
Casual is defined as any time of day without regard to time since last meal. The classic 
symptoms of hyperglycaemia include polyuria, polydipsia, and unexplained weight loss. 
3. 2-h plasma glucose ≥200 mg/dl (11.1 mmol/l) during an oral glucose tolerance test 
(OGTT). The test should be performed as described by the World Health Organization, 
using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in 
water.* 
*In the absence of unequivocal hyperglycaemia, these criteria should be confirmed by repeat 
testing on a different day. 
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Although the 75-g OGTT is more sensitive and modestly more specific to diagnose 
diabetes than FPG, it is poorly reproducible and difficult to perform in practice. 
Therefore, the determination of FPG represents the preferred diagnostic test. Though 
the OGTT is not recommended for routine clinical use, it may be useful for further 
evaluation of patients in whom diabetes is still strongly suspected but who have 
normal FPG or impaired FPG (IFG). 
An additional intermediate group of subjects whose glucose levels, although not 
meeting criteria for diabetes, are nevertheless too high to be considered normal has 
been admitted. This group is defined as having FPG levels between 100–125 mg/dl 
(5.6-6.9 mmol/l) or 2 h values in the OGTT of 140-199 mg/dl (7.8-11.1 mmol/l). These 
persons are consequently classified according the criteria stated in Table 2.3. 
Table 2.3: Classification of patients with equivocal glucose levels 
FPG <100 mg/dl (5.6 mmol/l) → normal fasting glucose 
FPG 100–125 mg/dl (5.6–6.9 mmol/l) → IFG (impaired fasting glucose) 
FPG ≥ 126 mg/dl (7.0 mmol/l) 
→ provisional diagnosis of diabetes (the 
diagnosis must be confirmed, as described 
below) 
when the OGTT is used 
2-h postload glucose <140 mg/dl 
(7.8 mmol/l) → normal glucose tolerance 
2-h postload glucose 140–199 mg/dl 
(7.8 –11.1 mmol/l) → IGT (impaired glucose tolerance) 
2-h postload glucose ≥200 mg/dl 
(11.1mmol/l) 
→ provisional diagnosis of diabetes (the 
diagnosis must be confirmed, as described 
below) 
 
Patients with IFG or IGT are considered “pre-diabetic” with a relatively high risk for 
the development of diabetes. IFG and IGT by their own (in absence of pregnancy) do 
not represent clinical entities, but can be considered as intermediate stages and are 
associated with the metabolic syndrome, which includes obesity (abdominal or 
visceral obesity), dyslipidaemia of the high-triglyceride and/or low-HDL type, and 
hypertension. 
Due to lack of global standardisation and uncertainty about diagnostic thresholds, the 
use of the HbA1C3 for the diagnosis of diabetes has previously not been 
                                            
3 Measurements of glycated proteins, including haemoglobin represent suitable methods to assess 
glycaemia. The term HbA1C is used to describe stable minor haemoglobin components which are 
formed nonenzymatically from haemoglobin and glucose (Reynolds et al. 2003). 
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recommended. However, a worldwide move toward a standardised assay and an 
increasing observational evidence about the prognostic significance of HbA1C will 
likely lead to a recommendation of HbA1C as the preferred diagnostic parameter for 
diabetes mellitus by the International Diabetes Federation. 
 
The criteria for abnormal glucose tolerance in gestational diabetes mellitus are 
adapted from Carpenter and Coustan (1982). Fasting plasma glucose levels >126 
mg/dl (7.0 mmol/l) or a casual plasma glucose >200 mg/dl (11.1 mmol/l) meets the 
threshold for the diagnosis of diabetes. If glucose levels are equivocal, the diagnosis 
must be confirmed on a subsequent day (Carpenter and Coustan 1982).  
2.4.3 Classification of diabetes mellitus 
The classification of diabetes mellitus according to the recommendations of the 
American Diabetes Association (ADA) and the WHO was fundamentally revised in 
1997 in order to establish a classification reflecting the aetiology and pathogenesis of 
diabetes mellitus. Therefore, the terms "juvenile-onset/insulin-dependent diabetes 
mellitus" and "maturity-onset/non-insulin-dependent diabetes mellitus" which were 
used to formerly distinguish between type 1 and type 2 diabetes mellitus are obsolete 
(Fajans 1998; Lehmann and Spinas 2000; Murphy et al. 2008; Sacks 1997). 
According to the recommendations of the ADA and the WHO, diabetes mellitus in 
human beings is classified into four main groups. 
I) Type 1 diabetes (β-cell destruction, usually leading to absolute insulin deficiency) 
• Immune mediated 
• Idiopathic 
II) Type 2 diabetes (may range from predominantly insulin resistance with relative 
insulin deficiency to a predominantly secretory defect with insulin resistance) 
III) Other specific types 
• Genetic defects of β-cell function 
- Chromosome 12, HNF-1α (MODY3) 
- Chromosome 7, glucokinase (MODY2) 
- Chromosome 20, HNF-4α (MODY1) 
- Chromosome 13, insulin promoter factor-1 (IPF-1; MODY4) 
- Chromosome 17, HNF-1β (MODY5) 
- Chromosome 2, NeuroD1 (MODY6) 
- Mitochondrial DNA and others 
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• Genetic defects in insulin action (type A insulin resistance, Leprechaunism, 
Rabson-Mendenhall syndrome, lipoatrophic diabetes and others) 
• Diseases of the exocrine pancreas (pancreatitis, trauma/pancreatectomy, 
neoplasia, cystic fibrosis, haemochromatosis, fibrocalculous pancreatopathy 
and others) 
• Endocrinopathies (acromegaly, Cushing's syndrome, glucagonoma, 
pheochromocytoma, hyperthyroidism, somatostatinoma, aldosteronoma and 
others) 
• Drug- or chemical-induced (vacor, pentamidine, nicotinic acid 
glucocorticoids, thyroid hormone, diazoxide, β-adrenergic agonists, 
thiazides, dilantin, α-Interferon and others) 
• Infections (congenital rubella, cytomegalovirus and others) 
• Uncommon forms of immune-mediated diabetes (“Stiff-man” syndrome, anti–
insulin receptor antibodies and others) 
• Other genetic syndromes sometimes associated with diabetes (Down’s 
syndrome, Klinefelter’s syndrome, Turner’s syndrome, Wolfram’s syndrome, 
Friedreich’s ataxia, Huntington’s chorea, Laurence-Moon-Biedl syndrome, 
Myotonic dystrophy, Porphyria, Prader-Willi syndrome and others) 
IV) Gestational diabetes mellitus (GDM) 
 Gestational diabetes mellitus (GDM) is defined as any degree of glucose 
intolerance with onset or first recognition during pregnancy (Metzger and Coustan 
1998). Approximately 7% of all pregnancies are complicated by GDM, resulting in 
more than 200,000 cases annually (American Diabetes Association 2003). 
2.4.4 Global burden of diabetes mellitus 
During the last decades, the prevalence of diabetes mellitus in industrial nations has 
taken on alarming dimensions. The worldwide prevalence of diabetes mellitus among 
adults is estimated to advance from 4% in 1995 to 5.4% in 2025 and the worldwide 
prevalence of diabetes for all age groups is predicted to rise from 2.8% in 2000 to 
4.4% in 2030. The total number of people suffering from diabetes mellitus is 
projected to rise from 171 million in 2000 to 366 million in 2030, and for adults to 
advance from 135 million in 1995 to 300 million in 2025 (King et al. 1998; Wild et al. 
2004). A dramatic increase of about 42% - from 51 to 72 million- is predicted for 
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developed countries and even a 170% increase - from 84 to 228 million people - is 
assumed for developing countries. Thus, by the year 2025, 75% of people with 
diabetes mellitus will reside in developing countries. According to this exceeding 
increase, diabetes mellitus is already considered an “epidemic” disease (Zimmet et 
al. 2001). India, China, and the United States are considered as the countries with 
the highest number of people suffering from diabetes mellitus (King et al. 1998). In 
Germany, the total number of diabetic persons currently amounts to four million 
(population prevalence of 5%) (Federal Health Monitoring 2006; www.gbe-bund.de) 
and is predicted to further increase dramatically in the future (www.who.int/diabetes). 
Type 2 diabetes, representing 90-97% of all diabetes cases, is reported to be the 
most common diabetes subtype (Bjork 2001; Printz and Granner 2005). Diabetes 
mellitus is accompanied by a 3-4 times higher risk of death as compared to those 
without diabetes and people with diabetes are on average 3 times more likely 
hospitalised. Recent data demonstrated that, in the United States, diabetes 
represents the leading cause of blindness and accounts for 40% of new cases of 
end-stage renal disease. The risk for leg amputation is 15–40 times higher and the 
risk for heart disease and stroke is 2-4 times higher for people with diabetes mellitus 
as compared too people without diabetes (Bjork 2001). The critical rise of the 
prevalence of diabetes and diabetes-associated complications is accompanied by 
exceeding costs (Hogan et al. 2003). Therefore, the urgent need for elucidating the 
pathomechanisms of diabetes mellitus is incontestable to combat this disease. 
2.5 Maturity-onset diabetes of the young (MODY) 
Maturity-onset diabetes of the young (MODY) was described for the first time in 
1974. R.B. Tattersall observed mild non-progressive diabetes in three families, 
appearing usually in juvenile subjects (in the early twenties), and he suggested that 
this phenotype might be inherited in a dominant Mendelian pattern (Tattersall 1974). 
One year later, the assumption of an autosomal dominant inheritance of MODY has 
been proven (Tattersall and Fajans 1975). During the following years, various 
MODY-associated genes have been discovered, resulting in novel subtypes of 
MODY. 
2.5.1 Characteristics of MODY 
MODY represents a clinically and genetically heterogeneous group of monogenic 
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disorders, characterised by an autosomal dominant mode of inheritance with high 
penetrance of the resulting diabetic phenotype. Affected individuals develop 
nonketotic diabetes due to defective insulin secretion resulting from an inherited β-
cell dysfunction, whereas insulin action is usually unaffected (American Diabetes 
Association 2009; Fajans et al. 2001; Velho and Froguel 1998). Even if a great 
phenotypic variability is reported to appear within a MODY pedigree as well as 
among the individual subtypes, the MODY phenotype is characterised in general by 
early age of onset of the diabetic phenotype (between childhood and early adulthood 
but usually before an age of 25 years) (Rehman 2001; Velho and Froguel 1998). The 
nature of the causative mutation, as well as modifying genes that are inherited 
independently, and environmental factors have been described to influence the age 
of clinical manifestation in MODY 3 patients (Kim et al. 2003). MODY 2 patients are 
known to exhibit hyperglycaemia from birth but the disease often remains 
undiagnosed due to the mild diabetic phenotype (Singh 2006; Timsit et al. 2005). 
Additionally, different phenotypic outcomes are reported in patients, exhibiting 
identical MODY subtypes (Fajans and Bell 2006). Considering the heterogeneity 
among the particular MODY subtypes, concerning the age of diagnosis, the pattern 
of diabetic outcome, the requirement of specific treatment and the occurrence of 
extrapancreatic manifestations, the unifying term “MODY” would no longer fulfil the 
manifold spectrum of this polymorphic disease. Consequently, the current opinion 
according to the reconditioned classification of diabetes in 1997 is to choose the 
correct monogenic terms of the different forms of young-onset diabetes appropriate 
to their aetiology and to classify them into four groups under the main topic 
“Monogenic forms of β-cell dysfunction” (Murphy et al. 2008; Sacks 1997): 
1. Diagnosis before 6 months of age (transient (TNDM) or permanent neonatal 
diabetes mellitus (PNDM)) 
2. Mild familial hyperglycaemia (e.g. due to mutations in the glucokinase gene) 
3. Familial young-onset diabetes (e.g. mutations in the gene encoding the 
hepatocyte nuclear factor-1β) 
4. Diabetes with extrapancreatic features (like Wolfram syndrome, mutations in the 
hepatocyte nuclear factor-1α-encoding gene)  
 
However, the current classification of diabetes adheres to the established subtypes. 
The exact prevalence of MODY and its subtypes in particular is unknown, but 
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estimations suppose a worldwide prevalence for MODY of about 2-5% of all type 2 
diabetic subjects (McCarthy and Froguel 2002; van Tilburg et al. 2001; Velho and 
Robert 2002). The relative prevalence of the MODY subtypes varies greatly 
depending on the population, but all studies clearly point out that MODY 2 and 3 
account for the most cases (Chèvre et al. 1998; Hattersley 1998; Lindner et al. 1999). 
From the six official MODY-associated genes, five encode for tissue specific 
transcription factors, which are expressed in pancreatic β-cells and are known to be 
involved in complex regulation of genes controlling glucose homeostasis (MODY 1 
and MODY 3-6) (Mitchell and Frayling ; Thomas et al. 2001) (Fig. 2.4). 
2.5.2 MODY subtypes 
 
Table 2.4: MODY subtypes according to the classification of the ADA and the WHO (A, 
B) and MODY subtypes, not yet admitted to the official classification (C). 
A MODY 1 MODY 2 MODY 3 
OMIM ID 125850 125851 600496 
Affected gene HNF4A GCK HNF1A 
Chromosomal location 20q12-q13.1 12q22-qter; 12q24.2 
Affected protein Hepatocyte nuclear factor-4α Hepatocyte nuclear factor-1α 
Prevalencea Rare Very common 
Physiological 
function 
Regulation of hepatic and 
pancreatic β-cell gene 
expression 
Controls PDX1, HNF4A, and 
GLUT2 expression 
Diabetic phenotype 
(heterozygous state) 
Progressive hyperglycaemia 
macrosomia4, transient hypo- 
glycaemia and/or 
hyperinsulinaemia 
Severe diabetes, renal 
glucosuria pancreatic exocrine 
failure, increased sensitivity to 
sulfonylureas 
Extrapancreatic 
manifestations Alteration in liver triglycerides 
Low renal threshold for 
glucose, liver adenomatosis 
Diabetic complications Frequent Frequent 
Treatment Oral antidiabetics or insulin Insulin or oral antidiabetics 
References 
(Brink 2003; Fajans et al. 2001; 
Gupta and Kaestner 2004; 
Hattersley 1998; Ilag et al. 
2000; Matyka et al. 1998; 
Sladek et al. 1990; Stanger 
2008; Winter 2003; Yamagata 
et al. 1996) 
refer to 
chapter 
2.7.4 
(Bellanné-Chantelot et al. 
2008; Cerf 2006; Ellard and 
Colclough 2006; Kuo et al. 
1992; Menzel et al. 1998; 
Reznik et al. 2004; Vaxillaire 
and Froguel 2008; Vesterhus 
et al. 2008a; Vesterhus et al. 
2008b) 
 
 
                                            
4 MODY 1 subjects exhibit macrosomia most likely as a result of prolonged exposure insulin, due to 
surpassing fetal production of the anabolic acting hormone insulin (Pearson et al. 2007). 
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B MODY 4 MODY 5 MODY 6 
OMIM ID 606392 137920 606394 
Affected gene IPF1 HNF1B NEUROD1 
Chromosomal location 13q12.1 17cen-q21.3 2q32 
Affected protein Insulin promoter factor-1 
Hepatocyte nuclear factor-
1β BETA2/NeuroD1 
Prevalencea Rare Very rare Very rare 
Physiological 
function 
Essential for 
embryonic pancreas 
development, 
regulation of GCK, 
INS, and GLUT2 
expression 
Important role in embryonic 
development, regulates 
HNF4A expression 
Essential for neuronal 
differentiation and 
pancreatic 
development and 
function 
Diabetic phenotype 
(heterozygous state) 
Diabetes mellitus, 
intermediate between 
MODY2 and MODY1 
Renal cysts and diabetes 
(variable severity) (RCAD), 
partial pancreatic agenesis 
Probably severe but 
limited data 
Extrapancreatic 
manifestations Unknown 
Hepatic, biliary, and genito-
urinary manifestations, 
renal failure 
Unknown 
Diabetic complications Unknown Unknown Unknown 
Treatment Oral antidiabetic treatment, insulin Insulin Insulin 
References 
(Fajans and Bell 
2006; Mitchell and 
Frayling ; Nyunt et al. 
2009; Stoffers et al. 
1997a; Stoffers et al. 
1997b; Weng et al. 
2001; Winter 2000) 
(Bellanné-Chantelot et al. 
2004; Fajans and Bell 
2006; Furuta et al. 2002; 
Haldorsen et al. 2008; 
Igarashi et al. 2005; 
Kitanaka et al. 2004; Ulinski 
et al. 2006; Winter 2003) 
(Chao et al. 2007; 
Fajans et al. 2001; 
Lee et al. 1995; Liu et 
al. 2007; Malecki and 
Mlynarski 2008; 
Mitchell and Frayling 
; Naya et al. 1997) 
 
C MODY 7 MODY 8 MODY 9 
OMIM ID 610508 609812 612225 
Affected gene KLF11 CEL PAX4 
Chromosomal location 2p25 9q34.3 7q32 
Affected protein Krüppel-like factor 11 Pancreatic carboxyl-ester lipase Paired box protein 4 
Prevalencea Unknown 
Physiological 
function 
Involved in regulation 
of pancreatic β-cell 
function 
Hydrolysation of 
cholesteryl esters, 
triglycerides, and 
lysophospholipids 
Promotes differentiation of β- 
and δ-cells during early 
pancreas development 
Diabetic phenotype 
(heterozygous state) Diabetes mellitus 
Beta cell failure and 
exocrine pancreas 
dysfunction 
MODY-similar diabetic 
phenotype 
Extrapancreatic 
manifestations 
Diabetic complications 
Treatment 
Unknown 
References 
(Bieker 2001; Neve et 
al. 2005) 
(Ræder et al. 2006; 
Shamir et al. 1996) 
(Brun et al. 2004; Habener et 
al. 2005; Plengvidhya et al. 
2007; Smith et al. 1999; 
Sosa-Pineda et al. 1997) 
a Prevalence within the MODY population; Chromosmal locations refer to the NCBI database 
(http://www.ncbi.nlm.nih.gov/). 
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Novel potential MODY-associated candidate genes 
Heterozygous mutations in the paired box gene 6 (PAX6) have previously been 
reported in sporadic cases of maturity-onset diabetes in human subjects (Nishi et al. 
2005; Yasuda et al. 2002). The transcription factor Pax6 is known to be involved in 
oculogenesis and has also been suggested to play an indispensable role in the 
development of the endocrine pancreas (Hanson and Van Heyningen 1995; St-Onge 
et al. 1997). The mutation carriers were therefore diagnosed of aniridia and various 
degrees of diabetes (Nishi et al. 2005; Yasuda et al. 2002). Another transcription 
factor, suggested to be essential for endocrine pancreas development with focus on 
α-cell differentiation (Lee et al. 2005), the forkhead box A2 protein (Foxa2, formerly 
hepatocyte nuclear factor-3β (HNF-3β)), may also be a candidate to cause familial 
hypoinsulinism-mediated diabetes mellitus. As FOXA2 has been demonstrated to 
regulate the expression of HNF1A and HNF4A, which are both associated with 
MODY subtypes, a possible role of FOXA2 as an elicitor of MODY has been 
propagated (Duncan et al. 1998). However, previous studies failed to associate the 
MODY phenotype with mutations in the FOXA2 gene (Hinokio et al. 2000). 
 
Figure 2.4: Model of the molecular mechanisms of insulin secretion in pancreatic β-
cells and the proteins involved in MODY. Modified according to Fajans et al. 2001. 
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2.6 The catalytic enzyme glucokinase 
2.6.1 Physiological and biochemical function of the glucokinase enzyme 
The term glucokinase first appeared in the literature in 1950 and was established in 
1964 to designate a glucose-phosphorylating enzyme that has been identified in rat 
liver tissue (Slein et al. 1950; Walker and Rao 1964). Mammalian glucokinase (syn. 
hexokinase IV; EC 2.7.1.2), as one of the four members of the hexokinase family, is 
capable to phosphorylate hexoses, in the order of preference glucose>mannose>2-
deoxyglucose>fructose. Although all hexokinase members display a strong sequence 
homology, testifying of a close phylogenetic relationship, they exhibit different 
catalytic properties (Iynedjian 2009). In contrast to the hexokinases I-III, which have a 
low Km (0.01-0.1 mM) for glucose (high affinity), the Km for glucose of glucokinase 
amounts to 8.4-10 mM (low affinity). Thus, glucokinase activity can be directly 
influenced by plasma glucose concentrations, whereas other hexokinases are 
already saturated at normal plasma glucose concentrations due to their low Km. 
Since the rate of substrate phosphorylation by glucokinase is dependent on 
extracellular glucose concentrations, the glucokinase enzyme is considered to 
function as a “glucose sensor”. Other kinetic characteristics of the catalytic enzyme 
glucokinase are a sigmoidal glucose dependency, which, together with the low 
glucose affinity, guarantees optimal responsiveness at physiological glucose levels. 
Additionally, the allosteric glucokinase enzyme exhibits a positive cooperativeness 
with glucose (basic kinetic properties of the glucokinase enzyme are stated in 
chapter 10.1). These attributes make the enzyme most sensitive to glucose level 
changes close to the physiological range. In contrast to other hexokinases, which are 
inhibited by various phosphorylated intermediates (glucose-6-phosphate, glucose-
1,6-diphosphate, and 6-phosphogluconate), the glucokinase enzyme does not 
underlie any specific feedback inhibition by downstream products (Matschinsky 1990, 
2002; Matschinsky et al. 1998; Winter 2000). Apart from hepatocytes, the 
glucokinase enzyme is also widely expressed in different endocrine and 
neuroendocrine cells in various tissues. Glucokinase expressing cells for example 
reside in the endocrine pancreas, the intestine, and in the brain (Matschinsky 2002). 
In the islets of Langerhans, glucokinase is predominantly expressed in the insulin-
producing β-cells, but it has also been detected in glucagon-producing α-cells and in 
somatostatin-producing δ-cells (Heimberg et al. 1996; Toyoda et al. 1997; Toyoda et 
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al. 1999). In pancreatic β-cells, glucokinase catalyses the first, rate limiting step of 
glycolysis: the phosphorylation of glucose (on carbon 6 with MgATP as the second 
substrate) to glucose-6-phosphate (G6P). Glycolysis results in increased ATP 
generation in the cytoplasm, enhanced oxidative phosphorylation within the 
mitochondrion, and in turn to a decrease of ADP and anorganic phosphate 
concentrations. This shift in energy equilibrium leads to the closure of β-cell KATP 
channels, followed by membrane depolarisation and the opening of voltage-
dependent Ca2+-channels. Subsequently, increased intracytoplasmic calcium induces 
fusion of the insulin containing vesicles with the cytoplasmic membrane and, finally, 
insulin exocytosis (Winter 2003). Therefore, already minimal changes in glucokinase 
activity can result in serious consequences for the organism, because the threshold 
for glucose-induced insulin secretion is altered directly (Iynedjian 2009; Matschinsky 
2002; Postic et al. 2001). In hepatocytes, glucokinase stimulates glucose uptake and 
glycogen synthesis (Radziuk and Pye 2001). Glucokinase in neuroendocrine enteric 
cells (K- and L-cells) and specialised neurons (pituitary cells, neurons of various 
hypothalamic nuclei, of the tractus solitarius, the vagus, and of raphe nuclei) was 
initially thought to fulfil a function, similar to that in pancreatic β-cells (Matschinsky et 
al. 2006). However, a recent study in human MODY 2 patients proved that 
glucokinase, which is co-expressed with glucagon-like peptide-1 (GLP-1) and 
glucose-dependent insulinotropic peptide (GIP) in intestinal K-cells, does not function 
as the suggested “gut glucose sensor” in enteric cells of these patients (Murphy et al. 
2009). For anterior pituitary cells as well as for glucose-excited and glucose-inhibited 
neurons, by contrast, the concept of a glucose sensory function of the glucokinase 
enzyme in the brain was reinforced (Dunn-Meynell et al. 2002; Zelent et al. 2006). 
2.6.2 Regulation of glucokinase expression 
The human glucokinase gene (GCK), localised on chromosome 7p15.3-15.1, is 
comprised of 12 exons that span ~45 kb and encode for a 52.2 kDa protein, 
containing 465 amino acids5. The glucokinase protein therefore represents a much 
smaller molecule than other hexokinases, being about 100 kDa in size (Iynedjian 
1993; Postic et al. 2001). 
                                            
5 http://www.ncbi.nlm.nih.gov/ 
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The glucokinase coding sequence is highly conserved between human, rat, and 
mouse with >94% sequence identity among these species (Postic et al. 1995). The 
presence of 2 different tissue specific promoters enables differential glucokinase 
gene regulation and transcription and results in three tissue specific variants of exon 
1 (a-c). The upstream promoter is active in pancreatic β-cells and in the brain, 
whereas the downstream promoter activity is restrained to hepatocytes. Thus, 
multiple glucokinase mRNAs, resulting from alternate transcription and RNA 
processing, are produced from the single gene. Exon 1b and 1c are expressed in the 
liver, whereas exon 1a is expressed in pancreatic β-cells. Due to alternative 
transcription start sites, the liver- and β-cell-specific glucokinase isoforms differ in 15 
amino acids at the N-terminus. Additionally, hepatic glucokinase gene expression in 
rats is strongly induced by refeeding after a certain fasting period, whereas β-cell-
specific glucokinase expression remains stable during the fasting and refeeding 
state, indicating that different mechanisms might control glucokinase gene 
expression in liver and β-cells (Gloyn 2003; Iynedjian 1993; Iynedjian et al. 1989b; 
Magnuson and Shelton 1989). Hepatic glucokinase gene expression has already 
been proven to be induced by insulin and to be inhibited by glucagon in a cAMP-
dependent manner (Iynedjian 1993; Iynedjian et al. 1989a; Nouspikel and Iynedjian 
1992), whereas the role of sterol regulatory element binding protein-1c (SREBP-1c) 
as the propagated major mediator of insulin-induced hepatic glucokinase gene 
expression was argued recently (Foretz et al. 1999; Gregori et al. 2006). Moreover, 
glucokinase gene expression in the liver is controlled by multiple DNA-protein 
interactions like cis-acting DNA sequences in the liver-specific promoter that bind to 
various hepatocyte nuclear transcription factors (Postic et al. 2004). 
On the posttranslational level, liver-specific glucokinase is under the control of a 
small high-affinity protein, the glucokinase regulatory protein (GKRP), which 
influences the activity as well as the subcellular compartmentation of the glucokinase 
enzyme. The 62 kDa GKRP acts as both a competitive inhibitor of glucokinase 
activity and a nuclear receptor, and regulates glucokinase translocation from the 
cytoplasm to the nucleus. Due to the presence of two binding sites for fructose 
phosphates, the interaction of GKRP with the glucokinase protein is enhanced in the 
presence of fructose-6-phosphate and impeded in the presence of fructose-1-
phosphate. Glucose, by contrast, induces the release of the GKRP from its complex 
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with glucokinase and therefore reinforces enzyme activity (Baltrusch and Tiedge 
2006; van Schaftingen et al. 1994). 
The regulation of glucokinase gene expression in endocrine and neuroendocrine 
cells seems to be more complex and is discussed controversially. In contrast to the 
liver, β-cell-specific glucokinase mRNA expression seems to be more constitutive, 
enabling the stable regulation of glucose turnover and insulin secretion rates in 
pancreatic β-cells (Matschinsky et al. 1998). Therefore, glucokinase regulation on the 
transcriptional level might play a minor role in pancreatic β-cells (Baltrusch and 
Tiedge 2006; Heredia et al. 2006; Kamata et al. 2004). A protruding role of glucose 
as the main regulator of glucokinase gene transcription in pancreatic β-cells was 
widely accepted for a long time. However, in isolated human and rat islets, 
glucokinase mRNA levels were shown to be independent of the nutrition status. 
Further, exposure to elevated glucose concentrations impressively enhanced 
glucokinase protein, but not glucokinase gene expression, thereby advising the role 
of glucose as a potential regulating factor of glucokinase on the posttranscriptional 
level (Gasa et al. 2000; Iynedjian et al. 1989b; Matschinsky et al. 2006). In contrast to 
these findings, another study demonstrated that glucose is nevertheless capable to 
induce glucokinase mRNA expression in rat pancreatic islets (Tiedge and Lenzen 
1991), and that this effect was supposed to be also mediated by insulin (Matschinsky 
2002). However, glucose is considered to be an important regulator of β-cell-specific 
glucokinase on posttranscriptional and posttranslational levels (Chen et al. 1994; 
Matschinsky 2002). Other factors influencing glucokinase expression seem to be 
numerous, and the specific mechanisms involved are still not completely elucidated. 
Thyroid hormone, glucocorticoids, biotin, placental lactogen (PL) and retinoic acid are 
known potential regulators of glucokinase induction (Matschinsky 2002; Printz et al. 
1993). Moreover, recent studies have demonstrated the regulatory function of the 
bifunctional enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFK-
2/FBPase-2) on glucokinase activity in pancreatic β-cells and on glucokinase protein 
expression in hepatocytes.  
2.6.3 Structure-function relationship in human glucokinase 
Three-dimensional modelling of the human glucokinase (Kamata et al. 2004; 
Mahalingam et al. 1999; St Charles et al. 1994) led to the discovery of the 
conformational transition pathway of the glucokinase enzyme during glucose 
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metabolism and to the identification of small allosteric activator molecules (Baltrusch 
and Tiedge 2006; Grimsby et al. 2003). The glucokinase protein consists of two 
domains, a large and a small one - with a glucose binding site, located in the 
interdomain cleft - and an allosteric binding site in the hinge region between the large 
and small domains. During catalysis, glucokinase undergoes greater conformational 
changes than hexokinases. The thermodynamically favourable inactive form 
(apoenzyme form) of the glucokinase, which is held in the absence of glucose is 
characterised by a “wide-open” (also called “super-open”) form. Glucose binding to 
the catalytic centre induces a conformational change of the glucokinase to a more 
complex form, the so-called “intermediate” or “open form” that proceeds to the active 
“closed form” in the presence of ATP. The mechanism of the positive 
cooperativeness of glucokinase with glucose is based on these three conformations. 
Once glucose binds to the catalytic centre, the enzyme undergoes a slow transition 
from the wide-open to the open form with ongoing enzymatic reaction by changing to 
the closed form in the presence of ATP. After completion of the reaction, glucokinase 
turns back to the open form to release glucose-6-phosphate and ADP. Once 
glucokinase forms a complex with glucose during this period, the enzyme re-entries 
the catalytic cycle through a fast “closed-open” transition, whereas in absence of 
glucose binding, glucokinase returns to the super open form (Fig. 2.5). The ratio of 
these two transition flows, the slow and the fast cycle, is depending on the glucose 
concentration (the fast cycle is favoured in presence of high, the slow cycle in 
presence of low glucose concentrations) and the time of glucokinase remaining in the 
open form. The shift between the two cycles explains the catalytic characteristics of 
the glucokinase enzyme, especially the low affinity for glucose and the sigmoidal 
saturation kinetic (Baltrusch and Tiedge 2006; Heredia et al. 2006; Kamata et al. 
2004). 
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Figure 2.5: Illustration of glucokinase conformational changes (A) and protein 
conformation (B). Glucokinase shuttles between closed, open, and super-open form within 
the fast and the slow cycle (A). Ribbon drawing of the glucokinase in the closed conformation 
in complex with glucose (yellow) and an allosteric activator (black); helices, β-sheets, and 
flexible loops are coloured in red, blue, and green, respectively (B). From Heredia et al. 2006 
and Kamata et al. 2004. 
2.6.4 Glucokinase-associated diseases in human subjects 
According to the pivotal importance of the glucokinase enzyme in glucose 
homeostasis, variations in the glucokinase gene (GCK) are predicted to have incisive 
impact on glucose metabolism and cause glycaemic diseases. To date, a total 
number of 446 naturally occurring point mutations within the coding region of GCK 
have been described, with missense mutations representing the most common 
defect (about 91% of all point mutations) (Osbak et al. 2009). GCK mutations are 
capable to cause hyperglycaemia or hypoglycaemia, resulting in three 
distinguishable phenotypes depending on the number of the mutated alleles and the 
functional consequences of the corresponding mutation (Gloyn 2003; Gloyn et al. 
2008): 
• Heterozygous gain-of-function mutations in human GCK cause persistent 
hyperinsulinaemic hypoglycaemia of infancy (PHHI), a rare disorder characterised 
by hypoglycaemia, present from birth, which is caused by exceeding insulin 
secretion. Inappropriate insulin secretion results from a reduced S0.5 for glucose 
A B
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and/or an increased Vmax of the glucokinase enzyme, leading to a lowered 
threshold for glucose-induced insulin secretion. These changes in enzyme 
kinetics are most often a consequence of mutations located ~20 ångstroms distal 
from the substrate-binding site in the region of the putative allosteric activator 
domain (Matschinsky et al. 2006; Printz and Granner 2005). The resulting 
phenotype can vary from chronic low fasting plasma glucose to severe persistent 
hypoglycaemia, accompanied by ataxia, seizures, and coma. Endocrine 
pancreatic manifestations of the inherited β-cell hyperfunction are characterised 
by β-cell hypertrophy, which can be present only in foci of hyperplastic islets or in 
all islets of the pancreas (Cuesta-Munoz et al. 2004; Pal and Miller 2009; 
Reinecke-Luthge et al. 2000). 
• Homozygous loss-of-function mutations in GCK are associated with permanent 
neonatal diabetes mellitus (PNDM). Neonatal diabetes mellitus, a quite rare 
disease (incidence of 1:300,000–500,000 live births), can either be transient 
(TNDM) or permanent (PNDM) (Glaser 2008). Nevertheless, complete functional 
disruption of human GCK might be a rather rare cause of neonatal diabetes 
mellitus or possibly results in intra-uterine death (Edghill et al. 2008; Gloyn et al. 
2002). The pathognomonic symptoms of neonatal diabetes mellitus are 
hyperglycaemia, usually requiring insulin treatment, hypoinsulinaemia, exocrine 
pancreatic manifestations, and low birth weight. However, a successful initial 
sulphonylurea treatment has been reported in a child with a homozygous GCK 
mutation (Fosel 1995; Glaser 2008; Turkkahraman et al. 2008) 
• Heterozygous loss-of function mutations in GCK are associated with a subtype of 
maturity-onset diabetes of the young: MODY 2. The close linkage of the 
glucokinase locus to elevated fasting plasma glucose concentrations in MODY 
families in France and the UK was first discovered in 1992 and the hypothesis 
was set that defects in GCK potentially account for a MODY subtype and may 
even play a role in the pathogenesis of type 2 diabetes mellitus (Froguel et al. 
1992; Hattersley et al. 1992). According to their location, GCK mutations can be 
divided into three main groups (Gloyn et al. 2008; St Charles et al. 1994; Velho et 
al. 1997). 
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1. Mutations of conserved active site residues may seriously impair the catalytic 
activity of the glucokinase. 
2. Mutations, which are predicted to distort the enzyme structure and result in 
decreased glucokinase activity; and mutations of surface residues that 
eliminate interactions with other residues. These mutations are predicted to 
impair the structural stability or affect the conformational change induced by 
glucose binding to the catalytic centre, and often exert only minor effects on 
glucokinase activity. 
3. Other mutations, that may impede interactions between glucokinase and 
regulatory or binding partners like GKRP. Furthermore, glucokinase mutations 
might affect the interplay with the bifunctional enzyme PFK/FBPase-2, which 
has been recently demonstrated to regulate both glucokinase activity in 
pancreatic β-cells and glucokinase protein expression in hepatocytes (Massa 
et al. 2004; Payne et al. 2005). 
However, the molecular mechanisms underlying some specific mutations are not 
ultimately ascertained. In vitro studies, based on the molecular model of human 
glucokinase, revealed a GCK mutation, associated with a diabetic phenotype despite 
unaltered kinetic properties (Davis et al. 1999). Another mutation, located near the 
allosteric activator site and associated with familial hyperglycaemia, appeared to be 
kinetically activating and was therefore expected to cause hypoglycaemia rather than 
hyperglycaemia. Glucokinase activity of the mutated protein was proven to be 
refractory to allosteric activator compounds in vitro. Therefore, the loss of allosteric 
activation of the mutated glucokinase was considered to represent the key 
mechanism leading to the diabetic phenotype (Arden et al. 2007). The MODY 2 
diabetic phenotype in general reflects the manifestations of a disturbed hepatic 
glucose clearance and a primary β-cell secretory defect due to an impaired glucose 
sensing and a decreased glycolytic flux in pancreatic β-cells. MODY 2 patients 
usually display mild, but chronic hyperglycaemia, with development of impaired 
fasting glucose (IFG), disturbed glucose tolerance (IGT), and increased postprandial 
gluconeogenesis (Velho and Froguel 1998). The defective glucokinase function in 
MODY 2 subjects leads to an increased threshold for glucose-induced insulin 
secretion in pancreatic β-cells, resulting in a disturbed glucose-induced insulin 
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secretion. The glucose response curve for insulin secretion exhibits a “right-shift”, 
whereas the first phase of insulin secretion following an intravenous glucose bolus 
application was proven to be well preserved in affected persons (Velho et al. 1992; 
Winter 2003). Even if some MODY 2 patients display peripheral insulin resistance, 
this phenomenon might be secondary to the disease rather than a direct 
consequence of the mutation (Clement et al. 1996; Hattersley and Pearson 2006). 
The diabetic phenotype in MODY 2 subjects may deteriorate little with age, but 
usually remains considerably stable due to compensatory mechanisms like 
overexpression of the wild-type allele (van de Bunt and Gloyn 2007). Despite being 
present from birth, the diabetic phenotype often remains undiagnosed for a 
remarkable time, because the occurrence of the disease varies, depending on the 
severity of glucokinase impairment, from asymptomatic mild hyperglycaemia over 
various degrees of glucose intolerance up to the development of persistent fasting 
hyperglycaemia with less than 50% of affected persons developing overt diabetes 
(Fajans et al. 2001; Velho and Froguel 1998). Due to this mild diabetic phenotype, 
diabetes-associated macro- and microvascular complications, overweight, and 
dyslipidaemia are uncommon in MODY 2 patients (Velho and Froguel 1998; Velho et 
al. 1996). Further, patients usually manage blood glucose control by diet and 
exercise alone, and only 1 of 50 MODY 2 patients requires insulin therapy (Fajans et 
al. 2001; Winter 2003). Defects in GCK can already be evident in the prenatal period. 
Infants with GCK mutations born to unaffected mothers display remarkably lower 
birth weights than their non-affected siblings, reflecting the effect of insulin deficiency 
on embryonic growth in utero. In contrast, unaffected children, born to a GCK 
mutation carrier, often exhibit macrosomia (van de Bunt and Gloyn 2007; Winter 
2003). The worldwide prevalence of MODY is not exactly known but it is estimated 
that 2-5% of type 2 diabetic patients may be in fact MODY subjects. MODY 2 and 
MODY 3 are supposed to be the most common MODY subtypes (American Diabetes 
Association 2009), whereby the relative prevalence of MODY 2 varies extremely 
depending on the prevailing population, the applied diagnosis criteria, and the mode 
of patient recruitment (Massa et al. 2001). In European Caucasian, MODY 2 is 
reported to account for only 8%  of all MODY cases in Germany (Lindner et al. 1999), 
for 10% in Denmark (Johansen et al. 2005), for 12% in Norway (Sagen et al. 2008), 
for 10-20% in the UK (Froguel et al. 1993; Thomson et al. 2003), for 31% in the 
Czech republic (Pruhova et al. 2003), for 25-41% in Spain (Barrio et al. 2002; Costa 
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et al. 2000), for 41-61% in Italy (Mantovani et al. 2003; Massa et al. 2001), and for 
about 50% in France (Froguel et al. 1993). Taken together, a worldwide population 
prevalence for MODY 2 of 0.04-0.1% is suggested (Gloyn 2003). However, the rare 
incidence of this disease and the genetic heterogeneity of the affected subjects 
impede detailed clinical studies in human medicine. For this reason, genetically 
modified animal models are essential to survey relevant clinical and 
pathophysiological aspects of this disease. Albeit, up to now, few advances were 
made in human medicine as well as in animal models, to disclose the 
pathomorphology of this putative mild diabetes subtype (Osbak et al. 2009). 
2.6.5 Clinical screening criteria for MODY 2  
Considering the various treatment challenges for the specific MODY subtypes, the 
importance of a genetic diagnosis in MODY subjects reaches more and more priority. 
Therefore, practice guidelines for the most common monogenic forms of diabetes 
caused by mutations in the GCK, HNF1A, and HNF4A were elaborated by the 
European Molecular Genetics Quality Network (EMQN), comprising clinical criteria for 
selection of patients for testing, methodologies, and interpretation of results (Ellard et 
al. 2008). 
The following features suggest a diagnosis of a GCK mutation:  
1. Fasting hyperglycaemia ≥5.5 mmol/l (99 mg/dl) (observable in 98% of MODY 2 
patients), persistent (at least three separate occasions) and stable over a period 
of months or years.  
2. HbA1c typically just above the upper limit of the normal range and rarely 
exceeding 7.5%. 
3. A small increase during OGTT [(2 h glucose) − (fasting glucose)]: 71% of patients 
in the large European study had an increment <3 mmol/l (54 mg/dl) (Stride et al. 
2002). An increase of 4.6 mmol/l (83 mg/dl) is often used to prioritise testing. 
4. Parents may have ”type 2 diabetes” with no complications or may not be diabetic. 
On testing, one parent will usually have mildly raised fasting blood glucose (range 
of 5.5–8 mmol/l (99-144 mg/dl)) unless the mutation has arisen de novo. Testing 
of FPG of apparently unaffected parents is important when considering a 
diagnosis of a glucokinase mutation. 
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3. Research design and methods 
3.1 Animals 
3.1.1 Breeding, husbandry, and analyses 
The ENU strains GLS001 and GLS0066 were generated within Munich ENU mouse 
mutagenesis project on the genetic background of the inbred strain C3H. Both strains 
were further bred by mating male heterozygous mutants to wild-type C3H female 
mice. Segregation of most additional ENU-induced non-causative mutations was 
attained by breeding animals for more than 10 generations to wild-type C3H mice. 
Both strains were detected in the screen for dominant mutations, displaying elevated 
plasma glucose concentrations (Aigner et al. 2008; Hrabé de Angelis et al. 2000). 
Animals were maintained under standard (non-barrier) conditions (21-23°C, 55 ± 3% 
relative humidity, 12 hours light : 12 hours dark cycle) and received standard rodent 
diet (Altromin C1324, Germany) and tap water ad libitum. After a suckling period of 
21 ± 1 days, mice were weaned, weighed, and marked by ear punches. Further, tail 
tip biopsies for genotypic differentiation and 10 µl peripheral blood for determination 
of blood glucose levels were sampled from each mouse during weaning procedure. 
Twenty-one day-old male mice displaying ad libitum fed blood glucose levels ≥170 
mg/dl were considered diabetic, whereas blood glucose levels ≤125 mg/dl were 
allocated to the wild-type phenotype. Male animals showing blood glucose 
concentrations >125 mg/dl and <170 mg/dl were classified susceptible for diabetes 
and underwent iterated blood glucose determination seven days later. The respective 
cut-off levels for blood glucose concentrations in female mice were 120 mg/dl and 
165 mg/dl. Fasting and ad libitum fed blood glucoses levels of mutant mice and wild-
type littermates were screened regularly within clinical tests, including oral glucose 
tolerance (OGTT) and intraperitoneal insulin tolerance tests (ipITT) at the indicated 
age. Blood samples for the determination of serum insulin levels in the fasted state 
and after glucose application were also collected during OGTT. Clinical investigations 
were carried out with at least 5 animals per sex and genotype. At the end of the 
                                            
6 Mouse Genome Database: 
GLS001: http://www.informatics.jax.org/javawi2/servlet/WIFetch?page=markerDetail&key=382146 
GLS006: http://www.informatics.jax.org/searchtool/Search.do?query=GLS006&submit=Quick+Search 
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clinical investigation period, 4 mice per genotype and sex were sacrificed at an age 
of 210 days for necropsy. Four additional male mutant GLS006 mice and wild-type 
littermates were sacrificed at an age of 550 days. Post mortem investigations 
comprised the determination of organ weights and the procession of whole pancreata 
for subsequent histological and morphometric analyses. At an age of 90 days, 2 
additional GLS001 mice per sex and genotype were sacrificed and pancreatic islets 
were isolated for Western blot analysis. Liver tissue samples for determination of 
glucokinase activity were also obtained from 90-day-old mice. 
Homozygous mutants were generated by mating heterozygous littermates. The 
resulting offspring were weighed and tagged by foot pad tattoo at the first day post 
partum. Tail tip samples for DNA isolation and subsequent genotypic differentiation 
were collected, and litters were subsequently monitored twice a day to survey 
mortality rates. At an age of 3 and 21 days, body weights were determined again. 
Additional offspring of heterozygous mutants were sacrificed at the first day post 
partum (within the first 24 hours of life) and at an age of 1 (after the first 24 hours 
post partum) and 4 (only GLS001 mice) days to obtain blood samples for blood 
glucose determination. Moreover, pancreata for qualitative histological and 
quantitative stereological analyses and hepatic tissue for RNA isolation and 
subsequent quantitative real-time polymerase chain reaction (PCR), were obtained 
from neonatal GLS001 mice. 
The total number of animals used for the respective investigations is illustrated in 
Table 3.1. All experiments were performed under the approval and in accordance 
with the guidelines of the responsible animal welfare authority (Regierung von 
Oberbayern). 
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Table 3.1: Number of GLS001 and GLS006 mice used for the respective investigations 
during the suckling period (A) and after weaning (B). 
 Number of animals examined 
GLS001 GLS006 Investigations during the 
suckling period wt mt, het mt, homo wt mt, het mt, homo 
Body weight (days of age): 
0 (first day post partum)  
3 
 
13 
13 
 
18 
16 
 
8 
7 
 
16 
16 
 
19 
20 
 
18 
12 
Blood glucose (days of age): 
0 (first day post partum)  
1 
4 
 
6 
5 
11 
 
13 
7 
14 
 
11 
4 
7 
 
16 
9 
 
17 
12 
 
6 
7 
Morphometric analyses of the 
pancreas (days of age): 
0 (first day post partum) 
(male mice) 
 
3 
 
 
4 
 
6 
 
 
 
 
 
 
 
Number of animals examined 
GLS001 GLS006 
 
 
Investigations after  
weaning 
 
 m
, w
t 
 m
, h
et
 
 f
, w
t 
 f
, h
et
 
 m
, w
t 
 m
, h
et
 
 m
, h
om
o 
 m
t, 
w
t 
 m
, h
et
 
 m
, h
om
o 
Ad libitum fed body weight 
(days of age): 
21 
30 
90 
175 
 
 
5 
5 
10 
10 
 
 
5 
5 
10 
10 
 
 
5 
5 
10 
10 
 
 
5 
5 
10 
10 
 
 
7 
7 
7 
7 
 
 
7 
7 
7 
7 
 
 
7 
7 
7 
7 
 
 
7 
7 
7 
7 
 
 
7 
7 
7 
7 
 
 
7 
7 
7 
7 
Fasting body weight  
(days of age): 
30 
85 
180 
 
 
10 
10 
10 
 
 
10 
10 
10 
 
 
10 
10 
10 
 
 
10 
10 
10 
 
 
7 
7 
7 
 
 
7 
7 
7 
  
 
7 
7 
7 
 
 
7 
7 
7 
 
Ad libitum fed blood glucose  
(days of age): 
21 
30 
90 
175  
 
 
5 
5 
10 
10 
 
 
5 
5 
10 
10 
 
 
5 
5 
10 
10 
 
 
5 
5 
10 
10 
 
 
7 
7 
7 
7 
 
 
7 
7 
7 
7 
 
 
7 
7 
7 
7 
 
 
7 
7 
7 
7 
 
 
7 
7 
7 
7 
 
 
7 
7 
7 
7 
Fasting blood glucose 
(days of age): 
30 
85 
180 
 
 
10 
10 
10 
 
 
10 
10 
10 
 
 
10 
10 
10 
 
 
10 
10 
10 
 
 
7 
7 
7 
 
 
7 
7 
7 
  
 
7 
7 
7 
 
 
7 
7 
7 
 
A 
B 
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OGTT (days of age): 
30 
85 
180 
 
10 
10 
10 
 
10 
10 
10 
 
10 
10 
10 
 
10 
10 
10 
 
7 
7 
7 
 
7 
7 
7 
  
7 
7 
7 
 
7 
7 
7 
 
ipITT (days of age): 
30 
90 
175 
 
4 
10 
10 
 
6 
10 
10 
 
5 
10 
10 
 
5 
10 
10 
 
5 
7 
7 
 
5 
7 
7 
  
5 
7 
7 
 
5 
7 
7 
 
Serum insulin (days of age): 
30 
85 
180 
 
10 
10 
10 
 
10 
10 
10 
 
10 
10 
10 
 
10 
10 
10 
 
7 
7 
7 
 
7 
7 
7 
  
7 
7 
7 
 
7 
7 
7 
 
Glucokinase activitya (90 days of 
age): 
 
2 
 
4 
 
2 
 
3 
 
4 
 
3 
 
2 
 
2 
 
2 
 
2 
Western blot analysis (pancreatic 
islets) a (90 days of age): 
 
2 
 
2 
 
2 
 
2 
 
 
     
Necropsy (days of age): 
210 
550 
 
4 
 
4 
 
4 
 
4 
 
4 
4 
 
4 
4 
 
 
3 
 
4 
 
 
4 
 
4 
Morphometric analyses of the 
pancreas (days of age): 
210 
550 
 
 
4 
 
 
4 
 
 
4 
 
 
4 
 
 
 
4 
 
 
 
4 
 
 
 
3 
   
a animals of both genders were matched for statistical analyses. 
3.1.2 Breeding strategy for linkage analysis 
GLS001 mice already underwent backcross breeding and linkage analysis in 
cooperation with the Institute of Experimental Genetics (Prof. Dr. Martin Hrabé de 
Angelis, Helmholtz Zentrum München, Neuherberg, Germany), whereas linkage 
analysis of the ENU strain GLS006 was part of the present study. The breeding 
strategy for linkage analysis of both strains has been described previously (Aigner et 
al. 2008). 
Briefly, the following breeding regime was applied for GLS006 mice: Three 
heterozygous male phenotypic mutants (mice that were considered diabetic 
according to their blood glucose values) on the inbred C3H genetic background were 
mated to C57BL/6J female mice to produce G1 hybrid offspring. At an age of 21±1 
day, G1 mice were screened for elevated blood glucose concentrations. At an age of 
60 days, 8 male G1 mice that were classified diabetic were backcrossed to C57BL/6J 
wild-type female mice. The resulting G2 progeny were also tested for elevated blood 
glucose concentrations. Tail tip biopsies from total number of 75 phenotypic mutants 
and 25 phenotypic wild-type mice were taken in duplicates and stored at -80°C.  
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Linkage analysis of 70 phenotypic mutant and 22 phenotypic wild-type mice was 
carried out in cooperation with the Institute of Institute of Experimental Genetics as 
previously described (Hrabé de Angelis et al. 2000). 
3.2 Identification of the causative mutation 
3.2.1 Fine mapping in GLS001 mice 
With the knowledge of the approximate chromosomal location of the causative 
mutation, fine mapping was carried out in GLS001 mice to further define the mutation 
position. For this purpose, 3 additional microsatellite markers, positioned in the 
previously defined chromosomal region and a fourth marker, indicating a not yet 
classified polymorphism in intron 7 of the glucokinase (Gck) gene, were applied. 
Genotype analysis of polymorphic markers was accomplished by Polymerase Chain 
Reaction (PCR), using DNA from 75 phenotypic mutant and 15 phenotypic wild-type 
GLS001 backcross G2 mice and 19 mice, derived from mating phenotypic mutant G2 
backcross mice. 
3.2.1.1 DNA isolation 
DNA isolation was performed after overnight digestion of tissue samples in 400 μl 
Master Mix in a heating block (Biometra TB1 Thermoblock, Whatman, Germany) at 
55°C. Undigested components were separated by centrifugation (Sigma 1K15, 
Sigma, Germany) for 2 minutes at 15,300 rpm. DNA was precipitated after transfer of 
the supernatant into a sterile 1.5 ml reaction cup (Eppendorf, Germany), by addition 
of 400 μl 100% isopropanol (Merck, Germany). The DNA pellet was washed twice in 
70% ethanol (Merck, Germany) by vortexing. Thereafter, the DNA pellet was dried at 
room temperature for approximately 10 minutes. DNA was resuspended in 50-200 μl 
1xTE buffer (according to the pellet size) and incubated for 1 hour at 55°C. To ensure 
complete DNA dissolution, the resuspended DNA was stored at 4°C for at least 24h 
before further investigation. 
Master Mix for DNA isolation 
 Cutting Buffer 375 μl 
 20% SDS (Roth, Germany)  20 μl 
 Proteinase K (20 mg/ml)  5 μl 
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Cutting buffer 
 1 M Tris/HCl, pH 7.5 (Roth, Germany) 2.5 ml 
 0.5 M EDTA, pH 8.0 (Sigma, Germany) 5.0 ml 
 5 M NaCl (AppliChem, Germany) 1.0 ml 
 1 M DTT (Roth, Germany) 250 µl 
 Spermidine (500 mg/ml, Sigma, Germany) 127 µl 
Ad 50 ml aqua bidest.; stored at 4°C 
 
TE buffer 
 10 mM Tris/HCl, pH 8.0 (Roth, Germany) 
 1 mM EDTA (Sigma, Germany) 
Stored at room temperature 
3.2.1.2 PCR amplification of the polymorphic sequences 
PCR Master Mixes were prepared as described in Table 3.2A. The Taq DNA 
polymerase was stored at -20°C until it was added to the Master Mix (Taq PCR 
Master Mix Kit, Qiagen, Germany). Primers were synthesised by Thermo Scientific, 
USA. Primer sequences were obtained from the National Center for Biotechnology 
Information (NCBI; http://www.ncbi.nlm.nih.gov/). One μl of the resuspended DNA 
and 19 μl of the respective PCR Master Mix were mixed on ice in PCR analysis cups 
(Kisker, Germany). PCR reactions were performed as specified below on a 
Biometra® Uno II Thermocycler (Biometra, Germany). Primer sequences and cycling 
conditions are stated in Table 3.2 A, B. DNA from C3H and C57BL/6J wild-type mice 
served as positive control, H2O was applied as quality control (no template control). 
PCR products were stored at 4°C (short term) or -20° (long term) until assayed. 
Table 3.2: PCR conditions (A) and primer sequences (B) for amplification of the 
polymorphic sequences. 
 
Master Mix PCR 1-4 PCR conditions  PCR 1-3 PCR 4 
Aqua bidest.            8.65 µl 
Q-solution             4.00 µl 
10x buffer              2.00 µl 
MgCl2                  1.25 µl 
dNTPs (1 mM)          1.00 µl 
Primer sense (2 µM)     1.00 µl 
Primer antisense (2 µM)  1.00 µl 
Taq Polymerase         0.10 µl 
 
1. Initial denaturation
2. Denaturation  
3. Annealing  
4. Extension   
5. Final extension   
6. Hold      
 
 
 5 min  94°C 
45 sec  94°C 
45 sec   
45 sec  72°C 
10 min 72°C  
∞       4°C 
 
 5 min  94°C 
50 sec  94°C 
50 sec   
75 sec  72°C 
10 min 72°C 
∞        4°C 
 
 
40 cycles 
35 cycles 
A 
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PCR Oligo name Sequence (5'→3') Annealing temp. 
Map 
positiona
D11Mit226_for AGG TGA ACT CTT TTG AAG TTT GTG 1 
D11Mit226_rev AAA GGA GTG ACT GAG AAA GAC ACC
60°C 8.8 Mb 
D11Mit2_for CCC CCA GCC TAC ACA CAG 2 
D11Mit2_rev GCT ATT TCT CAC AGA AAG GGG 
54°C 12.2 Mb 
D11Mit78_for GTG GGA GAA ACC TTT ACG CA 3 
D11Mit78_rev TCC TAG TGA CCA CAC TAA TTT GTG 
60°C 17.8 Mb 
Gck_17_for TCT TCA CTG CAC AGC TGC TCC 4 
Gck_18_rev AGA ACC AGC TCA CAG ATG GCT C 
62°C 5.9 Mb 
a Nucleotide positions refer to Mouse Genome Database (MGI; 
http://www.informatics.jax.org/) 
3.2.1.3 Gel electrophoresis 
PCR products were separated on 3% (PCR 1-3) and 4% (PCR 4) TBE agarose gels 
(UltraPureTM Agarose, Invitrogen, Germany) containing 10 µl/100 ml of a 1:10 diluted 
ethidium bromide stock solution (1%, Merck, Germany) in a gel electrophoresis 
chamber (Thermo Scientific Owl B2 EasyCastTM Mini Gel System, Thermo Scientific, 
USA). After filling the gel chamber with 1x TBE buffer, containing 9 µl/l ethidium 
bromide, each well was charged with 24 µl of a 1:5 mixture of PCR product and 6x 
loading dye. The pUC Mix Marker 8 (MBI Fermentas, Germany) served as molecular 
weight marker. Gel electrophoresis was run at 70 V (Biorad PowerPac 300, Bio-Rad, 
USA) for the first 10 minutes to enable uniform emission of PCR products from the 
wells. For the remaining time, electrophoresis was run at 120 V until achievement of 
the desired PCR product fragmentation (approximately 45-90 minutes, dependent on 
the respective PCR product length and the desired product fragmentation). The 
amplified products were visualised under UV light (Intas Gel Jet Imager, Intas 
Science Imaging Instruments GmbH, Germany), and a digital photograph was taken 
for documentation. 
10x TBE stock solution 
 Tris base (Roth, Germany) 108 g 
 Boric acid (Roth, Germany) 55 g 
 0.5 M EDTA, pH 8.0 (Normapur, Germany) 40 ml 
Ad 1000 ml aqua bidest. and autoclaved. Ready-to-use 1x TBE electrophoresis 
buffer was prepared by 1:10 dilution with aqua bidest.  
 
 
 
B 
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6x loading dye 
 Glycerine (Roth, Germany) 3 ml 
 Aqua bidest.  7 ml 
 Bromphenol blue (Roth, Germany) 1 spatula tip 
Aliquoted and stored at 4-8°C 
Optional: 6x DNA Loading Dye (MBI Fermentas, Germany) 
Genotypic distribution was determined (Fig. 3.1), and linkage between the diabetic 
phenotype and the analysed genotype for the respective polymorphic marker was 
statistically evaluated by chi square testing according to the equation illustrated 
below (Silver 1995). 
  
Figure 3.1. Genotypic differentiation (PCR 4) of GLS001 
mice. M: Fragment size marker: marker bands represent 
fragment sizes of 1118, 881, 692, 501 (and 489), 404, 331 bp 
(from top to bottom). PCR products from mice, displaying a 
heterozygous genotype (1, 2) result in two visible bands of 
different sizes, whereas the C3H (3) C57BL/6J (4) genotypes are 
distinguishable by the presence of a single band of respective 
size.  
Chi square testing of phenotypic linkage 
(obsr-exp)2 (obsp-exp)2χ2 = 
 exp 
+
exp 
 
χ2     = chi square value 
obsr = number of observed recombinant outcomes (sum of phenotypic mutant mice, 
heterozygous for the investigated polymorphic marker and phenotypic wild-
type mice, showing the genotype of the outcross strain (C57BL/6J)) 
exp = expected numerical genotypic distribution (50%) ((total number of animals-
number of animals that failed analysis)/2) 
obsp = number of observed parental outcomes (sum of phenotypic mutants, 
displaying the genotype of the outcross strain (C57BL/6J) and phenotypic 
wild-type mice, heterozygous for the corresponding marker) 
 
 
M    1    2    3    4    
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3.2.2 Candidate gene sequencing 
Sequence analysis of the candidate gene glucokinase (Gck) was performed on 
genomic DNA samples, isolated from tail tip samples. Additionally, DNase I -digested 
and reverse transcribed total hepatic RNA was applied. Liver tissue was obtained  
from mice, anaesthetised by intraperitoneal injection of 200 µl of ketamine/ xylacine 
mixture (1 ml 10% ketamine hydrochloride (Selectavet, Germany), 0.25 ml 2% 
Rompun (Bayer, Germany), 5 ml 0.9% NaCl) and killed by cervical dislocation. In 
GLS006 mice, tissue samples from 2 adult animals were obtained from each, 
phenotypic heterozygous and homozygous mutants and wild-type littermates. In 
GLS001 mice, breeding approaches led to the assumption that the homozygous 
mutation might be associated with perinatal or intrauterine death. Therefore, first 
sequence analysis was performed with neonatal offspring from mating heterozygous 
G2 backcross mice. Two animals which displayed a homozygous C3H genotype with 
the last polymorphic marker (positioned within the glucokinase gene) were classified 
as homozygous mutants and were therefore chosen for sequence analysis. Further, 
tissue samples from 2 adult animals were used for each phenotypic heterozygous 
mutants and wild-type controls on the C3H inbred genetic background. 
3.2.2.1 Sample preparation for RNA and DNA isolation 
DNA isolation 
DNA isolation from tail tips for sequence analysis included additional steps of RNase 
digestion and protein precipitation in order to achieve high quality DNA. Using the 
Wizard® Genomic DNA Purification Kit (Promega, Germany), DNA was extracted 
after overnight digestion of tissue samples in 620 µl Master Mix at 55°C, according to 
manufacturer’s instructions. For RNase digestion, 3 µl Ribonuclease A (RNase A (0.2 
U/µl); Roche, Germany) were added to each sample, mixed by inversion for 25 times, 
and incubated for 20 minutes at 37°C. Afterwards, 200 µl Protein Precipitation 
Solution® (Promega, Germany) were added. After centrifugation, DNA in the 
supernatant was yielded by precipitation with 600 µl 100% isopropanol (Merck, 
Germany). The DNA pellet was washed twice with 70% ethanol (Merck, Germany), 
dried and resuspended in 50-150 µl (according to the pellet size) Rehydration 
solution® (Promega, Germany) at 65°C for 1 hour. 
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Master Mix 
 Nuclei Lysis Solution® (Promega, Germany) 500 µl 
 0.5 M EDTA, pH 8.0 (Normapur, Germany) 120 µl 
 Proteinase K (20 mg/ml) 17.5 µl 
3.2.2.2 RNA isolation 
Total RNA from liver tissue of GLS001 and GLS006 mice was isolated by guanidium 
thiocyanate-phenol-chloroform extraction. Whole liver samples from neonatal 
GLS001 mice, stored in RNA-later® RNA stabilisation reagent (Ambion, Germany) at 
-80°C, were obtained from the IEG. Tissue samples of about 40 mg each were 
transferred into a sterile and RNase-free 2 ml reaction cup (Eppendorf, Germany), 
containing 1 ml TRIzol® Reagent (Invitrogen, Germany). Hepatic tissue was 
subsequently homogenised for 1 minute (level D: 23,500 rpm) using a Miccra-D8 
dispersing device (Art-Labortechnik, Germany). In the strain GLS006, 2 animals per 
phenotype (homozygous and heterozygous mutants and wild-type controls) were 
sacrificed under general anaesthesia (ketamine/xylacine; chapter 3.2.2) and 
approximately 40 mg liver tissue was stabilised in 1 ml TRIzol® Reagent. Samples 
were immediately homogenised for 1 minute on the highest level (25,000 rpm), using 
a Polytron PT 1200 E tissue homogeniser (Kinematica AG, Switzerland). To avoid 
cross contaminations, the dispersing aggregate was deterged in a series of: aqua 
bidest, 0.2 N NaOH, and aqua bidest. between the samples. Homogenates were 
stored at -80°C until assayed. RNA preparation was carried out according to the 
manufacturer’s instruction manual. Following reagents and equipments were used: 
Chloroform, 100% isopropanol, 75% ethanol (Merck, Germany), sterile, RNase-free 
filter tips (Peske, Germany) and sterile, RNase-free reaction cups. To avoid 
contamination with RNases, all glassware was sterilised for 12 hours at 180°C and all 
buffers, except for Tris-containing solutions, were prepared with RNase-free H2O 
(Invitrogen, Germany) or 0.1% DEPC-H2O. 
 
0.1% DEPC-H2O 
 DEPC (Sigma, Germany) 1 ml 
Dissolved overnight in 1000 ml H2O by stirring, autoclaved afterwards for 3 times and 
stored at room temperature 
 
The RNA pellet was resuspended in 30-100 µl RNase-free H2O (Invitrogen, 
Germany) (dependent on the pellet size) for 60 minutes on an Eppendorf 
Thermomixer 5436 (Eppendorf, Germany) at 55°C. Resuspended RNA was further 
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kept on ice (short term) or was stored at -80°C (long term) until further analysis. RNA 
purity and total RNA amount were determined spectrophotometrically, using a 
NanoDrop® ND-1000 Spectrophotometer (NanoDrop Technologies, USA). 
3.2.2.3 cDNA synthesis by reverse transcription of total hepatic RNA 
Potential DNA contaminations were removed by incubation of 5 µg total RNA with 10 
IU RNase-free DNase I (Roche, Germany) and 10x DNase I digestion buffer in a total 
reaction volume of 20 µl for 30 minutes at 37°C on an Eppendorf Thermomixer. 
Enzyme inactivation was carried out at 75°C for 10 minutes. 
10x DNase I digestion buffer 
 250 mM Tris-HCl, (pH 8.3) (Roth, Germany) 
 375 mM KCl (Merck, Germany) 
 15 mM MgCl2 (Merck, Germany) 
Sterile filtered, autoclaved and aliquoted, and stored at –20°C 
Four µl (1 µg) of the DNase I-digested RNA solution were applied for reverse 
transcription to cDNA, using M-MLV Reverse Transcriptase (M-MLV RT; Invitrogen, 
Germany), random primers (Invitrogen, Germany), and RNasin® RNase Inhibitor 
(Promega, Germany) in a reaction volume of 40 µl as stated in Table 3.3. 
Table 3.3: cDNA synthesis from total hepatic RNA using M-MLV Reverse 
Transcriptase. 
Step 1 Step 2 Step 3 
Add Master Mix 1 
  RNase free H20   16 µl 
  Random primers   2 µl 
  10 mM dNTPs     2 µl 
Add Master Mix 2 
  RNase free H20          2 µl
  5x first strand buffer      4 µl
  0.1 M DTT              4 µl
  RNasin® RNase Inhibitor  1 µl
Add Master Mix 3 
  5x first stand buffer  4 µl 
  M-MLV RT         1 µl 
¾ 65°C, 5 minutes 
¾ quick chill on ice 
¾ 25°C, 10 minutes 
¾ 37°C, 2 minutes 
¾ 37°C, 50 minutes 
¾ 75°C, 10 minutes 
¾ chill on ice 
 
The reverse transcription success, the integrity of the resultant cDNA, and the 
absence of DNA contamination were controlled by PCR, using exon-specific primers, 
positioned in exon 4 and 6 of the β-actin gene. Amplification of DNase I-digested and 
reverse transcribed RNA resulted in 613 bp PCR products, whereas the presence of 
genomic DNA was indicated by an additional band of 832 bp in size (Fig. 3.2). One µl 
of DNase I-digested, reverse transcribed RNA, RT¯ (DNase I digested, but not 
reverse transcribed RNA), and DNA controls were constituted in standard PCR 
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reaction batches, described in 3.2.1.2. Primers were synthesised by Thermo 
Scientific, USA. Cycling conditions and primer sequences (Höfer 2006) are stated in 
Table 3.4. 
Table 3.4: Cycling conditions and primer sequences for β-actin gene PCR. 
PCR conditions Oligo name Primer Sequence (5'→3') 
1.    4 min   94°C 
2.     1 min   94°C 
3.    1 min   60°C 
4.   90 sec   72°C 
5. 10 min   72°C  
6.  ∞        4°C 
 
β-actin sense 
β-actin antisense  
 
 
GGC ATC GTG ATG GAC TCCG 
GCT GGA AGG TGG ACA GTG AG 
 
 
PCR products were separated by gel electrophoresis on a 1.5% TBE agarose gel as 
described above (chapter 3.2.1.3). 
 
 
 
 
Figure 3.2: Exemplary gel electrophoresis of successfully DNase I-digested and 
reverse transcribed RNA after PCR-based amplification of 613 bp sequence of the β-
actin gene. 1: DNase I-digested and reverse transcribed RNA; 2: DNA; 3: RT¯ control 
(DNase I-digested, but not reverse transcribed RNA); 4: H2O; M: fragment size marker (pUC 
mix 8; MBI Fermentas, Germany); marker bands represent fragment sizes of 1118, 881, 692, 
501 (and 489), and 404 bp (from top to bottom). 
3.2.2.4 PCR amplification of the candidate gene 
Amplification of the complete Gck mRNA sequence from hepatic cDNA was 
performed with 5 pairs of primers, resulting in overlapping PCR products (PCR 1-5). 
The sizes of the resulting PCR products did not exceed 690 bp to allow reliable 
bidirectional sequencing. Due to alternate tissue–specific mRNA splicing, mammalian 
hepatic and β-cell Gck transcripts exhibit different sequences for exon 1 (Jetton et al. 
1994; Liang et al. 1991; Magnuson and Shelton 1989; Printz et al. 1993). Therefore, 
an additional primer pair was designed to amplify the whole first exon sequence of 
the pancreas-specific transcript (PCR 6). Primer pairs spanning exon 9-11 failed to 
hybridise to cDNA of GLS001 mice. Therefore, amplification of the positional 
sequence was carried out with genomic DNA (PCR 7 and 8). Furthermore, the Gck 
M                                 1                                     2             3          4     M 
36 cycles 
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promoter sequence was amplified, using genomic DNA samples from homozygous 
and heterozygous mutants and wild-type controls of both strains. All primers were 
chosen without computational assistance and were synthesised by Thermo Scientific, 
USA. 
PCRs were performed with total reaction volumes of 40 µl, containing 4 µl cDNA 
solution (100 ng) each (PCR 1-5) or 2 µl genomic DNA (refer to chapter 3.2.1.2). 
PCR reactions were run on a Mastercycler® Gradient (Eppendorf, Germany) or a 
Gene Amp® PCR System 9700 (Perkin Elmer, Germany) according to the cycling 
protocols illustrated in Table 3.5. 
Table 3.5: PCR conditions for amplification of the candidate gene (A), applied primer 
sequences and combinations and their expected product length (B). 
 
PCR 1-5 PCR 6 PCR 7 PCR 8 and 9 
1.   5 min   94°C 
2.  45 sec    94°C 
3.  45 sec    61°C 
4.  90 sec    72°C 
5.  10 min   72°C 
6.   ∞        4°C 
 5 min    94°C 
50 sec    94°C 
50 sec    64°C 
60 sec    72°C 
10 min   72°C 
 ∞        4°C 
  5  min   94°C 
50   sec    94°C 
50   sec    60°C 
100 sec    72°C 
10   min   72°C 
 ∞         4°C 
 5 min    94°C 
50 sec    94°C 
50 sec    60°C 
90 sec    72°C 
10 min   72°C 
 ∞        4°C 
 
PCR Oligo name Sequence (5'→3') Nucleotide positiona 
Product 
length 
(bp) 
Gck_1_for ACA CTC AGC CAG ACA GTC CTC 5' UTR 1 
Gck_2_rev ACC ACA TCC ATC TCA AAG TCC 599-579 
688 
2b Gck_7_for ATG GCT GTG GAT ACT ACA AGG 1-21 599 
Gck_3_for ACA TCG TGG GAC TTC TCC GAG 539-559 
3 
Gck_4_rev TGA TGC GCA TCA CGT CCT CAC 1213-1193 
675 
Gck_5_for ATC CTT AAC ATC CTG AGC ACT C 1042-1063 
4 
Gck_6_rev TCA CTG GCT GAC TTG GCT TGC 3' UTR 
498 
5/7c Gck_8_rev ATG GCA TCT GGG AAA CCT GAC 3' UTR 566/1048 
Gck_20_for AAG AGG AAG CTG TGG CTT CAA CC 5' UTR 
6 
Gck_21_rev AGG CAT AGA CAC TTA TAG GTG GC Intron 1 
287 
Gck_22_for AGC CGA TCC TGC TTG ATT CTC C Intron 9 
8 
Gck_24_rev TCT CTG AAT GTT TGT GGC CTG 3' UTR 
850 
Gck_25_for ATC TCC ACT ACC CAC AAG TCT G 5' UTR 
9 
Gck_26_rev TCC TAC AGG ATC GCA CTC ATC Intron 1 
599 
a Nucleotide positions according to NCBI GenBank accession nos. NM_010292 and 
NW_001030444, respectively. b Primer combinations for PCR 2 were Gck_7_for and 
Gck_2_rev. c Primer combinations used for PCR 5 and 7, respectively, included Gck_5_for 
and Gck_8_rev. 
36 cycles 
36 cycles 
40 cycles 
36 cycles 
A 
B 
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3.2.2.5 Purification of PCR products 
PCR products were separated from unbound dNTPs and primers by either direct on-
column clean-up, by microdialysis, or after gel electrophoresis.  
Microdialysis 
Purification of PCR products was performed with MF-Millipore Membrane Filters 
(#VSWP04700; Millipore, USA) (pore size: 0.025 µl). Twenty µl PCR product were 
pipetted on the membrane filter, floating on 0.25x TE buffer in a Petri dish (Neolab, 
Germany). The membrane filter was then gently stirred for 1 hour on an IKA colour 
squid IKAMAG® magnetic stirrer (IKA, Germany). Thereafter, the remaining droplet 
was removed from the floating membrane and transferred into a sterile, RNase-free 
reaction cup. 
On-column purification was carried out, using the High Pure PCR Purification Kit® 
(Roche, Germany) according to the manufacturers’ recommendations.  
In case of additional, non-specific product amplification, PCR products were purified 
after gel electrophoresis on a 1.5% TBE agarose gel. To avoid cross contaminations 
during band excision, every second well was charged with PCR products. Thereafter, 
gel electrophoresis was performed as described (chapter 3.2.1.3). Bands were 
visualised by irradiation in the UV part of the spectrum (UV-Transilluminator FLX 
20M; Biometra, Germany). The specific bands of predicted size were excised with a 
sterile surgical blade and were transferred into sterile, RNase-free 2 ml reaction 
cups. Gel slices were weighed (MJ-3000; YMC Co. Ltd., Japan), and DNA was 
extracted using the QIAquick® Gel Extraction Kit (Qiagen, Germany) according to the 
Kit manual. In order to enhance DNA yield, the final elution step was conducted 
twice. 
After purification, PCR products were kept on ice (short term) or at -20°C until 
assayed. DNA concentration of the amplificates was quantified, using a NanoDrop® 
ND-1000 Spectrophotometer (NanoDrop Technologies, USA). Further, DNA 
concentration was evaluated after gel electrophoresis with a Lambda DNA/EcoRI + 
HindIII concentration marker, 3 (MBI Fermentas, Germany) (chapter 9.4). 
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3.2.2.6 Sequence analysis 
According to the required DNA concentrations (Table 3.6), purified PCR products 
were diluted to an appropriate concentration with 1x TE, if necessary. The final 
reaction mixture for sequence analysis contained 5 µl of purified PCR product 
solution and 1 µl the corresponding Gck-specific primer (3 µM in 1x TE). Afterwards, 
PCR amplificates were sequenced bidirectionally (Sequencing service of the Gene 
Center, AG Blum (LMU Munich, Germany)).  
Table 3.6: DNA concentrations, required for sequence analysis (adapted from the 
Sequencing service of the Gene Center, AG Blum, LMU Munich, Germany. 
PCR product  length  Purification by gel extraction 
Purification by 
microdialysis 
600 bp  20-70 ng 15-45 ng 
900 bp  35-110 ng 30-60 ng 
1200 bp  50-140 ng 40-75 ng 
 
The resulting sequences were aligned with the Gck sequence of the mouse genome 
database (NM_023514 NM_010292 and NW_001030444), using the NCBI blast tool 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). The consequences of the identified genomic 
mutations on the glucokinase protein were evaluated by analysis of the deduced 
amino acid sequence (http://www.expasy.ch/tools/dna.html). The probability of an 
additional confounding mutation between the 2 polymorphic markers with the highest 
linkage was estimated for both strains according to the method of Keays et al. 
(http://zeon.well.ox.ac.uk/git-bin/enuMutRat), assuming a mutation rate of 1 in 1 Mb 
(Keays et al. 2006). 
3.3 Genotyping of the identified mutations  
3.3.1 Restriction fragment length polymorphism (RFLP) analysis in GLS001 mice 
To establish genotyping of GLS001 mice by restriction fragment length polymorphism 
(RFLP) analysis, the identified mutation and flanking sequences were queried by the 
NEBcutter V2.0 tool, provided by New England Biolabs, UK 
(http://tools.neb.com/NEBcutter2/). The causative mutation was identified to create a 
novel restriction site for the restriction endonuclease BstYI (recognition site 
RGATCY). Therefore, primer pairs (synthesised by Thermo Scientific, USA) were 
designed to amplify a 343 bp fragment of the affected DNA sequence including the 
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mutation (Table 3.7). Incubation of PCR products with BstYI was predicted to result 
in restriction of the mutant allele into 2 fragments of 200 and 143 bp in size, whereas 
the wild-type allele remained unrestricted. PCR reaction was conducted with 1 µl 
DNA samples in a total reaction volume of 20 µl (chapter 3.2.1.2) in a Mastercycler® 
Gradient (Eppendorf, Germany) under the cycling conditions stated in Table 3.7. 
Table 3.7: PCR conditions and primer sequences for genotyping of GLS001 mice. 
PCR conditions  Oligo name Sequence (5'→3') 
1.  5   min   94°C 
2.  50 sec    94°C 
3.  50 sec    62°C 
4.  80 sec    72°C 
5.  10 min   72°C 
6.   ∞        4°C 
 
 
 
 
 
 
 
Gck_3_for  
Gck_16_rev 
 
ACA TCG TGG GAC TTC TCC GAG 
AGG CCT GTT CTG ACT GGC TC 
 
PCR products were stored at 4°C (short term) or at -20°C (long term) until assayed. 
The endonuclease reaction mixture contained 12 µl Master Mix and 12 µl PCR 
product each. The endonuclease was kept on -20°C until added to the Master Mix. 
The restriction digestion was carried out at a constant temperature of 60°C for 40 
minutes in a Mastercycler® Gradient (Eppendorf, Germany). Afterwards, digested 
PCR products were run on a 3% TBE agarose gel. 
Endonuclease digestion Master Mix 
 Aqua bidest. 9.1 µl 
 NEB buffer 2 (New England Biolabs, UK)  2.4 µl 
 BstYI (10,000 U/ml) (New England Biolabs, UK)  0.5 µl 
3.3.2 Amplification refractory mutation system PCR (ARMS PCR) in GLS006 mice 
NEBcutter query of the mutant sequence in GLS006 mice did not reveal a suitable 
restriction site for commercially available restriction endonucleases. Thus, for allelic 
differentiation of GLS006 mice, an allele-specific PCR (Amplification Refractory 
Mutation System PCR; ARMS PCR (Newton et al. 1989)) was designed. The 
principle of an ARMS PCR is the selective amplification of either the wild-type or the 
mutated allele by allele-specific inner primers, bearing either the reference or the 
mutant base at their 3'-end. The insertion of an additional mismatch, at nt 3 of the 3'-
end is predicted to increase primer specificity for the distinct alleles. If possible, 
ARMS PCR should be performed in a single reaction (Single Tube Allele Specific 
(STAS) PCR). Under established PCR conditions, the distinct inner primers 
recognise the allelic variation with their 3' nucleotide and, together with the 
35 cycles 
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corresponding outer primer, located at different distances from the mutation, 
selectively amplify sequences of different size. Furthermore, an additional product of 
both external primers, independent of the prevailing genotype, is amplified as PCR 
control (Zinovieva et al. 1996). The product of the outer primers in GLS006 mice had 
a length of 343 bp, whereas the genotype-specific products displayed a total length 
of 238 bp (for the wild-type allele) and 147 bp (for the mutant allele) (Fig. 3.3).  
 
Figure 3.3: Schematic illustration of allele-specific primer hybridisation in GLS006 
mice. A: Outline of both external (Ext_1 and Ext_2) and internal (Int_1 and Int_2) primers 
and the corresponding product lengths. B: Formation of a PCR product depended on the 
genotype: The mutation-specific primer (red, Int_2) failed to hybridise to the wild-type allele, 
whereas a PCR product resulted from wild-type specific (blue, Int_1) primer binding, and vice 
versa for the mutant allele. The appearance of a PCR product of both external primers 
(Ext_1 (orange) and Ext_2 (green)) is genotype-independent. Italic letters outline the position 
of the mutation (W, blue = reference nucleotide; M, red = mutated base); bold letters mark 
the auxiliary introduced mismatch. C: Predicted appearance of genotype-specific bands after 
gel electrophoresis. Wt = wild-type; het = heterozygous mutant; homo = homozygous mutant. 
A 
B C 
wild-type allele 
mutant allele 
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STAS PCR was carried out in a Mastercycler® Gradient (Eppendorf, Germany), using 
20 µl reaction volumes, containing 1 µl sample in 19 µl PCR Master Mix. The, 
respective cycling protocol is stated in Table 3.8. PCR products were separated 
according to their size by gel electrophoresis on a 3% TBE agarose gel with a 
GeneRuler™ 100 bp Plus DNA Ladder (Fermentas, Germany) as fragment size 
marker. 
Table 3.8: PCR Master Mix and cycling conditions for STAS PCR in GLS006 mice. 
 
 
 
 
 
 
 
 
External primers (Primers 1): Gck_3_for (Ext_1); Gck_16_rev (Ext_2) (refer to 
chapter 3.3.1) 
Internal primers (Primers 2): Primers were obtained from Eurofins MWG Operon  
(Germany) 
 Gck_1_int (antisense):  5’- TGC CGA CCT CAC ATT GGC AGT -3’ a 
 Gck_2_int (sense): 5’- TGA TCT CCT GCT ACT ATG ACG T -3’ b 
a wild-type specific; b mutation specific 
 
3.4 Ex vivo studies of functional consequences of the causative 
mutations 
3.4.1 Quantification of glucokinase enzyme activity 
Since strategies for direct measurement of glucokinase enzyme have not yet been 
developed, an indirect fluorometric coupled assay was performed to quantify 
glucokinase activity in liver homogenate of 90-day-old GLS001 and GLS006 mice. 
Based on the phosphorylation of glucose by glucokinase enzyme to glucose-6-
phosphate (G6P), which is in turn again metabolised by glucose-6-phosphate 
PCR Master Mix  Cycling conditions  
Aqua bidest               3.65 µl
Q-solution                4.00 µl
10x buffer                 2.00 µl
MgCl2                     1.25 µl
dNTPs (1 mM)             1.00 µl
Primer 1 sense (2 µM)      0.50 µl
Primer 1 antisense (2 µM)   0.50 µl
Primer 2 sense (2 µM)      3.00 µl
Primer 2 antisense (2 µM)   3.00 µl
Taq Polymerase            0.10 µl
 
 
1.  5 min    94°C 
2.  50 sec   94°C 
3.  50 sec   57°C 
4.  80 sec   72°C 
5.  10 min  72°C 
6.   ∞       4°C 
 
36 cycles 
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dehydrogenase (coupled to the reduction of nicotinamide adenine 
dinucleotidephosphate (NADP+)) into 6-phophogluconate (Fig. 3.4), glucokinase 
activity was evaluated by spectrophotometrical quantification of the turnover rate of 
NADP+ to NADPH in the presence of different glucose concentrations and excess 
glucose-6-phosphate dehydrogenase (G6PD) (Grupe et al. 1995; Hara et al. 1986; 
Trus et al. 1981).  
Figure 3.4: Schematic diagram of the first step of glycolysis, catalysed by glucokinase 
enzyme and the following downstream reactions, enabling indirect quantification of 
glucokinase activity. 
Complicating assay specifications represent the coincident presence of other 
hexokinases, catalysing the identical reaction and impeding therefore separate 
quantification of glucokinase activity. However, the high affinity of hexokinases for 
glucose leads to their saturation already at low glucose concentrations (Bell et al. 
1996). The kinetic property of hexokinases can be availed to selectively quantify 
glucokinase activity by assay performance in the presence of either low glucose 
concentrations (0.03-0.5 mM; to quantify hexokinase phosphorylation activity) or by 
applying glucose concentrations in a range of 6-100 mM, where hexokinases are 
predicted to minor contribute to glucose phosphorylation activity of the low affinity 
glucokinase enzyme. In order to exclude hexokinase contribution, the maximal 
reaction velocity (Vmax) for hexokinases, calculated by means of the particular 
reaction velocities in presence of the respective minor glucose concentrations, was 
subtracted from glucose phosphorylation velocities, determined by employing high 
glucose concentrations. The assay was performed according to a modified protocol 
adapted from Liang et al. (Liang et al. 1990). 
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3.4.1.1 Tissue sample preparation 
Ad libitum fed mice were sacrificed under general anaesthesia (ketamine/xylacine 
mixture; 3.2.2) by cervical dislocation and liver samples of approximately 20 mg 
weight (weighed on a Mettler AE200 Electronic Analytical Balance, Mettler-Toledo 
Intl. Inc., Germany) were obtained. Tissue samples were immediately transferred into 
2 ml reaction cups, containing 1 ml ice-cold 1x Homogenisation Buffer, and were 
homogenised for 1 minute with a Polytron PT 1200 E tissue homogeniser 
(Kinematica AG, Switzerland) at the highest level (25,000 rpm). Homogenates were 
subsequently sonicated by 7 strokes <1s each (Branson sonifier cell disruptor B15, 
Branson Ultrasonic Corporation, USA). Thereafter, tissue sonicates were centrifuged 
(75 minutes, 15,300 rpm at 4°C) and kept on ice until further assayed. 
10x Homogenisation Buffer 
 KCl (Roth, Germany) 820 mg 
 K2HPO4 (Merck, Germany) 348 mg 
 DTT (Roth, Germany) 77 mg 
 EDTA (Sigma, Germany) 29 mg 
Ad 10 ml aqua bidest.; stored at 4°C and diluted 1:10 to prepare ready-to-use 1x 
Homogenisation Buffer 
3.4.1.2 Work flow of glucokinase activity determination 
Glucose phosphorylation by glucokinase was initiated by addition of 500 µl Reaction 
Master Mix to 20 µl liver homogenate. The reaction mixture was incubated at 30°C 
for 35 minutes. A total number of 11 glucose concentrations were applied, covering 
either the low glucose range (0.5, 0,25, 0.125, 0.06, and 0.03 mM) or the high 
glucose spectrum (100, 50, 25, 12, and 6 mM). Each reaction series included a 
reaction blank with H2O instead of glucose. The reaction was finally stopped by pH 
alteration via addition of 480 µl 1M NaHCO3 pH 9.4 and sample mixtures were 
transferred into disposable semi-micro PMMA cuvettes (Neolab, Deutschland). 
Relative absorbance of each reaction was measured at a wavelength of 340 nm after 
reaction blank calibration, using a SPEKOL 1500 UV/vis spectrophotometer (Analytic 
Jena AG, Germany). 
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Reaction Buffer (prepared freshly) 
 KCl (Roth, Germany) 298 mg 
 β-mercaptoethanol (Sigma, Germany) 40.3 µl 
 MgCl2 (Merck, Germany) 28 mg 
 BSA (Sigma, Germany) 20 mg 
 NADP+ (AppliChem, Germany) 15 mg 
 ATP (Sigma, Germany) 110 mg 
Ad 20 ml 100mM Hepes pH 7.8; kept on ice until assayed 
 
Glucose stock solutions 
High glucose: 250 mM 
 α-D-glucose (Sigma, Germany) 0.45 g 
Ad 10 ml aqua bidest.; stored at 4°C (short term) or at -20°C (long term) 
Low glucose: 1.25 mM 
 250 mM stock solution 250 µl 
Ad 500 ml aqua bidest. 
 
Ready-to-use glucose solutions were prepared by serial 1:2 dilution of the 
corresponding stock solutions with aqua bidest. (exception: 12 and 0.06 mM glucose 
solutions were prepared by 48:100 dilutions of 25 and 0.125 mM glucose solutions, 
respectively). All glucose containing reagents were stored at 4°C (short term) or at     
-20°C (long term). 
Glucose-6-phosphate dehydrogenase (G6PD) solution (prepared freshly) 
 G6PD (1000 U/ml) (Roche, Germany) 20 µl 
¾ Centrifuge at 10,000 rpm for 45 minutes, 4°C 
¾ Discard the supernatant, resuspend with 250 µl ice-cold aqua bidest. and mix 
gently by pipetting 
¾ Dilute 1:10 with ice-cold aqua bidest. (200 µl resuspended G6P + 1800 µl aqua 
bidest.). Assay dilution contains 8 U/ ml G6PD and is kept on ice until assayed 
 
Reaction Master Mix 
 Reaction buffer 500 µl 
 High/Low glucose solution/aqua bidest. 400 µl 
 G6PD solution 100 µl 
Immediately applied for assay complementation 
 
The reaction velocities per time unit (minutes) in the presence of distinct glucose 
concentrations were calculated according to the Beer-Lambert law, assuming a coat 
thickness of 1 mm for the applied cuvettes and a molar decadic extinction coefficient 
(ε) for NADPH of 6.2 L×mmol-1. The reaction velocities V for glucokinase were 
obtained by subtracting the maximal velocity (Vmax) for hexokinase from the reaction 
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velocities, observed at the 5 high glucose concentrations. As the high affinity 
hexokinases follow Michaelis Menten kinetics, the Vmax and Michaelis constant (Km) 
for hexokinases were obtained after plotting reaction velocities at low glucose 
concentrations vs. the respective substrate concentrations. Using a non-linear 
regression curve fit tool, Km and Vmax were calculated according to the Michaelis-
Menten equation (GraphPad Prism 3.0 (GraphPad Software, USA)): 
Vmax × [S]V = Km + [S] 
 
V = Specific activity/substrate turnover rate in presence of the respective [S] 
[S] = Substrate concentration 
Vmax = Maximal reaction velocity 
Km = Michaelis constant 
 
Since the absence of allostericity and cooperativeness represent prerequisites for the 
applicability of the Michaelis-Menten equation, kinetic characteristics of the positive 
cooperative behaviour displaying allosteric glucokinase enzyme were determined, 
applying the Hanes-Woolf plot. Performing this graphic application, the ratio of the 
initial substrate concentrations [S] (high glucose fraction) to the reaction velocity v is 
plotted against the respective [S]. Vmax and S0.5 (glucose concentration that is needed 
to achieve the half-maximal rate of phosphorylation; S0.5 ≙ Km in Michaelis-Menten 
equation) were calculated according to the Hanes-Woolf transformation of the 
Michaelis-Menten equation after data extrapolation of the linear portion of the plotting 
curve by best-fit linear regression adaption (GraphPad Prism 3.0 (GraphPad 
Software, USA)). 
[S] S0.5 + [S]
V = Vmax 
 
V = Specific activity or turnover in presence of the respective [S] 
[S] = Substrate concentration 
Vmax = Maximal reaction velocity 
S0.5 = Equivalent to Michaelis constant 
All kinetic data were referred to the total protein content in the corresponding liver 
homogenate, determined by Bradford method (chapter 3.4.1.3). 
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3.4.1.3 Determination of protein contents 
Total protein amounts per µl liver sonicate were determined by Bradford method. 
From the initial standard (1% BSA (Sigma, Germany) in phosphate buffered saline 
(PBS)), a serial 1:2 dilution was prepared in duplicates in a NUNC™ 96-well Optical 
Bottom Plate (Thermo Fisher Scientific (Nunc GmbH & Co. KG), Germany). Steady 
state concentrations contained 25, 12.5, 6.25, 3.13, 1.56, 0.78, 0.39, 0.20 µg BSA. 
One µl of the sample was added to 199 µl PBS in the first well of the plate, and 
diluted 1:2 in PBS in the adjacent well. Reaction was initiated by addition of 100 µl 
40% Bradford reagent (Bio-Rad, Germany). After an incubation time of 5 minutes, 
absorbance at a wavelength of 595 nm was determined spectrophotometrically by a 
plate reader ((SUNRISE, Tecan, Germany) and the corresponding software 
(Magellan 2, Tecan, Germany). 
Phosphate buffered saline (PBS) 
 NaCl (AppliChem, Germany) 7.95 g 
 Na2HPO4 (Roth, Germany) 1.15 g 
 KCl (Merck, Germany) 0.20 g 
 KH2PO4 (AppliChem, Germany)  0.20 g 
Ad 1,000 ml distilled water 
3.4.2 Determination of glucokinase transcript abundances by quantitative real-time 
PCR 
Real-time PCR was performed with reverse transcribed RNA, isolated from neonatal 
heterozygous and homozygous GLS001 mice and wild-type littermates on a 7900HT 
Fast Real-Time PCR System with Fast 96-Well Block Module TaqMan ABI 7900 
Sequence Detection System® (Applied Biosystems, USA) and SDS Software v2.2.2.  
Primer pairs for amplification of the target gene (Gck) and the selected reference 
(housekeeping) genes β-actin (Actb) (Onishi et al. 2007), mitochondrial ribosomal 
protein S9 (Mrps9) (Herbach et al. 2009), 18S ribosomal RNA (18s rRNA) (Rohrl et 
al. 2008), and glyceraldehyde-3-phosphate dehydrogenase (Gapdh) (Siner et al. 
2007) were chosen by Primer Express version 3.0 (Applied Biosystems), and queried 
by NCBI Blast software (http://blast.ncbi.nlm.nih.gov/Blast.cgi) (Table 3.9). Prior to 
application to quantitative real-time PCR, the amplification efficiencies of all primers 
were tested as described in chapter 9.5. 
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3.4.2.1 Tissue sample preparation, RNA isolation and cDNA synthesis 
Mice were sacrificed by decapitation and hepatic tissue samples of approximately 30-
40 mg each were immediately transferred into sterile 2 ml reaction cups, containing 1 
ml TRIzol® Reagent. Tissue sample procession and RNA isolation was accomplished 
as described in chapter 3.2.2.2 and 800 ng total hepatic RNA were reverse 
transcribed to cDNA in a final volume of 40 µl as stated in chapter 3.2.2.3. 
3.4.2.2 Quantitative real-time PCR performance 
All reactions were performed in duplicates in a total reaction volume of 25 µl, 
comprising 2 µl (40 ng) cDNA in 23 µl Master Mix. Quantitative real-time PCR Master 
Mixes contained SYBR® Green (SensiMixPlus SYBR, Quantace Ltd, UK). For each 
target, sample duplicates including H2O instead of the cDNA template, served as no 
template controls (NTC). All samples belonging to corresponding groups to be 
compared were run on identical plates. As primer pairs, specific for the internal 
reference transcript of 18s rRNA and Gapdh did not cross intron-exon assemblies, 
DNase I - digested but not reverse transcribed RNA (RT¯) samples were run 
simultaneously with the cDNA (RT+) samples and the NTCs, to evaluate genomic 
DNA contamination. The prepared reaction plates (ABI PRISM® 96-Well Optical 
Reaction Plate; Applied Biosystems, USA) were covered with MicroAMP™ Optical 
Adhesive Films (Applied Biosystems, USA) and were then inserted into the Fast 96- 
Well Block Module of the real-time PCR instrument. After an initial hold of 10 minutes 
at 95°C, the samples were cycled 36 times at 95°C for 15 seconds, at 60°C for 30 
seconds, and at 72°C for 30 seconds with a final dissociation step at the end of the 
run. Identical threshold lines were manually adjusted in the exponential phase of 
amplification for all runs, designated to be compared. Comparison of expression 
levels of the target transcript (Gck) between the genotype groups was accomplished 
by relative quantification of the achieved transcript abundance using the 2-ΔCT method 
(Cohen and Kretzler 2003). After the mean CT (= threshold cycle) for duplicate 
measurements of each sample was calculated for both the target (Gck) and the 
internal reference transcripts, the target transcript abundances of each sample, 
relative to the expression of the reference transcripts were determined. Subtracting 
the mean CT value of the Gck transcript from the mean CT value of the respective 
reference transcript revealed the corresponding ΔCT value (ΔCT = mean CT (reference 
transcript) - mean CT (target transcript)). Transcript abundance of the target 
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transcript, normalised to reference transcript expression were defined as 2-meanΔCT 
copies of housekeeper transcripts. The means of 2-ΔCT values of all samples of the 
respective genotype groups were compared (mutants vs. wild-type mice; 
homozygous vs. heterozygous mutants), using a two-tailed unpaired Student’s t-test. 
 
SYBR Master Mix 
 SensiMixPlus SYBR 12.5 µl 
 RNase-free H2O (Invitrogen, Germany) 8.5 µl 
 Primer sense (5µM) 1 µl 
 Primer antisense (5µM) 1 µl 
 
Table 3.9: Primer sequences, applied for amplification of the target and reference 
transcripts. 
Gene symbol/NCBI 
accession ID 
Primer 
direction 
Sequence (5'→3') Product 
length 
sense CGA CCG GAT GGT GGA TGA Gck 
(NM_010292) antisense TCA TTG GCG GAA AGT ACA TGG 
79 bp 
sense GTA ACC CGT TGA ACC CCA TT 18s rRNA 
(XR_034450) antisense CCA TCC AAT CGG TAG TAG CG 
151 bp 
sense TGT GTC CGT CGT GGA TCT GA Gapdh  
(NM_008084) antisense CCT GCT TCA CCA CCT TCT TGA T 
84 bp 
sense GCT CTT TTC CAG CCT TCC TT Actb 
 (NM_007393) antisense AGG TCT TTA CGG ATG TCA ACG 
100 bp 
sense CCA TCA CAC AGG ACA GAG AAC AGT Mrps9 
(NM_023514) antisense CTC CCT CCC CCG GAG ACT 
97 bp 
3.4.3 Western blot analysis 
Western blot analyses were performed with isolated pancreatic islets from 90-day-old 
male and female heterozygous mutant GLS001 mice and wild-type littermates with 
regard to glucokinase and the apoptosis marker caspase-3. 
3.4.3.1 Isolation and preparation of pancreatic islets 
Two GLS001 mice per genotype and sex were anaesthetised by intraperitoneal 
injection of 200 µl of ketamine/ xylacine mixture (chapter 3.2.2), and sacrificed by 
cervical dislocation. After abdominal incision, the pancreas, the bile duct and its 
intestinal orifice were exposed. The bile duct was ligated close to the liver and the 
small intestine was clamped on both sides of the bile duct orifice by artery forceps to 
exclude collagenase solution efflux into the intestine. A total volume of 1.8 ml 
collagenase solution was injected into the pancreas after cannulation of the bile duct 
via the small intestine by a winged infusion set (Venofix®, B.Braun, Germany). The 
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bloated pancreas was cautiously removed from the adjacent tissue and transferred 
into a 15 ml screw-cap centrifuge tube (TTP AG, Switzerland), containing 3.75 ml 
perfusion solution. Immediately prior to digestion, 3.2 ml collagenase solution were 
added, and pancreatic tissue was digested for at least 20 minutes at 37°C under 
occasional gently agitation. The digested pancreas was conveyed into a Petri dish 
(Neolab, Germany), filled with ice cold 1x Hank’s with 0.3% BSA to stop the digestion 
reaction. During the ongoing procedure steps, all assay components and isolated 
islets were kept on ice. After digestion, all visible islets (at least 250) were hand 
picked under a stereomicroscope (Stemi DV4, Zeiss, Germany; magnification x32) 
(Fig. 3.5) into a 1.5 ml reaction tube and were centrifuged for 1 minute at 1,000 rpm 
(1K15, Sigma, Germany). Subsequently, the supernatant was discarded and 
pancreatic islets were resuspended in 1 µl protein extraction buffer/6 islets. Cell 
membranes were destroyed by freezing at -80°C, thawing on ice for 30 minutes, 
followed by sonication (7 strokes <1 s each by a Branson sonifier cell disruptor B15 
(Branson Ultrasonic Corporation, USA)), and lysing on ice for another 30 minutes. 
After centrifugation (5 minutes, 5,000 rpm), the supernatant was separated, and 
stored at -20°C until assayed. 
  
Figure 3.5: Generic appearance of hand picked pancreatic islets after collagenase I-
digestion. Under transmitted light (A), pancreatic islets occurred of light brown colour, 
whereas under reflected light on a black background (B), islets usually represented opaque 
structures with discrete granulation. 
 
 
 
 
B 
500 µm 
A 
500 µm 
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4x Hank’s solution 
 NaCl (AppliChem, Germany) 16.00 g 
 HEPES (Sigma, Germany) 4.76 g 
 KCl (Roth, Germany) 0.80 g 
 NaHCO3 (Merck, Germany) 0.70 g 
 KH2PO4 (Roth, Germany) 0.12 g 
 Na2HPO4 (Merck, Germany) 0.12 g 
 MgSO4 (Merck, Germany) 0.40 g 
 CaCl2 (Merck, Germany) 0.37 g 
 distilled water 500 ml 
Stored at 4°C 
 
1x Hank’s solution 
 Hank’s 4x 375 ml 
 α-D-Glucose (Sigma, Germany) 0.60 g  
Adjust to pH 7.25 and keep on ice 
 
1x Hank’s with 0.3% BSA 
 Hank’s 1x 500 ml  
 BSA (Sigma, Germany) 1.5 g 
 
Perfusion solution 
 Hank’s 1x 20 ml 
 CaCl2 1 M (Merck, Germany) 47 µl 
 Hepes 1 M (Sigma, Germany) 500 µl 
Kept on ice 
 
Collagenase solution 
 Perfusion solution 10 ml 
 Collagenase type 1 (#C0130, Sigma, Germany) 20 mg 
Kept on ice  
 
Protein extraction buffer 
 200 mM NaCl/Tris pH 7.6 100 µl 
 Igepal CA 630 (ICN Biomedicals GmbH, Germany) 5 µl 
 300 mM EDTA 10 µl 
 300 mM EGTA 10 µl 
 100 mM PMSF 10 µl 
 200 mM NaOV 10 µl 
 1M DTT 1 µl 
 25x Complete 40 µl 
 Aqua bidest. 814 µl 
 
Stock solutions 
200 mM NaCl/Tris pH 7.6: 
 Tris base(Roth, Germany) 1.58 g 
 NaCl (AppliChem, Germany) 7.31 g 
Dissolved in 30 ml aqua bidest and adjusted to pH 7.6; ad 50 ml aqua bidest 
 
300 mM EDTA: 1.12 g EDTA (Sigma, Germany) ad 10 ml aqua bidest 
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300 mM EGTA: 1.41 g EDTA (Sigma, Germany) ad 10 ml aqua bidest. 
 
100 mM PMSF: 17.4 mg PMSF (Sigma, Germany) dissolved in 1 ml isopropanol 
(Merck, Germany) and stored at -20°C.  
 
200 mM NaOV: 0.92 g NaOV (ICN Biomedicals GmbH, Germany) dissolved in 20 ml 
distilled water and adjusted to pH 10 until the solution turns yellow. Solutions were 
reiterated boiled and cooled down on ice until remaining clear and of stable pH. After 
addition of 22.5 ml aqua bidest., the solution was aliquoted and stored at -20°C. Prior 
to use, solutions were boiled for 10 minutes on a heating block to remove 
crystallisation. 
 
1 M DTT: 77.0 mg DTT (Roth, Germany) ad 500 µl aqua bidest. 
 
25x Complete: Complete Protease Inhibitor Cocktail Tablets (Roche, Germany) were 
dissolved according to manufacturer’s instructions 
 
3.4.3.2 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGEs were performed with islet samples on 10 and 12% separating SDS gels 
(Table 3.10). The respective separating gels were poured into the intercept of 2 glass 
plates, clamped in a Mini-Protean III® gel casting chamber (Bio-Rad, Germany), and 
were immediately covered with isopropanol. After a polymerisation time of 45 
minutes, isopropanol was drained and the stacking gel was casted onto the 
separating gel. A 10-well-comb was immediately inserted into the fluid stacking gel to 
create sample wells, and the stacking gel was allowed to polymerise for additional 45 
minutes. Thereafter, the comb was removed, and the gel was placed into an 
electrophoresis cell (Protean III®, Bio-Rad, Germany), which was then filled to the top 
of the inner cell with running buffer. About 1 half of the remaining buffer was 
disseminated in the outer cell of the electrophoresis chamber.  
Protein content in the respective islet sonicates was determined by Bradford method 
(chapter 3.4.1.3). Islet sonicates were diluted to a total concentration of 20 µg 
protein/20 µl with at least equal volumes of Sample Denaturation Buffer (the 
maximum final volume did not exceed 20 µl). After protein denaturation for 10 
minutes at 100°C, wells were charged and gel electrophoresis was run at 200 V 
(Biorad PowerPac 300, Bio-Rad, USA) until desired protein separation was achieved. 
A prestained molecular weight standard (Precision Plus ProteinTM, Bio-Rad, 
Germany) was applied to indicate proceeding protein separation during 
electrophoresis. 
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Reducing sample buffer 
 Sample buffer, stock solution 475 µl 
 β-mercaptoethanol (Sigma, Germany) 25 µl 
 
Sample buffer, stock solution 
 Tris/HCl 0.5 M, pH 6.8 1.3 ml 
 SDS 10% (Sigma, Germany) 2 ml 
 Glycerol (Merck, Germany) 1 ml 
 Bromphenol blue 0.05% (Merck, Germany) 0.6 ml 
 Aqua bidest. 4.8 ml 
 
Table 3.10: Composition of the distinct SDS-gels. 
Separating gel Compound 
10% 12% 
Stacking 
gel 
Aqua bidest. 4.17 ml 3.5 ml 3.05 ml 
Tris HCl (1.5mM, pH 8.8) 2.50 ml 2.50 ml - 
Tris HCl (0.5mM, pH 6.8) - - 1.25 ml 
10% SDS (Sigma, Germany) 0.1 ml 0.1 ml 0.1 ml 
30% acrylamide (Roti Phenol®, Roth, Germany) 3.33 ml 4.00 ml 0.65 ml 
APS 10% (Merck, Germany)* 0.05 ml 0.05 ml 0.05 ml 
TEMED (Roth, Germany)* 0.01 ml 0.01 ml 0.01 ml 
*added immediately before casting of the gels 
Tris/HCl 0.5 M, pH 6.8 
 Tris base (Roth, Germany) 6.06 g 
Ad 100 ml aqua bidest. 
Adjust to pH 6.8 with 1N HCl (Merck, Germany) 
 
Tris/HCl 1.5 M, pH 8.8 
 Tris base (Roth, Germany) 18.5 g 
Ad 100 ml aqua bidest. 
Adjust to pH 8.8 with 1 N HCl (Merck, Germany) 
 
Running buffer, stock solution 
 Tris base (Roth, Germany) 30.3 g 
 Glycine (Merck, Germany) 144.0 g 
Ad 1,000 ml aqua bidest. 
 
Running buffer 
 Stock solution 40 ml 
 SDS 10% (Sigma, Germany) 4 ml 
Ad 400 ml aqua bidest. 
 
3.4.3.3 Blotting 
After gel electrophoresis, SDS-gels were positioned onto a nitrocellulose membrane 
(Schleicher&Schuell, Germany), humidified with Towbin buffer. The gel-covered 
membrane was placed between 3 layers of absorbent paper and fibre pads each side 
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(both steeped in Towbin buffer) in a gel holder cassette. The cassettes were placed 
into the electrode module, which was then inserted in the buffer tank, containing ice 
cold Towbin buffer, a magnetic stir bar and a frozen cooling unit (Mini Trans-Blot Cell, 
Biorad, Germany). The transfer of the separated proteins was run for 90 minutes at 
100 V on a magnetic stirrer (IKA, Germany). Thereafter, the nitrocellulose membrane 
was washed in Tris buffered saline (TBS, pH 8.3). 
Towbin buffer 
 Tris base (Roth, Germany) 3.03 g  
 Glycine (Merck, Germany) 14.40 g 
 Methanol (neoLab, Germany) 200 ml 
 Distilled water 800 ml 
Stored at 4°C 
 
3.4.3.4 Western blot analysis 
Detection of specific antigens was performed by Western blot analysis. Washing and 
incubation procedures were accomplished under consequent agitation of the 
membranes on a tumbling shaker (Heidolph, Germany) to allow consistent 
moistening of the membranes. All reaction steps were carried out at room 
temperature unless stated otherwise. Between the distinct incubation steps, 
membranes were washed 3 times for 5 minutes with TBS-T. Blocking and antibody 
dilution solutions either consisted of 1% BSA in TBS (for determination of 
glucokinase and reference (β-actin) protein levels) or TBS Blotto A (for evaluation of 
apoptosis). 
After blocking for 1 hour, membranes were washed and incubated overnight at 4°C 
with the respective antibodies. Polyclonal rabbit anti-glucokinase (Abcam, Germany) 
antibody was diluted 1:250 in 1% BSA in TBS, monoclonal rabbit anti-caspase-3 
antibody was diluted 1:1,000 in TBS Blotto A. On the following day, membranes were 
washed and incubated for 1 hour with a horseradish peroxidase-conjugated goat 
anti-rabbit IgG (Cell Signaling Technology; 1:10,000 for glucokinase detection and 
1:2,000 for caspase-3 detection). After reiterate washing procedure, the membranes 
were tumbled for 1 minute in Luminol Reagent (Santa Cruz Biotechnology, 
Germany), immediately covered with an overhead transparency in a film cassette 
(Ortho Fine, AGFA, Germany), and then exposed to an Amersham Hyperfilm ECL 
(GE Healthcare, Germany) in a darkroom. Exposed films were successively 
processed in developer (Kodak professional developer, Kodak, USA) until 
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appearance of the specific bands, shortly dipped in 12% acetic acid solution, fixed 
(Kodak professional fixer, Kodak, USA), rinsed under running tap water and, finally, 
air dried. For repeated use, membranes were washed once and antibodies were 
detached from the membrane by incubation for 10 minutes in stripping buffer. After 
washing, twice in PBS for 10 minutes and twice in TBS-T for 5 minutes, membranes 
were ready to re-use. Protein levels of the constitutively expressed protein β-actin 
served as internal reference. The primary (mouse anti-actin antibody; Chemicon 
international, Germany) and the secondary antibody (horseradish peroxidase 
conjugated rabbit anti-mouse Ig; DAKO, Germany) were applied in a 1:10,000 
dilution in 1% BSA in TBS. 
TBS, stock solution (x10) 
 Tris base (Roth, Germany) 60.6 g 
 NaCl (AppliChem, Germany) 87.6 g 
Ad 1,000 ml aqua bidest. 
Adjust to pH 7.4 with 1 N HCl (Merck, Germany) 
 
TBS-T 
 TBS, stock solution 50 ml 
 Aqua bidest. 450 ml 
 Tween 20 (Merck, Germany) 250 µl 
 
TBS Blotto A  
 TBS-T 100 ml 
 Non-fat dry milk (Roth, Germany) 5.0 g 
 
Stripping buffer  
 Glycine (neoLab, Germany) 15 g 
 SDS (Sigma, Germany) 1 g 
 Tween 20 (Merck, Germany) 10 ml 
Ad 1,000 ml distilled water 
Adjust to pH 2.2 with 37% HCl (Merck, Germany) 
 
3.5 Clinical analyses and tests 
3.5.1 Body weights 
Body weights of GLS001 and GLS006 mice were determined at the first day post 
partum (within the first 24 hours of life) and at an age of 3 days to the nearest 0.01 g, 
using a Mettler AE200 Electronic Analytical Balance (Mettler-Toledo Intl. Inc., 
Germany). During the post-weaning period, body weights of ad libitum fed 21-, 30-, 
90-, and 175-day-old mice were quantified to the nearest 0.1 g on a Kern 440-43N 
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precision balance (Kern, Germany). Additionally, fasting body weights were 
determined at an age of 30, 85, and 180 days. 
3.5.2 Blood glucose determination 
Determination of blood glucose levels in GLS001 and GLS006 mice was 
accomplished within the first day post partum and at an age of 1 and 4 (only GLS001 
mice) days. Blood samples from suckling mice were obtained under general 
anaesthesia by intraperitoneal injection of 50 µl ketamine/xylacine mixture (chapter 
3.2.2; diluted 1:4 for neonatal and 1-day-old mice, and diluted 1:2 for 4-day-old mice). 
After opening the eyelids, the retroorbital plexus was punctured with an open-end 
capillary (HITADO, Germany). Thereafter, mice were sacrificed by decapitation. 
During the post-weaning period, blood samples of ad libitum fed 21-, 30-, 90-, and 
175-day-old mice were obtained from the nicked tail tip. Blood samples from fasted 
30-, 85-, and 180-day-old mice were collected, applying the identical procedure. 
Blood glucose concentrations were quantified using a SUPER GL® auto analyser 
(HITADO, Germany) and the corresponding analysing reagents. Blood glucose levels 
during glucose and insulin tolerance tests were determined analogically. 
3.5.3 Oral glucose tolerance tests (OGTT) 
Ten GLS001 and 7 GLS006 mice per sex and genotype underwent oral glucose 
tolerance testing at an age of 30, 85, and 180 days. Mice were fasted overnight for 
15 hours (7 pm - 10 am) and blood samples were taken from the nicked tail tip to 
determine basal blood glucose and serum insulin concentrations. Blood samples for 
serum separation were collected into 75 µl heparinised capillary tubes and emptied 
into 0.5 ml reaction cups. Each mouse was administered 11.1 µl of a 1 M glucose 
solution per gram mean body weight (1.8 g α-D-Glucose; Sigma, Germany), 
dissolved in 10 ml tap water) into the stomach via an olive probe per os (Eickemeyer, 
Germany). Blood samples for determination of blood glucose and serum insulin 
levels were taken 10 minutes after glucose challenge. Additional samples for blood 
glucose analyses were collected 20, 30, 60, 90, and 120 minutes after oral glucose 
application. For serum insulin quantification, blood samples were centrifuged for 10 
minutes at 10,000 rpm at 4°C. Thereafter, the serum was removed and stored at 
–80°C until assayed. The area under the blood glucose curve was calculated, using 
GraphPad Prism 3.0. software (GraphPad Software, USA). The β-cell function 
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indices homeostasis model assessment of a: baseline insulin secretion (HOMA B) 
and b: insulin resistance (HOMA IR) were calculated by means of fasting blood 
glucose and serum insulin concentrations according to the following equations 
(Wallace et al. 2004). 
HOMA B = (20 × FPI) / (FPG – 3.5)
HOMA IR = (FPI × FPG) / 22.5 
 
FPI = Fasting plasma insulin (mU/L) 
FPG = Fasting plasma glucose (mmol/L) 
 
3.5.4 Serum insulin determination by Enzyme-Linked Immunosorbent Assay 
(ELISA) 
Serum insulin levels of 30-, 85-, and 180-day-old heterozygous GLS001 and GLS006 
mutants and wild-type littermates in the fasted state and 10 minutes after oral 
glucose application were quantified by ELISA (Ultra Sensitive Mouse Insulin ELISA 
Kit; Crystal Chem Inc., USA). Fasting insulin concentrations were expected to be 
considerably low, especially in heterozygous mutants. Therefore, the assay 
sensitivity was enhanced by increasing the applied sample volume up to 30 µl 
(depending on age, genotype and time point of blood collection during OGTT). The 
serum volumes, applied for serum insulin determination of the respective animal 
groups are listed in Table 3.11. Quantification of serum insulin levels was performed 
according to the manufacturer's manual, using the low range assay (0.1-6.4 ng/ml). 
Absorbance was determined at 450 nm (reference wavelength: 630 nm) in a plate 
reader (SUNRISE, Tecan, Germany) and concentrations were calculated with the 
associated Magellan 2 software (Tecan, Germany). 
Table 3.11: Applied serum volumes for the distinct genders and genotypes and age 
groups. 
OGTT 30days OGTT 85 days OGTT 180 days  
T0 (µl) T10 (µl) T0 (µl) T10 (µl) T0 (µl) T10 (µl) 
wild-type 20a/30b 10 a/25 b 30 10 30 10 
male 
mutant 20a/30b 20a/25b 30 30 30 30 
wild-type 20a/30b 10 a/25 b 30 10 30 10 
female 
mutant 20a/30b 20a/25b 30 30 30 30 
a, b serum volumes applied for serum insulin determination in 30-day-old GLS001 (a) and 
GLS006 (b) mice, serum volumes for the remaining age groups were identical in both strains  
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3.5.5 Intraperitoneal insulin tolerance tests (ipITT) 
Intraperitoneal insulin tolerance tests (ipITTs) were carried out with ad libitum fed 
GLS001 and GLS006 mice at the age of 30, 90, and 175 days. The test was 
consistently performed at 2 pm. Prior to intraperitoneal insulin application, blood 
samples for the determination of basal blood glucose concentrations were collected. 
Subsequently, each mouse was injected 0.75 I.U. insulin per kilogram body weight 
(Insuman® Rapid 40 U/ml, Aventis, Germany; appropriately diluted in 0.9% NaCl 
(autoclaved) to a final volume of 100-120 µl), using a 30G x ½” BD Microlance 3™ 
cannula (Becton Dickinson, Germany). Samples for determination of blood glucose 
concentrations were taken 10, 20, 30, 60, and 90 minutes after insulin application. 
3.6 Necropsy and organ preparation 
3.6.1 Gravimetric organ analyses 
Organ weights of 210-day-old GLS001 and 210- and 550-day-old GLS006 mice were 
determined after exsanguination by punction of the retroorbital plexus with a capillary 
tube (75 µl capacity; Hirschmann® Laborgeräte, Germany) under general 
anaesthesia (refer to chapter 3.2.2). Mice were finally sacrificed by cervical 
dislocation and the skin was detached from the subcutaneous tissue. After 
determination of the nose-rump length, the body cavities were opened and 
abdominal and thoracic organs (lung, heart, thymus, liver, spleen, stomach, intestine, 
kidneys, adrenal glands, testes, epididymes, or ovaries) were removed and 
separated from the adjacent tissues. The gastrointestinal tract was weighed with and 
without ingesta. Organs were blotted dry on cellulose paper and weighed (Mettler 
AE200 Electronic Analytical Balance; Mettler-Toledo Intl. Inc., Germany). Abdominal 
adipose tissue weight included mesentery (without lymph node) and fat tissue from 
the abdominal and pelvic cave. Further, the weight of the carcass (including 
extremities and tail of the skinned animals) was determined. Organs, fat, and the 
animal carcass were fixed in 4% neutral buffered formaldehyde solution (SAV LP, 
Germany) at room temperature. 
3.6.2 Liver preparation 
Liver tissue for haematoxylin and eosin (HE), periodic acid-Schiff (PAS), and fat red 
staining was obtained from 4-day-old GLS001 mice. Animals were sacrificed by 
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decapitation under general anaesthesia (refer to chapter 3.2.2). Whole livers were 
divided into 2 equal tissue parts. One half was fixed in 96% ethanol, the other half 
was fixed overnight in 4% neutral buffered formaldehyde solution. Ethanol fixed 
tissue samples were cut to appropriate size, placed into plastic biopsy capsules, and 
processed in an Autotechnicon (Histomaster 2050/DI; Bavimed, Germany) by 
omitting the H2O rinsing step to avoid glycogen elution. Tissue samples were 
embedded in paraffin (SAV-LP, Germany) and approximately 4 µm thick sections 
were cut, using a HM 315 microtome (Microm GmbH, Germany). Sections were 
mounted on glass slides (Engelbrecht, Germany) and dried in a heating cabinet 
(37°C). For fat red staining, frozen sections of formalin fixed liver tissue were cut on a 
freezing microtome (Frigomobil, Leitz, Germany). 
3.6.3 Pancreas preparation 
Pancreata were obtained from neonatal and 210-day-old GLS001 mice and from 
550-day-old GLS006 mice for qualitative histological, immunohistochemical, and 
quantitative stereological analyses. The pancreas was separated from the adjacent 
tissue and weighed (Mettler AE200 Electronic Analytical Balance; Mettler-Toledo Intl. 
Inc., Germany). Thereafter, the pancreas was placed evenly on a biopsy pad (Bio-
optica, Italy) in a plastic tissue capsule (Engelbrecht, Germany) and covered with an 
additional biopsy pad to avoid distortion. Formalin fixation of the pancreas was 
carried out by overnight incubation at room temperature. 
The fixed pancreas was embedded in agar (BactoTM Agar, Becton&Dickinson, USA) 
and routinely processed and embedded in paraffin (Histomaster 2050/DI; Bavimed, 
Germany). 
The length of the embedded pancreas was determined before the whole pancreas 
was sliced perpendicular to its longitudinal axis into parallel sections of approximately 
1 mm thickness. The first cut was positioned randomly within an interval of 1 mm 
length at the splenic end of the pancreas. The slices were placed into embedding 
moulds with the right cut surface facing downward, and paraffin embedding was 
finished. Paraffin sections for immunohistochemical analyses were prepared as 
described above (chapter 3.6.2), mounted on 3-aminopropyltriethoxy-silane-treated 
glass slides (Starfrost® microscope slides, Engelbrecht, Germany), and dried in a 
heating cabinet (Wagner&Munz GmbH, Germany) at 37°C for at least 12 hours. 
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3.7 Immunohistochemical procedures 
3.7.1 Insulin immunostaining of pancreas sections 
Immunohistochemistry of paraffin embedded pancreas sections was performed by 
indirect immunoperoxidase method. Pancreas sections were immunohistochemically 
stained for insulin to allow differentiation of insulin producing β-cells from non-β-cells. 
Pancreas sections were dewaxed for 20 minutes in xylene (SAV, Germany), 
rehydrated in a descending alcohol series (2 x 100%, 2 x 96%, 1 x 70% ethanol), and 
rinsed in distilled water. Endogenous peroxidase was blocked by incubation in 1% 
hydrogen peroxide (neoLab, Germany) solution for 15 minutes. After washing in TBS 
(chapter 3.4.3.4) for 10 minutes, sections were pre-treated with rabbit normal serum 
(MP Biomedicals, USA; dilution 1:10, 30 minutes) to reduce non-specific binding. 
Subsequently, sections were incubated with guinea pig anti-swine insulin (DAKO®, 
Germany), diluted 1:1,000 in TBS, for 1.5 hours at room temperature. Thereafter, 
tissue sections were rinsed for 10 minutes in TBS and incubated with a horseradish 
peroxidase conjugated rabbit anti-guinea pig IgG (DAKO®, Germany; diluted 1:50 in 
TBS, containing 5% mouse serum) for 1 hour at room temperature. After washing (10 
minutes), chromogen substrate (DAB, KEM-EN-TEC, Denmark) containing 0.1% 
H2O2 was added to visualise immunoreactivity. Slides were rinsed in tap water for 5 
minutes, counterstained with Mayer’s Haemalaun (Applichem, Germany), and 
washed under running tap water (5 minutes). Subsequently, the sections were 
dehydrated in an ascending alcohol series, cleared in xylene (SAV, Germany), and 
mounted under glass coverslips, using Roti® Histokitt II (Roth, Germany). 
Hydrogen peroxide 1% 
 30% H2O2 (neoLab, Germany) 6 ml 
 Aqua bidest. 194 ml 
 
DAB solution 
 DAB pellets (KEM-EN-TEC, Denmark) 1 piece 
 Aqua bidest. 10 ml 
Dissolved for 1 hour (protected from light), filtered, aliquoted, and stored at -20°C. 
Add 1µl 30% H2O2 (neoLab, Germany) per 1 ml DAB solution directly before use. 
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3.8 Quantitative stereological investigations of the pancreas 
Quantitative stereological investigations of pancreata from neonatal and 210-day-old 
GLS001 and 550-day-old GLS006 mice were performed, using unbiased model-
independent methods (Gundersen et al. 1988; Wanke et al. 1994) as previously 
described (Herbach et al. 2005; Herbach et al. 2007). As conventional tissue 
procession for histological analysis provokes embedding shrinkage of the organ, 
stereological parameters were corrected for the individual tissue shrinkage factor if 
possible. Due to the low weight of pancreata from neonatal mice, stereological 
parameters could not be corrected for individual tissue shrinkage in this age group. 
3.8.1 Quantification of the pancreas volume according to Cavalieri's principle 
The total volume of the embedded pancreas was evaluated stereologically according 
to Cavalieri's principle, applying the following equation (Gundersen et al. 1988): 
Vspan = Σ Aspan × t 
Vspan = Volume of the embedded (shrunken) pancreas 
Σ Aspan = Sum of all cross sectional areas of the embedded pancreas 
t = Mean distance of the parallel sections (mean pancreas slice thickness) 
For determination of ΣApan, the complete cut surface of H&E-stained pancreas 
sections was photographed (Leica DFC 320 Digital Camera System, Leica, 
Germany) at a final magnification of 16x (adult mice) or 25x (neonatal mice), using a 
M400 photomacroscope (Wild, Switzerland) or a Leitz Orthoplan microscope (Leitz 
Wetzlar, Germany), respectively. For calibration, an object micrometer (Zeiss-
Kontron, Germany) was photographed at the same magnifications. All photographs 
were printed under equal conditions. 
Point counting was performed with a 10 mm point counting grid photocopied onto an 
overhead transparency. Weibel (1979) defines a test point as the true point of 
intersection between the upper edge of the horizontal line of a cross, and the right-
hand side edge of the vertical line of the cross (Weibel 1979). The sum of points (∑P) 
hitting pancreatic tissue (endocrine and exocrine pancreas, including connective 
tissue of the pancreas; ∑Ppan), and the sum of points hitting the whole section 
(∑Psection, including extrapancreatic tissue) were determined separately (Fig. 3.6).  
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Figure 3.6: Illustration of the point counting method for determination of the sum of 
cross sectional areas of the pancreas (ΣApan). HE stained pancreas section, overlaid with 
a point counting grid (counted points are illustrated in black, n=71). 
To calculate the volume fraction of pancreatic tissue in the section (Vv(pan/section)), 
∑Ppan was divided by ∑Psection. The pancreas weight was corrected for non-pancreatic 
tissue by multiplying the pancreas weight and Vv(pan/section). 
The area corresponding to one point was determined by 30 iterate measurements, 
each at different positions of the point counting grid, using the Videoplan® image 
analysis system (Zeiss-Kontron, Germany) after calibration with the printed object 
micrometer. The mean area, equal to 1 point of the grid was obtained by dividing the 
sum of measured areas by the total number of measurements. The sum of cross-
sectional areas of the pancreas (∑Apan) was obtained by multiplying ∑Ppan with the 
calculated mean area, equal to 1 point on the point-counting grid. The pancreas 
volume before embedding (Vpan) was calculated by dividing the pancreas weight, 
corrected for extrapancreatic tissue, by the specific weight of mouse pancreas (1.08 
mg/mm3; (Wanke et al. 1994)). 
3.8.1.1 Determination of the individual tissue shrinkage 
The individual shrinkage factor (fs) was calculated according to the following equation 
(Kluge 1994): 
fs =Vspan / Vpan 
fs = Linear correction factor for embedding shrinkage 
Vspan = Volume of the embedded pancreas 
Vpan = Pancreas volume before embedding 
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The respective parameters of all animals were corrected with the individual correction 
factor fs. 
3.8.2 Specific morphometric parameters in mice of different age groups 
Morphometric evaluation of pancreas sections, immunohistochemically stained for 
insulin, was carried out on a Videoplan® image analysis system (Zeiss-Kontron, 
Germany) coupled to a light microscope (Orthoplan; Leitz, Germany) via a colour 
video camera (CCTV WVCD132E; Matsushita, Japan). Images of paraffin embedded 
pancreas sections were displayed on a colour monitor at a final magnification of 
x250. The sum of cross-sectional areas of islets, β-cells, and isolated β-cells (∑Aislets, 
∑Aβ-cells, ∑Aisol. β-cells, respectively) was measured planimetrically by circling their 
outlines with a cursor on the digitising tablet of the image analysis system after 
calibration with an object micrometer (Zeiss, Germany). In adult mice, a subsampling 
was performed by systematically meandering through the section. The lateral lines of 
a frame displayed on the monitor were used as “allowed and forbidden lines” 
according to the unbiased counting rule (Gundersen 1977; Gundersen 1978). The 
structures in between the lines or touching the “allowed line” were measured. In 
neonatal mice, no subsampling was performed.  
Volume fractions of the structures of interest (islets, β-cells, isolated β-cells) in the 
reference compartments (pancreas, islets) were calculated according to the principle 
of Delesse (Delesse 1847; Weibel 1979):  
AA=Vv 
AA= Estimated area fraction of a target structure in a reference compartment 
Vv= Estimated volume fraction of a target structure in a reference compartment 
3.8.2.1 Neonatal mice 
The volume density of β-cells in the pancreas (Vv(β-cells/pan)) was calculated by dividing 
∑Aβ-cells by ∑Apan. The total β-cell volume was obtained by multiplying Vv(β-cells/pan) and 
Vpan. 
3.8.2.2 Adult mice 
The volume density of islets in the pancreas (Vv(islets/pan)) was calculated by dividing 
∑Aislets by ∑Apan. The total volume of islets in the pancreas (V(islets,pan)) was attained 
by multiplying Vv(islets/pan) with Vpan. 
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The volume density of β-cell in the islets (Vv(β-cells/islets)) was determined by dividing 
∑Aβ-cells by ∑Aislets. The total volume of β-cell in the islets (V(β-cells,islets)) was calculated 
by multiplying Vv(β-cells/islets) with V(islets,pan). 
Isolated β-cells, which are considered as an indicator for islet neogenesis, are 
defined as single insulin-positive (insulin+) cells within or budding from pancreatic 
ducts (Fig. 3.8. A, B), scattered β-cells (Fig. 3.8. C), and extra-islet β-cell clusters 
(EICs; < 4 insulin+ cells, Fig. 3.8. D) (Bonner-Weir 2001; Butler et al. 2003; Kauri et 
al. 2007) . The volume density of isolated β-cells in the pancreas (Vv(isol. β-cells/pan)) was 
obtained by dividing ∑Aisol. β-cells by ∑Apan. The total volume of isolated β-cells was 
determined by multiplying Vv(isol. β-cells/pan) and Vpan. 
    
Figure 3.8: Spectrum of insulin+ stained pancreatic cells, classified as isolated β-cells: 
Insulin positive cells within (A) or budding from pancreatic ducts (B), scattered β-cells (C), 
and extra-islet β-cell clusters (EICs; < 4 insulin+ cells) (D). 
3.9 Statistical analysis and data presentation 
Data from all analyses displayed a normal distribution, as evinced by the 
Kolmogorow-Smirnov test (SPSS 16.0, SPSS GmbH Software, Germany). Therefore, 
means were compared by a two-tailed unpaired Student’s t-test (GraphPad Prism 
3.0; GraphPad Software, USA). Statistical analysis of the linkage between the 
diabetic phenotype of GLS001 G2 backcross mice and the examined polymorphic 
markers was performed by the chi2-test as described in chapter 3.2.1.3. P values 
<0.05 were considered significant throughout the study. Data are presented as 
means ± standard deviation (SD) or standard error of the mean (SEM; calculated 
dividing the SD by the square root of the number of animals examined), as indicated. 
Data charts were generated with GraphPad Prism 3.0. 
 
10 µm 10 µm 10 µm 10 µm 
A C D B 
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4. Results 
4.1 Identification of the causative mutation 
4.1.1 GLS001 mice: Munich GckM210R mutants 
4.1.1.1 Fine mapping 
In GLS001 mice, further narrowing of the chromosomal region of the causative 
mutation, which was already indicated by genome-wide SNP analysis, was 
performed by fine mapping. For this purpose, genotype analysis of 4 additional 
polymorphic markers, located upstream of the SNP with the highest linkage on 
chromosome 11 (14.3 Mb; Table 9.1) was performed. A total number of 90 GLS001 
G2 backcross mice (75 phenotypic heterozygous and 15 wild-type animals) and 19 
animals, resulting from mating phenotypic heterozygous G2 backcross mice, were 
investigated. Genotype classification for the polymorphic markers, positioned at 17.8, 
12.2, 8.8, and 5.9 Mb, revealed a continuous increase of the χ2-values from 67.6 up 
to 74.1 (Table 4.1). The highest χ2-value, and therefore the strongest linkage to the 
diabetic phenotype, was observed for the polymorphic marker, located at 5.9 Mb. 
MGI database query for diabetes-associated candidate genes, revealed the 
glucokinase (Gck) gene, which is localised in the corresponding mapping region (5.8-
5.9 Mb), as a potential candidate gene.  
Table 4.1: Genotype analysis of further polymorphic DNA markers, positioned 
upstream of the SNP with the highest linkage. 
Locus (Mb) χ2-value p-value 
5.9 74.1 p<0.001 
8.8 71.1 p<0.001 
12.2 67.6 p<0.001 
17.8 67.6 p<0.001 
 
4.1.1.2 Candidate gene sequencing of the glucokinase (Gck) gene 
Genomic DNA and hepatic cDNA were applied for analysis of the complete mRNA 
sequence of Gck. For this purpose, neonatal mice on the mixed C3H and C57BL/6J 
inbred genetic background (derived from mating phenotypic heterozygous G2 
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backcross mice), which were homozygous for the C3H genotype with the 
polymorphic marker in intron 7 of Gck, were analysed. Further, adult phenotypic 
heterozygous mutants and wild-type mice on the C3H inbred genetic background 
were investigated. Analyses of the sequences of the pancreas-specific exon 1 and of 
the Gck promoter of homozygous and heterozygous mutants revealed no nucleotide 
exchange as compared to both the mouse reference (NCBI GenBank accession no. 
NW_001030444) and the wild-type C3H sequence. Alignment of the hepatic Gck 
mRNA sequences of homozygous mutants with the mouse genome reference 
sequence (NCBI GenBank accession no. NM_010292) disclosed a defined point 
mutation. The identified base exchange was apparent in the bidirectional sequence 
analysis in all homozygous mutants examined. In contrast, wild-type controls 
displayed the mouse genome reference sequence (Fig. 4.1A). Evaluation of the 
corresponding electropherograms of heterozygous mutants, harbouring both the 
mutant and the wild-type sequence, a double peak was detected at the position of 
the mutation (Fig. 4.1B). The identified mutation represents a T→G transversion (Fig. 
4.1C) at nucleotide position 629 in exon 6 of Gck. Translation of the mutated 
sequence resulted in an amino acid exchange from methionine to arginine at position 
210. According to the mutation, the surrogate name GLS001 was replaced by the 
official term Munich GckM210R mutant mouse to designate this mutant strain. The 
probability of an additional confounding ENU-induced mutation between the last 2 
polymorphic markers with the highest linkage as well as within the region upstream of 
the last polymorphic marker was 0.0006 and 0.0045, respectively. 
A  B    C 
   
Figure 4.1: Electropherogram of the sequence analysis of Gck in wild-type controls (A), 
heterozygous (B) and homozygous Munich GckM210R mutants (C). The position of the base 
exchange at nucleotide position 629 is marked by an arrow. Wild-type mice displayed the 
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mouse genome reference sequence. Heterozygous mutants exhibited a double peak, 
whereas homozygous mutants exhibited the base exchange from T to G. 
4.1.2 GLS006 mice: Munich GckD217V mutants 
Since the diabetic phenotype of GLS006 mice mapped to the almost same 
chromosomal region as in GLS001 mice, Gck was also chosen for candidate gene 
analysis. 
4.1.3 Candidate gene sequencing of the glucokinase (Gck) gene 
Sequence analysis of Gck, accomplished with adult homozygous and heterozygous 
mutants and wild-type littermates on the C3H inbred genetic background was carried 
out as mentioned above. Sequence alignment of the complete Gck mRNA sequence 
disclosed an A→T transversion (Fig. 4.2) at nt 650 in exon 6 of the glucokinase gene, 
leading to an amino acid exchange from aspartic acid to valine at position 217. The 
probability of an additional confounding ENU-induced mutation between the last 2 
polymorphic markers with the highest linkage as well as within the region upstream of 
the last polymorphic marker was 0.0019 and 0.0078, respectively. In accordance to 
Munich GckM210R mutants the official term Munich GckD217V mutant mouse was 
chosen for GLS006 mice. 
A   B    C 
   
Figure 4.2: Electropherogram of the sequence analysis of Gck in wild-type controls 
(A), heterozygous (B) and homozygous Munich GckD217V mutants (C). The position of the 
base exchange at nucleotide position 650 is marked by an arrow. Wild-type mice displayed 
the mouse genome reference base, heterozygous mutants showed a double peak, whereas 
homozygous mutants exhibited the base exchange from A to T. 
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4.2 Allelic differentiation of mutant mice 
4.2.1 Genotyping of Munich GckM210R mutants 
The single base exchange from T to G in Munich GckM210R mutants created a novel 
restriction site for the enzyme BstYI, which displays the recognition sequence 
RGATCY (R = adenine or guanine; G = guanine; A = adenine; T = thymine; C = 
cytosine; Y = cytosine or thymine). Thus, PCR products (343 bp) of the mutant allele 
were restricted into two fragments (200 and 143 bp), whereas wild-type PCR 
products were not restricted. Since the particular restriction fragments differ enough 
in size to be reliably separated even on a 1.5% electrophoresis gel, allelic 
differentiation of Munich GckM210R mutants was feasible by RFLP analysis (Fig. 4.3). 
                     M        wild-type      heterozygous  homozygous       M 
 
Figure 4.3: Genotyping of Munich GckM210R mutants by RFLP: Genotype-specific RFLP 
analysis resulted in a 343 bp band of the wild-type allele and in 2 fragments (200 and 143 
bp) for the mutant allele. In heterozygous mutants, 3 fragments are visible. M: Fragment size 
marker (pUC mix 8 MBI Fermentas, Germany); marker bands represent fragment sizes of 
1118, 881, 692, 501 (and 489), 404, 331, 242, 190, 147, and 111 bp (from top to bottom). 
4.2.2 Genotyping of Munich GckD217V mutants 
Genotyping of Munich GckD217V mutants was accomplished by selective PCR-based 
amplification of either the wild-type allele (in wild-type controls) or the mutant allele 
(in homozygous mutants), or both (in heterozygous mutants). Allelic differentiation 
was performed by Amplification Refractory Mutation System PCR (ARMS), which 
was established as single-tube allele-specific PCR (STAS PCR; chapter 3.3.2). 
Hybridisation of both external primers resulted in PCR-based amplification of a 343 
bp fragment in both alleles. Successful amplification of this fragment therefore served 
as a PCR control. The allele-specific 3' nt termination and the insertion of an 
343 bp 
200 bp 
143 bp 
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additional mismatch at nt 3 upstream of the 3' end restricted primer hybridisation of 
both internal primers to the respective allele. Amplification of the corresponding 
alleles resulted in genotype-specific PCR products of 238 bp (wild-type allele) and 
147 bp (mutated allele). Thus, wild-type mice and homozygous mutants were 
differentiated by the presence of the corresponding allele-specific DNA fragment, 
whereas heterozygous mutants were identified by the presence of both fragments 
(Fig. 4.4). 
                    M        wild-type       heterozygous   homozygous       M 
 
Figure 4.4: Genotyping of Munich GckD217V mutants by STAS PCR: Amplification of the 
control (343 bp) fragment was observed in samples from all genotypes. In heterozygous 
mutants, PCR products of both the mutant and the wild-type allele were apparent. In 
homozygous mutants and wild-type mice only one allele-specific PCR product (238 bp for the 
wild-type, 147 bp for the mutant allele) was detectable. M: Fragment size marker 
(GeneRuler™ 100 bp plus DNA Ladder; Fermentas, Germany); marker bands represent 
fragment sizes of 1100, 1000, 900, 800, 700, 600, 500, 400, 300, 200, and 100 bp (from top 
to bottom). 
4.3 Functional consequences of the mutations 
4.3.1 Quantification of glucokinase activity 
Hepatic glucokinase activity was determined in 90-day-old Munich GckM210R and 
GckD217V mutants and wild-type littermate control mice. Plotting the distinct reaction 
velocities in the presence of the 5 high glucose concentrations against the respective 
substrate concentrations (Cornish-Bowden diagram; chapter 9.1) revealed an 
approximately sigmoidal appearance of the glucokinase substrate-velocity curve in 
mice of both strains up to a glucose concentration of about 10 mM. Nevertheless, 
deviance from hyperbolic Michaelis-Menten kinetics was marginal. The discrete 
sigmoidal glucose dependency of wild-type and mutant glucokinase of both strains 
343 bp 
238 bp 
147 bp 
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indicates a Hill coefficient slightly above 1 and therefore, a positive cooperativity with 
the main substrate glucose. Thus, kinetic constants of the glucokinase enzyme were 
determined after linear data transformation (Hanes-Woolf plot), whereby only the 
linear portion of the curve was employed for calculation after data extrapolation by 
linear regression curve fitting. 
 
Munich GckM210R mutants 
The glucokinase of heterozygous Munich GckM210R mutants exhibited a significant 
(p<0.05) reduction of glucose turnover rate per time unit as compared to wild-type 
littermates at all investigated glucose concentrations (Fig. 4.5A). Substrate turnover 
velocity (specific glucokinase phosphorylating activity) in the presence of 100 mM 
glucose was decreased by about 47% in heterozygous mutants vs. wild-type controls 
(Fig. 4.5B). Furthermore, the maximal substrate turnover velocity (Vmax) for 
glucokinase was significantly (p<0.05) reduced in mutants (by about 43% vs. wild-
type mice; range from 22-70%). The S0.5 for glucokinase, reflecting glucokinase 
substrate affinity, was only slightly but not significantly increased in heterozygous 
mutants, and also the Vmax and Km values for the high-affinity glucose 
phosphorylating enzyme hexokinase did not differ significantly between mutants and 
wild-type littermates. On the contrary, heterozygous mutants displayed a slightly 
increased Vmax for hexokinase and a by tendency decreased Km for hexokinase (Fig. 
4.5C). Taken together, murine M210R mutant glucokinase exhibited a significantly 
(p<0.05) decreased, but only marginally right-shifted substrate-velocity curve, 
indicating the marked reduction of glucokinase activity in these animals as compared 
to wild-type mice. 
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 Hexokinase Glucokinase 
 Vmax Km  Vmax S0.5 
 absolute % of wt absolute % of wt  absolute % of wt absolute % of wt 
wt 
(n=4) 
1.7 
(± 0.5) 
 0.3 
(± 0.2) 
  25.0 
(± 1.4) 
 10.88 
(± 1.4) 
 
mt, het 
(n=7) 
2.1 
(± 0.3) 
122.0 
(± 17.5) 
0.1 
a 
34.5 
(± 7.8) 
 14.3* 
(± 1.6) 
57.0* 
(± 6.5) 
13.5 
(± 0.7) 
123.9 
(± 6.2) 
 
Figure 4.5: Kinetic characteristics of hepatic glucokinase of 90-day-old heterozygous 
Munich GckM210R mutants and wild-type littermates. Illustration of the marginal differences 
between the original glucokinase substrate-velocity curve of wild-type mice and 
heterozygous mutants (without extrapolation by non-linear regression curve fitting, black line) 
and the hyperbolic curve (dotted grey line), resulting from non-linear regression data fitting. 
For all examined glucose concentrations, the substrate turnover rate by glucokinase (A) and 
the specific activity of glucokinase in the presence of 100mM glucose (B) was significantly 
decreased in heterozygous (het) mutants (mt) vs. wild-type mice (wt). The absolute (µmol*g-
1*min-1) and relative (% of wild-type Vmax) Vmax for glucokinase was significantly decreased in 
mutant mice, whereas the S0.5 for glucokinase and Vmax and Km for hexokinase were not 
significantly altered. Data represent means ± SEM; n=number of animals examined per 
group; *p<0.05 mt, het vs. wt. a (± 0.01). 
 
Munich GckD217V mutants 
Quantification of glucokinase activity in liver homogenates of 90-day-old 
heterozygous and homozygous Munich GckD217V mutants disclosed a significant 
(p<0.05) reduction of glucose turnover velocity (specific activity in the presence of 
various glucose concentrations) for glucokinase in the presence of 12, 25, 50, and 
100mM glucose as compared to age-matched wild-type littermates (Fig. 4.6A). 
Specific glucokinase activity at 100mM glucose was diminished by about 32% in 
heterozygous mutants, by about 90% in homozygous mutants vs. wild-type mice, and 
by 84% in homozygous vs. heterozygous mutants (Fig. 4.6B). The maximal glucose 
phosphorylating velocity (Vmax) and the Michaelis-Menten constant (Km) for the high-
affinity glucose phosphorylating enzyme hexokinase, did not differ between the 
respective genotypes, whereas Vmax for the low-affinity glucokinase enzyme was 
significantly diminished in both heterozygous and homozygous mutants (by about 
33% in heterozygous and by about 84% in homozygous mutants vs. wild-type mice). 
The S0.5 for glucokinase was only significantly (p<0.05) increased in homozygous vs. 
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heterozygous mutants and wild-type mice, but not in heterozygous mutants as 
compared to wild-type mice (Fig. 4.6C). 
  
 
 Hexokinase Glucokinase 
 Vmax Km  Vmax S0.5 
 absolute % of wt absolute % of wt  absolute % of wt absolute % of wt 
wt 
 (n=6) 
2.5 
(± 0.8)  
0.7 
(± 0.3)   
21.5 
(± 1.5)  
13.4 
(± 1.2)  
mt, het 
(n=5) 
2.4 
(± 1.1) 
97.0 
(± 44.1) 
0.7 
(± 0.5) 
98.9 
(± 75.4)  
14.4* 
(± 2.0) 
66.9* 
(± 9.4) 
14.0 
(± 2.7) 
107.4 
(± 10.2) 
mt, homo 
(n=3) 
0.9 
(± 0.3) 
37.6 
(± 13.5) 
0.7 
(± 0.4) 
96.7 
(± 65.7)  
3.5†§ 
(± 1.4) 
16.1†§ 
(± 6.3) 
74.2†§ 
(± 25.6) 
554.3†§ 
(± 191.3) 
 
Figure 4.6: Kinetic parameters of hepatic glucokinase of 90-day-old heterozygous and 
homozygous Munich GckD217V mutants and wild-type mice. Substrate turnover velocity 
(A) was significantly decreased in heterozygous (het) and homozygous (homo) mutants (mt) 
vs. wild-type animals (wt) from a substrate concentration of glucose of 6 mM onwards. Note 
the initial insinuated sigmoidicity of the glucokinase substrate-velocity curve prior to 
extrapolation (black line) vs. the hyperbolic character of the fitted (dotted grey line) saturation 
curve. Furthermore, specific activity of glucokinase in the presence of 100 mM glucose (B) 
was significantly lower in mutants of both genotypes (B). The absolute (µmol*g-1*min-1) and 
relative (% of wild-type Vmax) Vmax for glucokinase was significantly diminished in 
heterozygous and homozygous mutant mice, whereas S0.5 for glucokinase was only reduced 
in homozygous mutants (C). Vmax and Km values for the high-affinity hexokinases were 
comparable among all genotypes. Data represent means ± SEM; n=number of animals 
examined per group; *p<0.05 mt, het vs. wt; †p<0.05 mt, homo vs. mt, het; §p<0.05 mt, homo 
vs. wt. 
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Comparison between glucokinase kinetic characteristics in Munich GckM210R and 
GckD217V mutants 
The substrate turnover rate per minute, relative to wild-type mice, was marginally 
lower (range of 22-32%) in heterozygous Munich GckM210R mutants as compared to 
GckD217V mutants in the presence of all 5 glucose concentrations (Fig. 4.7A). 
Likewise, the maximal reaction velocity of glucokinase (Vmax) (Fig. 4.7B) was slightly, 
but not significantly decreased. Further, the relative S0.5 for glucokinase (Fig. 4.7C) 
was elevated by tendency in GckM210R vs. GckD217V mutants. 
 
 
 
4.3.2 Determination of glucokinase RNA expression in Munich GckM210R mutants 
The relative expression abundance of the hepatic glucokinase (Gck) transcripts of 
homozygous and heterozygous Munich GckM210R mutants and wild-type littermates 
was determined at the first day of life by quantitative real-time PCR. All primers 
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Figure 4.7: Comparison of kinetic parameters of 
hepatic glucokinase of 90-day-old heterozygous 
Munich GckM210R and GckD217V mutants relative to wild-
type parameters (%). Relative reaction velocities of the 
glucokinase enzyme (A) and Vmax for glucokinase (B) 
were considerably, but not significantly, lower, and the 
S0.5 for glucokinase was slightly higher in GckM210R 
(M210R) mutants vs. GckD217V (D217V) mutants. Data 
represent means ± SD. A total number of 7 (GckM210R) 
and 5 (GckD217V) animals were investigated. 
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showed a comparable efficiency of 0.75 ± 0.02. Moreover, the relative transcript 
abundances of the reference genes Mrps9, Actb and 18s rRNA did not differ 
significantly among the genotype-specific groups (Fig. 4.8A), demonstrating their 
eligibility for quantification of the relative abundance of the target transcript. In the 
following, target gene expression levels were compared to Actb as reference 
transcript. The relative abundances of the Gck transcripts were quite low in liver 
samples of all genotypic groups. However, Gck transcript abundance, relative to 
Actb, was markedly decreased in homozygous mutants vs. wild-type littermates and 
heterozygous mutants (p<0.05). Moreover, relative transcript abundance of Gck was 
significantly (p<0.05) decreased in heterozygous mutants as compared to age-
matched wild-type littermates (Fig. 4.8B). 
2-ΔCT values 
A     Primer combinations 
wt (n=7) mt, het (n=8) mt, homo (n=7)
18s rRNA vs. Mrps9 (x104) 3.86 (± 0.63) 3.62 (± 1.13) 3.78 (± 0.37) 
Mrps9 vs. 18s rRNA (x10-5) 2.67 (± 0.54) 2.98 (± 0.85) 2.67 (± 0.25) 
Actb vs. Mrps9 (x102) 2.39 (± 0.36) 2.37 (± 0.38) 2.15 (± 9.26) 
Mrps9 vs. Actb (x10-3) 4.27 (± 0.79) 4.33 (± 0.27) 4.70 (± 0.62) 
Mrps9 vs. Actb (x10-3) 1.62 (± 0.24) 1.52 (± 0.33) 1.77 (± 0.17) 
Actb vs. 18s rRNA (x10-3) 6.27 (± 0.86) 6.85 (± 1.36) 5.70 (± 0.55) 
 
  
wt mt,het mt,homo
0.00
0.05
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0.15
(n=7)        (n=8)       (n=7)
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†
§
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)
B Figure 4.8: Relative transcript abundances of the 
applied reference genes (A) and Gck expression 
of paired liver samples from neonatal mice (B): 
Relative transcript abundances of Mrps9, Actb and 
18s rRNA did not significantly differ between 
heterozygous (het) mutants (mt), homozygous 
(homo) mutants, and wild-type controls (wt). (B) Gck 
expression was significantly decreased in 
homozygous and heterozygous mutants vs. wild-type 
controls. Data represent means ± SD; n=number of 
animals examined; *p<0.05 mt, het vs. wt; †p<0.05 
mt, homo vs. mt, het; §p<0.05 mt, homo vs. wt. 
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4.3.3 Western blot analysis in Munich GckM210R mutants 
4.3.3.1 Quantification of glucokinase protein levels 
Glucokinase protein abundance was investigated in isolated islets of 90-day-old 
heterozygous mutants and sex- and age-matched wild-type littermates. The 
specificity of the applied antibody was considerably high, resulting in only 
1 detectable band of 65 kDa, which represents the predicted molecular weight of the 
glucokinase protein. Staining intensity of the 65 kDa glucokinase specific band in 
general appeared comparable in heterozygous mutants of both genders vs. wild-type 
controls (Fig. 4.9A). Quantification of glucokinase protein abundance, relative to β-
actin, revealed a reduction of glucokinase protein levels in heterozygous mutants by 
about 28% as compared to wild-type mice, but this difference was not significant (Fig 
4.9B). 
 
 
 
 
 
 
 
Figure 4.9: Western blot of glucokinase (A; top) in isolated pancreatic islets from 90-
day-old Munich GckM210R mutants and wild-type littermates in comparison to β-actin 
(A; bottom) and quantification of the relative optical density (O.D.) of the specific 
signals (B). Staining intensity of the glucokinase-specific band in general did not differ 
between heterozygous (het) male (m) and female (f) mutants vs. wild-type controls (wt). 
Quantification of the relative abundance of the glucokinase-specific band revealed slightly, 
but not significantly decreased glucokinase protein levels in heterozygous mutants. 
4.3.3.2 Determination of apoptosis 
Intracellular cysteine proteases (caspases), especially the effector caspase-3, are 
major regulators of programmed cell death (apoptosis). In presence of cell death 
stimuli, inactive pro-caspase-3, which is usually expressed in mammalian cells, is 
activated by autoproteolytic procession from the inactive heterodimer into its active 
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heterotetrameric form, consisting of a large (~20 kDa) and a small (~10 kDa) active 
subunit (Porter et al. 1999; Thornberry et al. 1998). Since β-cell apoptosis is 
considered to represent an important aspect in pathogenesis and progression of both 
type 1 and type 2 diabetes mellitus (Leonardi et al. 2003; Thomas et al. 2009), 
apoptosis in islets of 90-day-old heterozygous Munich GckM210R mutants and wild-
type littermates was investigated by Western blot analysis, using an antibody that 
detects both the inactive and active form of caspase-3. Lymph node homogenate 
was applied as positive control for the activated subunits. Pro-caspase-3 was 
detectable in all samples and the active large subunit of caspase-3 was also 
apparent in lymph node homogenate (size 17/19 kDa), whereas no band was 
detectable in heterozygous mutants and wild-type controls (Fig. 4.10). 
 
 
 
 
 
 
 
Figure 4.10: Detection of the apoptosis marker caspase-3 in lymph node homogenate 
(+) and pancreatic islets of 90-day-old heterozygous Munich GckM210R mutants and 
wild-type controls in comparison to β-actin. The 33 kDa band of pro-caspase-3 was 
detectable in all samples, whereas the 17/19 kDa fragment of activated caspase-3 was only 
apparent in lymph node homogenate but not in pancreatic islets of heterozygous male (m) 
and female (f) mutants (mt) and wild-type controls (wt). 
4.4 Clinical findings in Munich GckM210R and GckD217V mutants 
4.4.1 Basic clinical features 
Body weight and blood glucose levels of homozygous and heterozygous Munich 
GckM210R and GckD217V mutants and wild-type littermates were first determined within 
the first 24 hours post partum. Additionally, animals were weighed at an age of 4 
days and blood glucose concentrations were quantified in 1-day-old mice of both 
+          m,wt           f,wt            m,mt             f,mt 
Pro-caspase-3, inactive (33 kDa) 
Caspase-3, active (17/19 kDa) 
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strains and in 4-day-old Munich GckM210R mutants and wild-type littermates. Body 
weight and blood glucose levels of ad libitum fed Munich GckM210R and GckD217V 
mutants were determined at the day of weaning (21 days of age) and during the post-
weaning period at an age of 21, 30, 90, and 175 days. Body weight and blood 
glucose levels after a 15 h fasting period were determined at an age of 30, 85 and 
180 days. 
4.4.1.1 Body weight 
Munich GckM210R mutants 
The birth weight of homozygous and heterozygous mutants was unaltered as 
compared to wild-type littermates (Fig. 4.11A). However, at an age of 3 days, 
homozygous mutants exhibited a markedly reduced body weight as compared to wild-
type littermates (Fig. 4.11C). At this age, the body weight of homozygous mutants 
was almost the same as their birth weight and was by about 50% decreased vs. wild-
type mice and heterozygous mutants (p<0.05) (Fig. 4.11B), whereas the body weight 
of age-matched heterozygous mutants was unchanged. Furthermore, the fasting 
body weight of 30-day-old heterozygous male mutants was significantly (p<0.05) 
reduced vs. wild-type controls. At all other time points investigated, the body weight of 
ad libitum fed and fasted heterozygous mutants of both sexes did not differ 
significantly from those of age- and sex-matched wild-type littermates (Table 4.2). 
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Figure 4.11: Body weight of homozygous and heterozygous neonatal (A) and 3-day-old 
(B) Munich GckM210R mutants vs. wild-type littermates. Birth weight was unaltered in 
homozygous (homo) and heterozygous (het) mutants (mt) vs. wild-type mice (wt), whereas 
homozygous mutants displayed a significantly reduced body weight at an age of 3 days vs. 
wild-type mice and heterozygous mutants (B). Data represent means ± SD, †p<0.05 mt, homo 
vs. mt, het; §p<0.05 mt, homo vs. wt; n=number of animals examined. 
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Figure 4.11 C: Typical appearance of 3-day-old homozygous Munich GckM210R mutants 
vs. a wild-type control. Homozygous mutants displayed severe growth retardation. 
 
Table 4.2: Ad libitum fed and fasting body weight of male (m) and female (f) 
heterozygous mutants and age- and sex-matched wild-type littermates (wt). 
 Ad libitum fed body weight (g) Fasting body weight (g) 
Age (days) Age (days) Group 
21 30 90 175 30 85 180 
m, wt 11.1 (± 2.1) 
14.1 
(± 1.2) 
27.7 
(± 2.0) 
31.7 
(± 2.1) 
14.9 
(± 1.2) 
28.4 
(± 1.0) 
28.4 
(± 2.7) 
m, mt 9.6 (± 2.6) 
14.3 
(± 0.5) 
26.9 
(± 2.0) 
31.2 
(± 1.7) 
12.5* 
(± 2.7) 
27.0 
(± 2.0) 
28.6 
(± 1.7) 
f, wt 9.9 (± 2.7) 
11.8 
(± 0.6) 
23.3 
(± 2.0) 
27.3 
(± 1.6) 
11.7 
(± 1.8) 
23.7 
(± 1.0) 
24.6 
(± 1.8) 
f, mt 8.7 (± 2.6) 
11.9 
(± 0.4) 
21.9 
(± 1.0) 
25.9 
(± 1.3) 
10.5 
(± 1.3) 
22.3 
(± 1.0) 
23.7 
(± 1.3) 
Data represent means ± SD, * p<0.05 m, mt vs. m, wt; a total number of 10 animals per sex 
and genotype were investigated except for ad libitum fed body weights of 21- and 30-day-old 
mice, which were determined from 5 animals per sex and genotype. 
 
Munich GckD217V mutants 
The body weight of neonatal and 3-day-old homozygous and heterozygous mutants 
did not differ from those of wild-type controls (Fig.4.12A, B). From an age of 30 days 
onwards, ad libitum fed homozygous mutants of both sexes weighed significantly 
(p<0.05) less than wild-type mice. Additionally, the body weight of ad libitum fed 
C
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female homozygous mutants was significantly (p<0.05) decreased vs. female 
heterozygous mutants from an age of 30 days onwards (Table 4.3). 
  
Figure 4.12: Body weight of homozygous and heterozygous Munich GckD217V mutants 
vs. wild-type littermates at the first day post partum (A) and at an age of 3 days (B). 
Birth weight and body weight of 3-day-old homozygous (homo) and heterozygous (het) 
mutants (mt) were unaltered vs. wild-type mice (wt); Data represent means ± SD; n=number 
of animals examined 
Table 4.3: Ad libitum fed and fasting body weight of male (m) and female (f) 
homozygous (homo) and heterozygous (het) Munich GckD217V mutants and wild-type 
littermates (wt). 
 Ad libitum fed body weight (g) Fasting body weight (g) 
Age (days) Age (days) Group 
21 30 90 175 30 85 180 
m, wt 10.4 (± 0.5) 
17.1 
(± 1.7) 
28.1 
(± 1.7) 
35.0 
(± 2.7) 
12.2 
(± 1.5) 
23.4 
(± 2.3) 
28.3 
(± 3.2) 
m, het 10.3 (± 0.9) 
17.1 
(± 1.7) 
27.7 
(± 1.9) 
34.5 
(± 2.9) 
12.0 
(± 1.4) 
23.2 
(± 1.1) 
27.4 
(± 1.6) 
m, homo 10.6 (± 1.4) 
14.6§ 
(± 2.4) 
26.8§ 
(± 2.2) 
31.7§ 
(± 1.8) 
not determined 
f, wt 10.4 (± 1.3) 
14.2 
(± 1.1) 
24.4 
(± 0.9) 
29.0 
(± 1.2) 
9.7 
(± 1.3) 
19.1 
(± 1.4) 
22.9 
(± 1.3) 
f, het 10.1 (± 0.5) 
14.2 
(± 0.8) 
24.0 
(± 1.3) 
27.5 
(± 1.4) 
9.7 
(± 1.1) 
19.2 
(± 1.6) 
23.0 
(± 0.7) 
f, homo 8.8 (± 1.0) 
12.1§† 
(± 1.6) 
21.3§† 
(± 2.1) 
26.1§† 
(± 1.9) not determined 
Data represent means ± SD; †p<0.05 homo vs. het; §p<0.05 homo vs. wt; a total number of 7 
animals per sex and genotype were investigated. 
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4.4.1.2 Blood glucose levels 
Munich GckM210R mutant mouse 
Determination of blood glucose levels at the first day post partum revealed 
significantly (p<0.05) elevated blood glucose levels in both homozygous and 
heterozygous Munich GckM210R mutants as compared to wild-type controls. Blood 
glucose levels in neonatal homozygous mutants were 6.0- and 4.1-fold increased vs. 
wild-type mice and heterozygous mutants (p<0.05), respectively (Fig 4.13A). Until an 
age of 1 day (second day post partum), blood glucose levels of homozygous mutants 
raised to 438 ± 24 mg/dl, representing a 1.7-fold increase as compared to the blood 
glucose levels at first day of life. Four of 5 homozygous mutants displayed glucosuria 
at the first day post partum. From the second day of life onwards, all investigated 
homozygous mutants displayed marked glucosuria. Blood glucose levels of 
heterozygous mutants and wild-type littermates remained considerably stable during 
the period of the first and the second day post partum (Fig. 4.13B). At an age of 4 
days, blood glucose levels of homozygous mutants were 8.3-fold increased vs. wild-
type littermates and were 5.8-times higher than in heterozygous mutants (p<0.05) 
(Fig. 4.13C). Blood glucose levels of 4-day-old homozygous mutants were 4.0-fold 
increased as compared to the blood glucose concentrations at the first day post 
partum, whereas blood glucose values of heterozygous mutants remained 1.4-fold 
increased as compared to wild-type littermates during this period. 
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Post-weaning blood glucose levels of ad libitum fed heterozygous mutants of both 
sexes were also significantly (p<0.05) elevated vs. age- and sex-matched controls. 
As compared to wild-type mice, disturbances in glucose homeostasis remained 
almost stable from an age of 30 days onwards. Fasting blood glucose levels of 
heterozygous mutants were first found to be elevated at an age of 30 days and 
remained stable for the period of investigation (Table 4.4). 
Table 4.4: Ad libitum fed and fasting blood glucose of male (m) and female (f) 
heterozygous Munich GckM210R mutants and wild-type littermates (wt). 
 Ad libitum fed blood glucose levels (mg/dl) Fasting blood glucose levels (mg/dl) 
Age (days) Age (days) Group 
21 30 90 175 30 85 180 
m, wt 99 (± 12) 
106 
(± 7) 
131 
(± 12) 
112 
(± 10) 
84 
(± 27) 
86 
(± 10) 
86 
(± 12) 
m, mt 152* (± 35) 
176* 
(± 21) 
198* 
(± 14) 
193* 
(±16) 
130* 
(± 24) 
113* 
(± 15) 
123* 
(± 16) 
f, wt 95 (± 35) 
106 
(± 5) 
125 
(± 20) 
107 
(± 8) 
79 
(± 7) 
78 
(± 9) 
86 
(± 11) 
f, mt 150* (± 36) 
182* 
(± 22) 
184* 
(± 32) 
174* 
(± 11) 
113* 
(± 13) 
110* 
(± 11) 
114* 
(± 1) 
Data represent means ± SD, *p<0.05 mt vs. sex- and age-matched wt; a total number of 10 
animals per sex and genotype were investigated except for ad libitum fed blood glucose of 
21- and 30-day-old mice which was determined in 5 animals per sex and genotype. 
 
C Figure 4.13: Blood glucose concentrations 
of neonatal (A), 1-day-old (B) and 4-day-old 
(C) homozygous and heterozygous Munich 
GckM210R mutants vs. wild-type littermates. 
Blood glucose levels of homozygous (homo) 
and heterozygous (het) mutants (mt) were 
significantly elevated vs. wild-type (wt) mice. 
Blood glucose remained stable in mt, het but 
increased largely in mt, homo mt until 4 days 
of age. Data represent means ± SD; *p<0.05 
mt, het vs. wt; †p<0.05 mt, homo vs. mt, het; 
§p<0.05 mt, homo vs. wt; n=number of animals 
examined. 
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Munich GckD217V mutants 
Homozygous and heterozygous Munich GckD217V mutants displayed significantly 
(p<0.05) elevated blood glucose levels already from birth. Blood glucose levels of 
neonatal homozygous mutants were 2.0- and 1.6-fold increased vs. wild-type 
littermates and heterozygous mutants, respectively. Blood glucose levels of neonatal 
heterozygous mutants were increased about 1.3-fold as compared to wild-type 
littermates (Fig. 4.14A). At an age of 1 day, blood glucose levels of homozygous 
mutants have raised to 125 ± 33 mg/dl (2.2-fold increase vs. wild-type), whereas the 
blood glucose concentrations of heterozygous mutants and wild-type mice increased 
slightly and to the same extent (Fig. 4.14B). At an age of 4 days, all homozygous 
mutants investigated displayed marked glucosuria.  
  
Figure 4.14: Blood glucose concentrations of neonatal (A) and 1-day-old (B) 
homozygous and heterozygous Munich GckD217V mutants vs. wild-type littermates. 
Blood glucose levels of homozygous and heterozygous mutants were significantly elevated 
during the period of investigation, remaining stable in heterozygous mutants and 
deteriorating little in homozygous mutants. Data represent means ± SD; *p<0.05 mt, het vs. 
wt; †p<0.05 mt, homo vs. mt, het; §p<0.05 mt, homo vs. wt; n=number of animals examined. 
 
Blood glucose levels of ad libitum fed homozygous mutants raised to 382 ± 36 mg/dl 
in male, and to 391 ±31 mg/dl in female mice until the time of weaning (at an age of 
21 days), representing a 3.3-fold increase as compared to wild-type mice, and a 2.6-
fold (in female homozygous mutants) and a 2.4-fold (in homozygous male mutants) 
increment as compared to age and sex- matched heterozygous mutants (p<0.05). 
Additionally, the diabetic phenotype of homozygous mutants deteriorated little until 
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an age of 90 days, remaining stable thenceforth. Blood glucose levels of ad libitum 
fed heterozygous mutants of both sexes were significantly elevated during all time 
points investigated, but remained considerably stable until and age of 175 days. 
Fasting blood glucose levels of heterozygous mutants of both sexes were first found 
to be elevated at an age of 30 days and remained stable for the period of 
investigation (Table 4.5). 
Table 4.5: Ad libitum fed and fasting blood glucose levels of male (m) and female (f) 
heterozygous (het) and homozygous (homo) Munich GckD217V mutants and wild-type 
littermates (wt). 
 Ad libitum fed blood glucose levels (mg/dl) Fasting blood glucose levels (mg/dl)
Age (days) Age (days) Group 
21 30 90 175 30 85 180 
m, wt 116 (± 16) 
131 
(± 11) 
127 
(± 5) 
133 
(± 13) 
79 
(± 10) 
91 
(± 12) 
101 
(± 15) 
m, het 161* (± 29) 
176* 
(± 8) 
184* 
(± 14) 
174* 
(± 22) 
101* 
(± 13) 
128* 
(± 13) 
138* 
(± 23) 
m, homo 382
§† 
(± 36) 
382§† 
(± 52) 
462§† 
(± 43) 
464§† 
(± 46) not determined 
f, wt 117 (± 11) 
118 
(± 9) 
111 
(± 3) 
118 
(± 11) 
86 
(± 15) 
79 
(± 8) 
82 
(± 8) 
f, het 151* (± 22) 
164* 
(± 24) 
191* 
(± 37) 
161* 
(± 9) 
107* 
(± 17) 
110* 
(± 10) 
105* 
(± 9) 
f, homo 391
§† 
(± 31) 
389§† 
(± 34) 
458§† 
(± 51) 
446§† 
(± 44) not determined 
Data represent means ± SD, *p<0.05 het vs. wt; †p<0.05 homo vs. het; §p<0.05 homo vs. wt; 
a total number of 7 animals per sex and genotype were investigated. 
4.4.2 Specific clinical findings 
Oral glucose tolerance tests (OGTT) were accomplished in 30-, 85-, and 180-day-old 
heterozygous Munich GckM210R and GckD217V mutants of both sexes and wild-type 
littermate control mice after a 15 h fasting period. During OGTT, basal blood glucose 
and serum insulin levels as well as changes in blood glucose and serum insulin 
concentrations in response to oral glucose application were determined for 
subsequent calculation of β-cell function indices and the area under glucose curve. 
Relative changes of blood glucose concentrations after intraperitoneal insulin 
application (intraperitoneal insulin tolerance test; ipITT) were determined in 
heterozygous mutants of both strains and wild-type controls at an age of 30, 90, and 
 91 
 
175 days, in order to assess peripheral insulin sensitivity. 
4.4.2.1 Course of blood glucose levels after oral glucose application 
Munich GckM210R mutant mouse 
During OGTT, 30-day-old male and female heterozygous mutants showed 
significantly (p<0.05) elevated blood glucose levels until 90 minutes after oral glucose 
application. At 120 minutes, blood glucose concentrations of heterozygous mutants 
were similar to those of wild-type mice (Fig. 4.15A). At an age of 85 and 180 days, 
blood glucose levels of heterozygous mutants were significantly increased at all time 
points during OGTT as compared to age- and sex-matched wild-type animals (Fig. 
4.15B, C). Blood glucose concentrations of male heterozygous mutants reached their 
maximum 30 minutes after glucose application, whereas blood glucose 
concentrations of wild-type mice and female heterozygous mutants had already 
reached the maximal glucose peak at 10-20 minutes in the 2 older age groups. The 
area under the glucose curve (AUC) was already significantly increased in 30-day-old 
heterozygous mutants of both sexes, and further deteriorated with age, while the 
AUC of wild-type mice remained almost constant until an age of 180 days. At an age 
of 30 days the AUC was 1.5-fold increased in male heterozygous mutants, and was 
1.6-fold higher in female mutants as compared to age- and sex-matched wild-type 
mice. At 180 days, the AUC was 1.9- (male) and 1.8-fold (female) increased vs. wild-
type mice (Fig. 4.15D). 
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C  
Figure 4.15: Oral glucose tolerance tests of 30- (A), 85- (B), and 180-day-old (C) Munich 
GckM210R mutants and wild-type control mice. (D) Area under the glucose curve (AUC) 
during oral glucose tolerance tests. Blood glucose levels during OGTT were significantly 
increased in heterozygous male (m) and female (f) mutants (mt) as compared to wild-type 
littermates (wt) (A-C), resulting in a significantly increased AUC (D). Data represent means ± 
SD. *p<0.05 m, mt vs. m, wt; †p<0.05 f, mt vs. f, wt; a total number of 10 animals per sex and 
genotype were examined. 
 
Munich GckD217V mutants 
During the OGTT at an age of 30 days male heterozygous mutants displayed 
significantly elevated blood glucose levels as compared to age- and sex-matched 
wild-type littermates at all time points investigated, whereas blood glucose 
concentrations of female heterozygous mutants were only significantly increased at 
30, 60, and 90 minutes after oral glucose load (Fig. 4.16A). At an age of 85 and 180 
days, blood glucose levels of heterozygous mutants of both sexes were significantly 
elevated during all time points investigated. Additionally, 180-day-old male 
heterozygous mutants displayed a maximum blood glucose peak at 30 minutes and a 
markedly prolonged decrease of blood glucose levels after reaching the maximum, 
whereas blood glucose concentrations of wild-type mice and female heterozygous 
mutants reached the maximum levels at 10-20 minutes after glucose administration 
(Fig. 4.16B, C). The area under the blood glucose curve (AUC) was already 
increased in 30-day-old heterozygous mutants by about 1.6-fold in male, and by 
about 1.3-fold in female mutants vs. wild-type mice. In 85-day-old heterozygous 
mutants, the AUC of heterozygous mutants was increased about 1.8- (male) and 1.7-
fold (female) as compared to age- and sex-matched wild-type littermates and this 
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C
increase vs. wild-type mice remained constant thereafter (Fig. 4.16D). 
  
  
Figure 4.16: Oral glucose tolerance tests of 30- (A), 85- (B), and 180-day-old Munich 
GckD217V mutants and wild-type control mice (C). (D) Area under the glucose curve 
(AUC) during oral glucose tolerance tests. Blood glucose levels during OGTT were 
significantly increased in heterozygous male (m) and female (f) mutants (mt) as compared to 
wild-type littermates (wt) (A-C), resulting in a significantly increased AUC (D). Data represent 
means ± SD; *p<0.05 m, mt vs. m, wt; †p<0.05 f, mt vs. f, wt; a total number of 7 animals per 
sex and genotype were examined. 
4.4.2.2 Serum insulin 
Munich GckM210R mutant mouse 
Serum insulin quantification by ELISA revealed unchanged basal (fasting) serum 
insulin concentrations in 30-day-old male, and in 30-, 85-, and 180-day-old female 
heterozygous mutants as compared to wild-type controls. At an age of 85 days, 
fasting serum insulin levels of male heterozygous mutants were found to be 
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decreased by about 50%, at an age of 180 days by about 57% (p<0.05) vs. wild-type 
littermates (Fig. 4.17A). Glucose-induced insulin secretion (difference of fasting 
insulin levels and insulin concentrations 10 minutes after glucose administration) was 
reduced by about 54-56% in male (p<0.05), and by about 53-71% (p<0.05) in female 
mutants vs. wild-type mice (Fig. 4.17B). 
  
Figure 4.17: Fasting serum insulin concentrations (A) and glucose-induced insulin 
secretion (Δ insulin = serum insulin concentrations 10 minutes after oral glucose 
bolus application minus fasting insulin levels) (B) in 30-, 85-, and 180-day-old Munich 
GckM210R mutants and wild-type control mice. Fasting serum insulin concentrations were 
significantly decreased in 85- and 180-day-old male heterozygous mutants (mt) vs. wild-type 
mice (wt). Additionally, glucose-induced insulin secretion was significantly decreased in 
heterozygous mutants of both genders vs. wild-type controls. Data represent means ± SEM; 
number of animals examined per group: n=10; *p<0.05 m, mt vs. m, wt; †p<0.05 f, mt vs. f, 
wt. 
 
Munich GckD217V mutant mouse 
Fasting serum insulin levels were decreased in heterozygous Munich GckD217V 
mutants of both sexes as compared to wild-type littermates, but reached a significant 
level only in 30- and 180-day-old male, and in 30-day-old female mutants (p<0.05) 
(Fig. 4.18A). At an age of 30 days, glucose-induced insulin secretion in heterozygous 
mutants was unaltered (104% of the wild-type delta insulin levels in male, and 93% in 
female mutants). However, from an age of 85 days onwards, heterozygous mutants 
of both genders displayed significantly (p<0.05) reduced insulin secretion after oral 
glucose administration. At an age of 85 days, delta insulin levels were decreased by 
about 46% in male, and by about 56% in female mutants, whereas in 180-day-old 
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mutants, this parameter was decreased by about 56% in male, and by about 80% in 
female mutants as compared to age- and sex-matched wild-type controls (Fig. 
4.18B). 
  
Figure 4.18: Fasting serum insulin concentrations (A) and glucose-induced insulin 
secretion (delta insulin = serum insulin concentrations 10 minutes after oral glucose 
bolus application minus fasting insulin levels) (B) in 30-, 85-, and 180-day-old Munich 
GckD217V mutants and wild-type control mice. Fasting serum insulin concentrations were 
decreased in heterozygous mutants (mt) vs. wild-type mice (wt). From an age of 85 days 
onwards, both genders displayed significantly reduced insulin secretion after oral glucose 
administration vs. wild-type controls. Data represent means ± SEM; a total number of 7 
animals per sex and genotype were examined; *p<0.05 m, mt vs. m, wt; †p<0.05 f, mt vs. f, 
wt. 
4.4.2.3 Beta cell function indices 
The homeostasis model assessments of baseline insulin secretion (HOMA B) and of 
insulin resistance (HOMA IR) were calculated by means of fasting blood glucose and 
serum insulin levels from heterozygous Munich GckM210R and GckD217V mutants and 
wild-type littermates, obtained in the course of OGTTs at an age of 30, 85, and 180 
days. 
 
Munich GckM210R mutant mouse 
The HOMA B was significantly (p<0.05) reduced in male heterozygous mutants of all 
examined age groups (range from 77-82% diminution) and in 30- and 180-day-old 
female heterozygous mutants (by about 74%-82%) vs. wild-type controls (Fig. 
4.19A). In contrast, the HOMA IR was not significantly altered in mutants of both 
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genders as compared to wild-type mice (Fig. 4.19B). 
  
Figure 4.19: Homeostasis model assessment of baseline insulin secretion (HOMA B) 
(A) and insulin resistance (HOMA IR) (B) in 30-, 85-, and 180-day-old Munich GckM210R 
mutants and wild-type control mice. The HOMA B was decreased in heterozygous 
mutants (mt) of both sexes, whereas the HOMA IR was not significantly altered as compared 
to wild-type controls (wt). Data represent means ± SEM. A total number of 10 animals per 
sex and genotype were investigated; *p<0.05 m, mt vs. m, wt; †p<0.05 f, mt vs. f, wt. 
 
Munich GckD217V mutant mouse 
The HOMA B of heterozygous mutants was 75-83% decreased in all examined age 
groups (Fig. 4.20A). The HOMA IR of heterozygous mutants of both sexes was not 
significantly altered vs. wild-type controls at all time points investigated. In male 
heterozygous mutants, the insulin resistance index even appeared slightly decreased 
vs. wild-type mice, at all time points investigated (Fig 4.20B). 
  
Figure 4.20: Homeostasis model assessment of baseline insulin secretion (HOMA B) 
(A) and insulin resistance (HOMA IR) (B) in 30-, 85-, and 180-day-old Munich GckD217V 
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mutants and wild-type control mice. The HOMA B was decreased in heterozygous 
mutants (mt) of both sexes, whereas the HOMA IR was comparable to wild-type controls (wt) 
or slightly decreased. Data represents mean ± SD. A total number of 7 animals per sex and 
genotype were investigated; *p<0.05 m, mt vs. m, wt; †p<0.05 f, mt vs. f, wt. 
4.4.2.4 Intraperitoneal insulin tolerance test (ipITT) 
Munich GckM210R mutant mouse 
At an age of 30 days, blood glucose decrease during ipITT was comparable between 
heterozygous mutants and wild-type mice (Fig. 4.21A), while 90- and 175-day-old 
male mutants showed a significantly (p<0.05) less pronounced decrease of blood 
glucose levels from basal, 10 and 90 minutes, and 10 and 20 minutes after 
intraperitoneal insulin application, respectively (Fig. 4.21B, C). In contrast, relative 
blood glucose decrease relative from basal was unchanged in female heterozygous 
mutants of all investigated age groups as compared to age- and sex-matched wild-
type littermates (Fig. 4.21A-C). 
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tolerance test (ipITT) in 30- (A), 90- (B), and 
175-day-old (C) Munich GckM210R mutants 
and wild-type controls. Relative blood 
glucose decrease was significantly less 
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Munich GckD217V mutants 
In 30- and 90-day-old male heterozygous Munich GckD217V mutants, blood glucose 
decrease 10 minutes after intraperitoneal insulin application was less pronounced as 
compared to wild-type mice (Fig. 4.22A, B). At 175 days of age, course of blood 
glucose decrease was unchanged in heterozygous male mutants vs. wild-type mice, 
at all time points investigated. In contrast, age-matched female heterozygous 
mutants displayed a significantly less pronounced decrease of relative blood glucose 
levels from basal, 10 and 20 minutes after insulin challenge as compared to wild-type 
controls (Fig. 4.22C). 
  
  
 
4.4.3 Comparison of clinical parameters of both strains 
For comparison of phenotypic features of Munich GckM210R and GckD217V mutants, 
clinical parameters were expressed relative to the respective sex-, and age-matched 
wild-type littermates. 
Figure 4.22: Intraperitoneal insulin 
tolerance test (ipITT) in 30- (A), 90- (B), and 
175-day-old (C) Munich GckD217V mutants 
and wild-type mice. Relative blood glucose 
decrease was significantly less pronounced in 
30- and 90-day-old male (m) and in 175-day-
old female (f) heterozygous mutants (mt) vs. 
wild-type mice (wt). Data represent means ± 
SD; n=number of animals investigated; 
*p<0.05 m, mt vs. m, wt; †p<0.05 f, mt vs. f, wt. 
0 10 20 30 60 90
0
50
100
m,wt (n=4)
m,mt (n=6)
f,wt (n=5)
f,mt (n=5)
*
Time  (min)
B
lo
od
 g
lu
co
se
 d
ec
re
as
e
re
la
tiv
e 
fr
om
 b
as
al
 (%
)
A 
C
0 10 20 30 60 90
0
50
100
m,wt (n=6)
m,mt (n=7)
f,wt (n=7)
f,mt (n=7)
*
Time  (min)
B
lo
od
 g
lu
co
se
 d
ec
re
as
e
re
la
tiv
e 
fr
om
 b
as
al
 (%
)
0 10 20 30 60 90
0
50
100
m,wt (n=7)
m,mt (n=7)
f,wt (n=7)
f,mt (n=7)†
†
Time  (min)
B
lo
od
 g
lu
co
se
 d
ec
re
as
e
re
la
tiv
e 
fr
om
 b
as
al
 (%
)
B 
 99 
 
4.4.3.1 Body weight of neonatal and 3-day-old mutants 
Relative birth weight of heterozygous and homozygous Munich GckM210R and 
GckD217V mutants did not differ (Fig.4.23A). However, at an age of 3 days, the relative 
body weight of homozygous GckM210R mutants was about 46% (p<0.05) lower vs. 
homozygous GckD217V mutants (Fig 4.23B). 
  
Figure 4.23: Body weight of neonatal (A) and 3-day-old (B) heterozygous and 
homozygous Munich GckM210R (M210R) and GckD217V (D217V) mutants, illustrated as 
percent of wild-type body weight. Relative birth weight of mutants (mt) of both strains was 
comparable, whereas 3-day-old homozygous GckM210R mutants (M210R) showed a 
significantly reduced relative body weight as compared to homozygous GckD217V (D217V) 
mutants. Data represent means ± SD; n=number of animals investigated. *p<0.05 M210R 
mt, homozygous vs. D217V mt, homozygous 
4.4.3.2 Blood glucose levels of neonatal and 1-day-old mutants 
Blood glucose levels, relative to wild-type controls, of neonatal and 1-day-old 
heterozygous mutants did not differ between Munich GckM210R and GckD217V mutants 
(Fig. 4.24A, B). Relative blood glucose concentrations were about 2.9- and 3.8-fold 
higher in neonatal and 1-day-old homozygous GckM210R mutants vs. homozygous 
GckD217V mutants, respectively (Fig. 4.24A, B). 
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Figure 4.24: Blood glucose levels of neonatal (A) and 1-day-old (B) heterozygous and 
homozygous Munich GckM210R (M210R) and GckD217V (D217V) mutants, illustrated as 
percent of wild-type blood glucose levels. Blood glucose levels of heterozygous mutants 
(mt) of both strains were comparable, whereas neonatal and 1-day-old homozygous GckM210R 
mutants (M210R) exhibited significantly higher relative blood glucose concentrations than 
homozygous GckD217V (D217V) mutants. Data represent means ± SD; n=number of animals 
investigated; *p<0.05 M210R mt, homozygous vs. D217V mt, homozygous. 
4.4.3.3 Glucose tolerance in heterozygous mutants 
The area under the glucose curve (AUC), relative to wild-type controls, did not 
significantly differ in 30- and 85-day-old male and female heterozygous mutants of 
both strains, whereas at an age of 180 days, the relative AUC was significantly 
higher in male GckM210R mutants as compared to age- and sex-matched GckD217V 
mutants (Fig. 4.25). 
 
Figure 4.25: Area under the blood glucose curve (AUC) during oral glucose tolerance 
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tests of 30-, 85-, and 180-day-old male and female heterozygous Munich GckM210R and 
GckD217V mutants, presented as percentage of wild-type AUC. The relative AUC of 180-
day-old male GckM210R mutants was significantly higher as compared to male GckD217V 
mutants. Data represent means ± SD; number of animals investigated per sex: GckM210R 
mutants: 10; GckD217V mutants: 7; *p<0.05 male GckM210R mutants vs. male GckD217V mutants. 
4.4.3.4 Serum insulin levels in heterozygous mutants 
Munich GckM210R and GckD217V mutants of both genders displayed comparable fasting 
serum insulin concentrations relative to wild-type controls in all examined age groups 
(Fig. 4.26A), whereas delta insulin secretion, relative to wild-type littermates, was 
significantly (p<0.05) lower in 30-day-old male and in 30- and 85-day-old female 
GckM210R mutants vs. GckD217V mutants. However, at an age of 180-days, glucose-
induced insulin secretion relative to wild-type controls was significantly lower in 
female GckD217V mutants as compared to age- and sex-matched GckM210R mutants 
(Fig. 4.26B). 
  
Figure 4.26: Fasting serum insulin concentrations (A) and delta insulin secretion after 
glucose application (B) of 30-, 85-, and 180-day-old male and female heterozygous 
Munich GckM210R and GckD217V mutants, relative to wild-type serum insulin 
concentrations (%). Relative fasting serum insulin concentrations did not differ between 
mutants of both strains, whereas delta insulin secretion relative to wild-type mice was 
significantly lower in 30-day-old male, and in 30- and 85-day-old female GckM210R mutants but 
higher in 180-day-old female GckM210R mutants vs. sex-matched GckD217V mutants. Data 
represent means ± SEM; number of animals investigated per sex: GckM210R mutants: n=10; 
GckD217V mutants: n=7; *p<0.05 male GckM210R mutants vs. male GckD217V mutants; †p<0.05 
female GckM210R vs. female GckD217V mutants. 
A
30 85 180      30 85 180       30 85 180       30 85 180
0
50
100
150
   Male animals       Female animals
   days          days           days          days
GckM210R
GckD217V
Fa
st
in
g 
in
su
lin
 re
la
tiv
e
to
 w
ild
-t
yp
e 
(%
)
B 
30 85 180     30 85 180      30 85 180      30 85 180
0
50
100
150
   Male animals       Female animals
   days          days          days          days
GckM210R
GckD217V
*
†
† †
Δ  i
ns
ul
in
 r
el
at
iv
e 
to
w
ild
-t
yp
e 
(%
)
 102 
 
30 85 180     30 85 180      30 85 180      30 85 180
0
25
50
75
   Male animals     Female animals
   days          days         days          days
GckM 210R
GckD217V
H
O
M
A
 B
 re
la
tiv
e 
to
w
ild
-ty
pe
 (%
)
4.4.3.5 Homeostasis model assessment of baseline insulin secretion (HOMA B) 
The β-cell function index, relative to wild-type mice was not significantly different 
comparing age- and sex-matched heterozygous mutants of both strains (Fig. 4.27) 
 
Figure 4.27: Homeostasis model assessment of baseline insulin secretion (HOMA B) 
of 30-, 85-, and 180-day-old male and female heterozygous Munich GckM210R and 
GckD217V mutants, relative to wild-type. The HOMA B index relative to wild-type mice of 
both strains was comparable. Data represent means ± SEM; number of animals investigated 
per sex: GckM210R mutants: n=10; GckD217V mutants: n=7. 
4.5 Survival studies in Munich GckM210R and GckD217V mutants 
Munich GckM210R mutant mouse 
The survival rates of heterozygous and homozygous Munich GckM210R mutants and 
wild-type littermates were determined from the first day post partum until an age of 
365 days. Mice of all genotypes were born as expected according to the Mendelian 
pattern of inheritance. At the first day post partum, 2 of 6 male homozygous mutants 
died within the first 6 hours of life. During the following days, 2 male homozygous 
mutants deceased at 4 days of age, the other 2 male homozygous mutants died at 
an age of 5 and 6 days (Fig. 4.28A). Within the group of female homozygous 
mutants, 3 of 4 mice died between an age of 5 and 6 days, the last homozygous 
littermate died at 6 days of age (Fig. 4.28B). All homozygous mutants showed 
reduced body condition, marked glucosuria, and hyperglycaemia within the first 4 
days of life as described in chapter 4.4.1.1 and 4.4.1.2. Homozygous mutants 
displayed a significantly reduced life span as compared to wild-type mice and 
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heterozygous mutants and were suspected to have died of severe diabetes mellitus 
with an average survival period of 4 days. Pathological organ findings in homozygous 
mutants are described in chapter 4.7.  
One male heterozygous mutant deceased at an age of 4 days, one female 
heterozygous mutant died at an age of 7 days. The affected animals displayed 
reduced body condition and low body weight during the days ante mortem, so that 
asthenia might be causal for the early death of these animals. Post-weaning, 1 of 10 
male wild-type mice died at 134 days of age without any obvious organ alteration. 
One of 10 female wild-type and 1/9 male heterozygous mutant mice were euthanised 
at the age of 174 and 287 days, respectively, due to severely reduced body condition 
and malignant tumours (lymphoma).  
In summary, the survival rate of heterozygous Munich GckM210R mutants of both 
genders was comparable to wild-type littermates, while homozygous mutants 
exhibited a markedly constrained life span. 
  
Figure 4.28: Survival rates of male (A) and female (B) heterozygous and homozygous 
Munich GckM210R mutants and wild-type littermates. While homozygous (homo) mutants 
(mt) died until an age of 6 days, life span of heterozygous mutants (het) was not constrained 
as compared to wild-type controls (wt). Data represent percentage of live animals out of all 
mice born per group; n=number of animals examined per group. 
 
Munich GckD217V mutant mouse 
The mean survival period of heterozygous and homozygous Munich GckD217V 
mutants and wild-type littermates was determined from the first day post partum until 
an age of 200 days. Mice of all 3 genotypes and both genders were born in the 
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expected pattern of Mendelian inheritance. One of 10 male homozygous mutants and 
1 of 10 female wild-type mice died at an age of 1 day. One of 10 male heterozygous 
mutants displayed low birth weight, growth retardation, and died at an age of 8 days, 
most likely as a consequence of general weakness and energy poverty (Fig. 4.29A, 
B). None of the remaining animals deceased until an age of 200 days and the animal 
collective will be under ongoing survey until an age of 365 days. 
  
Figure 4.29: Survival rates of male (A) and female (B) heterozygous and homozygous 
Munich GckD217V mutants and wild-type littermates. Life span of heterozygous (het) and 
homozygous (homo) mutants (mt) was not constrained as compared to wild-type controls 
(wt). Data represent percentage of living mice out of all mice born per group. A total number 
of 10 animals per sex and genotype were investigated. 
4.6 Organ weights 
Organ weights were determined in 210-day-old heterozygous Munich GckM210R and 
GckD217V mutants of both sexes and wild-type littermates as controls. Absolute kidney 
weight of male heterozygous GckD217V mutants was significantly increased vs. sex-
matched wild-type controls. However, kidney weight relative to the body weight was 
unaltered in these animals vs. wild-type mice (2.01 ± 0.13% vs. 1.88 ± 0.12%). 
Further, the absolute and relative weights of the intestine filled with ingesta and 
without ingesta were inconsiderably increased in female Munich GckD217V mutants as 
compared to wild-type mice. Other absolute (Table 4.6) and relative organ weights 
(data not shown) of heterozygous mutants of both strains and genders were 
comparable to those of wild-type mice. 
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Table 4.6: Organ weights of 210-day-old male (m) and female (f) heterozygous Munich 
GckM210R and GckD210V mutants (mt) and wild-type littermates (wt). 
Munich GckM210R mutant mouse Munich GckD217V mutant mouse 
 
Organ 
m, wt m, mt f, wt f, mt m, wt m, mt f, wt f, mt 
Carcass 
(g) 
15.4 
(± 1.1) 
15.1 
(± 0.7) 
14.3 
(± 0.3) 
13.8 
(± 0.3)  
14.7 
(± 0.5) 
15.3 
(± 0.9) 
12.6 
(± 0.5) 
12.4 
(± 0.3) 
GIT (filled 
with ingesta) 
(g) 
3.8 
(± 0.2) 
3.4 
(± 0.3) 
3.5 
(± 0.5) 
3.4 
(± 0.3)  
2.4 
(± 0.2) 
2.4 
(± 0.2) 
2.2 
(± 0.1) 
2.4† 
(± 0.2) 
GIT (without 
ingesta) (g) 
2.0 
(± 0.1) 
1.9 
(± 0.1) 
1.9 
(± 0.1) 
2.0 
(± 0.1)  
1.6 
(± 0.1) 
1.7 
(± 0.2) 
1.5 
(± 0.1) 
1.8† 
(± 0.1) 
Abdominal  
fat (mg) 
406 
(± 163)
430 
(± 114) 
317 
(± 135)
425 
(± 123)  
523 
(± 169)
669 
(± 537) 
246 
(± 137) 
295 
(± 95) 
Mesentery 
(mg) 
251 
(± 54) 
239 
(± 16) 
149 
(± 72) 
275 
(± 86)  
215 
(± 56) 
278 
(± 81) 
208 
(± 50) 
168 
(± 34) 
Liver 
(g) 
1.6 
(± 0.1) 
1.5 
(± 0.1) 
1.4 
(± 0.1) 
1.5 
(± 0.1)  
1.2 
(± 0.1) 
1.3 
(± 0.1) 
1.1 
(± 0.1) 
1.1 
(±0.1) 
Kidney 
(mg) 
589 
(± 69) 
561 
(± 65) 
514 
(± 120)
475 
(± 192)  
526 
(± 24) 
602*a 
(± 47) 
316 
(± 13) 
323 
(± 16) 
Spleen 
(mg) 
82 
(± 14) 
85 
(± 5) 
106 
(± 10) 
118 
(± 8)  
64 
(± 9) 
70 
(± 6) 
81 
(± 7) 
90 
(± 20) 
Lung 
(mg) 
160 
(± 15) 
172 
(± 12) 
177 
(± 12) 
173 
(± 18)  
150 
(± 4) 
149 
(± 6) 
130 
(± 15) 
133 
(± 13) 
Heart 
(mg) 
153 
(± 14) 
144 
(± 11) 
131 
(± 4) 
128 
(± 5)  
163 
(± 23) 
152 
(± 12) 
132 
(± 3) 
124 
(± 13) 
Adrenal 
glands (mg) 
5.1 
(± 0.8)
4.8 
(± 0.8) 
7.2 
(± 1.5) 
7.7 
(± 1.1)  
5.6 
(± 1.2) 
5.4 
(± 2.2) 
5.9 
(± 0.6) 
5.3 
(± 0.5) 
Thymus 
(mg) 
22 
(± 3) 
24 
(± 2) 
34 
(± 8) 
25 
(± 4)  
20 
(± 4) 
25 
(± 1) 
26 
(± 5) 
22 
(± 7) 
Testes 
(mg) 
160 
(± 4) 
145 
(± 4)    
143 
(± 10) 
135 
(± 1)   
Epididymes 
(mg) 
70 
(± 8) 
69 
(± 5)    
57 
(± 5) 
56 
(± 7)   
Ovaries 
(mg)   
17 
(± 5) 
18 
(± 6)    
14 
(± 2) 
15 
(± 4) 
 
Data represent means ± SD. A total number of 4 animals per sex and genotype were 
examined. *p<0.05 male mutant (m, mt) vs. male wild-type (wt); †p<0.05 female (f) mutant vs. 
f, wt. a relative kidney weight of m, mt was unaltered vs. wt, m. 
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4.7 Analysis of specific organ alterations in Munich GckM210R mutants 
Necropsy of 4-day-old homozygous and heterozygous Munich GckM210R mutants and 
wild-type littermates disclosed genotype-dependent gross liver alterations. Livers of 
homozygous mutants showed a pale beige colour vs. dark red-brown livers of 
heterozygous mutants and wild-type control mice (Fig. 4.30A). Histological analysis 
of haematoxylin-eosin (HE) stained liver sections from 4-day-old mice revealed 
normal hepatic tissue of wild-type mice (Fig. 4.30B), discrete vacuolisation of 
hepatocytes in heterozygous mutants (Fig. 4.30C), and extensive hepatocyte 
vacuolisation in homozygous mutants (Fig. 4.30D). In frozen liver sections from wild-
type mice, stained for neutral lipids, only singular and small fat droplets (Fig. 4.30E) 
were identified, whereas fat accumulation in the liver of heterozygous mutants was 
more pronounced (Fig. 4.30F). Liver sections of homozygous mutants, by contrast, 
displayed massive hepatocellular deposition of large fat droplets, reflecting marked 
hepatic steatosis (Fig. 4.30G). Furthermore, high amounts of glycogen granules were 
observable in periodic acid-Schiff (PAS) stained liver sections of wild-type mice (Fig. 
4.30H), whereas glycogen storage was obviously reduced in heterozygous mutants 
(Fig. 4.30I) and almost undetectable in homozygous mutants (Fig. 4.30J). 
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Figure 4.30: Gross appearance of livers from a 4-day-old homozygous Munich 
GckM210R mutant and a wild-type littermate (A). B-J: liver sections of a wild-type mouse 
(B, E, H); a heterozygous mutant (C, F, I), and a homozygous (D, G, J) mutant, paraffin 
embedded, stained with HE (B-D) or PAS (H-J), and Fat red staining of frozen liver 
tissue (E-G). Grossly, the liver of the homozygous mutant appeared markedly lighter in 
colour vs. the wild-type mouse. Histology revealed slight vacuolisation and lipid droplets in 
hepatocytes of heterozygous mutants (C, F) and marked vacuolisation and lipid 
accumulation in hepatocytes of homozygous mutants (D, G). Additionally, hepatocytes of 
heterozygous mutants exhibited discrete (I), those of homozygous mutants striking glycogen 
depletion (J), vs. wild-type mice (H). 
4.8 Qualitative histological evaluation of the endocrine pancreas 
4.8.1  Munich GckM210R mutants 
4.8.1.1 Pancreata from neonatal mice 
Due to the premature morphologic organisation of pancreatic islets in neonatal mice, 
the predominance of cumulative, duct-associated pancreatic islets, and the presence 
of widespread, connective tissue-similar, fibrous cords, islet demarcation was difficult 
to define at this age. Haematoxylin-eosin (HE) as well as connective tissue staining 
(Masson’s trichrome stain modified according to Goldner and Weigert) and 
immunohistochemical staining for insulin could not reveal a defined pancreatic islet 
contour (Fig 4.31A-C). Therefore, with regard to subsequent quantitative histological 
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analysis of the pancreas sections, pancreatic islets could not serve as reference 
compartment at this age group. However, immunohistochemical staining for insulin of 
pancreas sections of neonatal mice suggested comparable profiles of insulin positive 
stained β-cell areas in homozygous and heterozygous Munich GckM210R mutants vs. 
wild-type littermates (Fig. 4.32A-C). 
  
  
 
   
Figure 4.32: Pancreas sections from neonatal heterozygous (B) and homozygous (C) 
Munich GckM210R mutants (mt) and a wild-type control animal (A) in an 
immunohistochemical staining for insulin. The cross-sectional area of β-cells 
immunostained for insulin appeared unaltered among the different genotypes. 
Figure 4.31: Pancreas sections of a 
neonatal heterozygous Munich GckM210R 
mutant mouse, stained with HE (A) and 
modified Masson's trichrome (B). C: 
immunohistochemical staining for insulin 
(C). None of the stainings could reveal 
defined islet demarcation.  
100 µm 
B 
100 µm 
A
100 µm 
C
wild-type, m mt, homozygous, m mt, heterozygous, m 
A C B 
100µm 100µm 100µm 
 109 
 
4.8.1.2 Pancreata from 210-day-old mice 
Considering gross morphology and histological appearance, pancreata from 210-
day-old heterozygous mutants of both sexes were unaltered as compared to wild-
type littermates and no evidence for the presence of any inflammatory event in the 
pancreatic islets was detectable in these animals. Insulin-immunostaining of 
pancreas sections from heterozygous mutants revealed typical islet composition and 
distribution of insulin+ stained cells within the islets. Additionally, β-cell staining 
intensity for insulin was also comparable to control mice and the relative amount of 
insulin+ cells seemed to be unaltered vs. wild-type mice. However, the cross-
sectional area of pancreatic islets appeared conspicuously smaller in male 
heterozygous mutants as compared to wild-type control mice (Fig. 4.33 A-D). 
  
  
Figure 4.33: Pancreas sections of a 210-day-old male (m) heterozygous Munich 
GckM210R mutant (mt) and a male wild-type mouse immunostained for insulin. Staining 
intensity and the distribution of the insulin producing β-cells in the islets did not differ 
between male heterozygous mutants (B, D) and male wild-type controls (A, C). Broad 
overview over pancreas sections (A, B) and exemplary depiction of single islets (C, D) 
revealed the impression that islet area was considerably smaller in male heterozygous 
mutants vs. the wild-type control. 
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4.8.2 Munich GckD217V mutants  
4.8.2.1 Pancreata from 550-day-old mice 
Macroscopically and histologically, pancreata from 550-day-old heterozygous and 
homozygous Munich GckD217V mutants appeared normal and no evidence for any 
inflammatory event in the islets was observable. Staining intensity of insulin+ β-cells 
and their distribution in pancreatic islets was comparable to wild-type mice. However, 
the broached area of pancreatic islets appeared strikingly decreased in male 
homozygous mutants as compared to wild-type mice and heterozygous mutants. 
Additionally, the amount of insulin producing β-cells was slightly reduced in 
heterozygous mutants, and considerably less insulin expressing cells were 
detectable in homozygous mutants as compared to wild-type mice (Fig. 4.34 A-F)  
   
  
Figure 4.34: Pancreas sections from 550-day-old male heterozygous and homozygous 
Munich GckD217V mutants and a wild-type control immunohistochemically stained for 
insulin. As already visible in a minor magnification (A-C), the cross sectional areas of islets 
appeared comparable in male (m) heterozygous mutants (mt) and wild-type mice, but were 
considerably smaller in homozygous mutants. Higher magnification of these sections (D-F) 
also suggested conspicuously reduced β-cell content in pancreatic islets of homozygous and 
heterozygous mutants. 
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4.9 Quantitative stereological analysis of the endocrine pancreas 
4.9.1 Munich GckM210R mutants 
4.9.1.1 Stereological findings in pancreata from neonatal male mice 
At the first day post partum, the pancreas volume (V(pan), Fig. 4.35A) of male 
heterozygous and homozygous Munich GckM210R mutants was unaltered as 
compared to wild-type littermates. Even if the volume density of β-cells in the 
pancreas (Vv(β-cells/pan); Fig 4.35B) and the total β-cell volume (V(β-cells,pan); Fig. 4.35C) 
of heterozygous and homozygous mutants did not significantly deviate from wild-type 
controls, both parameters were decreased by tendency in homozygous mutants at 
this age. 
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Figure 4.35: Quantitative stereological 
analysis of pancreata from neonatal Munich 
GckM210R mutants and wild-type control mice: 
The pancreas volume (V(pan); A), the volume 
density of β-cells in the pancreas (Vv(β-cells/pan); 
B) and the total β-cell volume (V(β-cells,pan); C) 
was unaltered in both, male (m) heterozygous 
(het) and homozygous (homo) mutants vs. wild-
type mice (wt). Data represent means ± SD; 
n=number of animals examined per group. 
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4.9.1.2 Quantitative stereological parameters of pancreata from 210-day-old mutants 
The pancreas volume (V(pan), Fig. 4.36A) was unaltered in 210-day-old heterozygous 
mutants of both genders as compared to wild-type mice. The volume density of islets 
in the pancreas (Vv(islets/pan); Fig. 4.36B) was significantly (p<0.05) decreased by 
about 25% (range from 18-36%) in male, but not female heterozygous mutants, 
whereas the volume density of β-cells in the islets (Vv(β-cells/islets) Fig. 4.36D) was 
unaltered in mutants of both genders. Consistent with these findings, male mutants 
exhibited reduced total islet (V(islets,pan); Fig. 4.36C) and total β-cell volumes (V(β-cells, 
islets); Fig. 4.36E) by about 25% and 33% (p<0.05), respectively, whereas these 
parameters were unchanged in female heterozygous mutants as compared to age- 
and sex-matched wild-type littermates. Additional quantification of isolated β-cells in 
pancreata from male mice revealed a significant (p<0.05) reduction of the volume 
density of isolated β-cells in the pancreas (Vv(isolated β-cells/pan); Fig. 4.36F) by about 
33% in male heterozygous mutants vs. wild-type controls. Analogically, the total 
volume of isolated β-cells (V(isolated β-cells,pan); Fig. 4.36G) was diminished by about 31% 
in these animals. 
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Figure 4.36: Quantitative stereological evaluation of pancreas sections from 210-day-
old heterozygous Munich GckM210R mutants and wild-type littermates. The pancreas 
volume (V(pan); A) and the volume density of β-cells in the islets (Vv(β-cells/islets); D) were 
unaltered in male (m) and female (f) mutants (mt) vs. wild-type mice (wt), whereas the 
volume densities of islets (Vv(islets/pan); B) and of isolated β-cells (Vv(isolated β-cells/pan); F) in the 
pancreas, as well as the total volumes of islets (V(islets,pan); C), β-cells (V(β-cells,islets); E) and 
isolated β-cells (V(isolated β-cells,pan); G) were significantly decreased in male mutants. Data 
represent means ± SD. A total number of 4 animals per sex and genotype were examined. 
*p<0.05 m, mt vs. m, wt. 
4.9.2 Munich GckD217V mutants 
4.9.2.1 Stereological findings in pancreata from 550-day-old male mice 
At an age of 550 days, the pancreas volume (V(pan), Fig. 4.37A) was comparable 
between male heterozygous and homozygous Munich GckD217V mutants and age- 
and sex-matched wild-type littermates. The volume density of the islets in the 
pancreas (Vv(islets/pan); Fig. 4.37B) in homozygous mutants was reduced by about 45% 
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as compared to wild-type mice, and by about 35% vs. heterozygous mutants, 
whereas Vv(islets/pan) was unaltered in heterozygous mutants. Further, homozygous 
and heterozygous mutants exhibited a significantly (p<0.05) reduced volume density 
of the β-cells in the islets (Vv(β-cells/islets), Fig. 4.37D). However, this reduction was 
marginal, especially in heterozygous mutants (diminution by about 14% in 
homozygous mutants and by about 6% in heterozygous mutants as compared to 
wild-type mice). Additionally, the total islet (V(islets,pan); Fig. 4.37C) and β-cell volumes 
(V(β-cells,islets); Fig. 4.37E) of homozygous mutants were significantly (p<0.05) 
decreased by about 47% and 54%, respectively as compared to wild-type mice. In 
contrast to homozygous mutants, heterozygous mutants exhibited an unaltered 
V(islets,pan) and an only slightly reduced V(β-cells,islets). 
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Figure 4.37: Quantitative stereological parameters of pancreas sections from 550-day-
old male heterozygous and homozygous Munich GckD217V mutants and wild-type 
animals. The pancreas volume (V(pan); A) did not differ between mice of all genotypes. The 
volume density of the islets in the pancreas (Vv(islets/pan); B), the volume density of the β-cells 
in the islets (Vv(β-cells/islets); D), and, consequentially, the total islet (V(islets,pan); C) and β-cell 
volumes (V(β-cells,islets); E) were significantly decreased in male (m) homozygous mutants vs. 
wild-type mice (wt) and heterozygous mutants (het), whereas in heterozygous mutants only 
Vv(β-cells/islets) was significantly diminished. Data represent means ± SD; n=number of animals 
investigated per genotype. *p<0.05 het vs. wt; †p<0.05 homo vs. het; §p<0.05 homo vs. wt. 
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5. Discussion 
In the present study, two hyperglycaemic mutant mouse strains, which were detected 
in the clinical-chemical screen for dominant mutations within the Munich ENU mouse 
mutagenesis project, were investigated. The location and nature of the respective 
causative mutations were characterised, as well as the resulting diabetic phenotype 
and the pathomorphological features of both strains were investigated. Both strains 
were established by breeding diabetic heterozygous mutants for more than 10 
generations onto the inbred C3H genetic background, which is supposed to be a 
diabetes-resistant strain (Leiter et al. 1999). This led to the loss of most additional 
ENU-induced non-causative mutations and excluded eventual phenotypic influences 
of these mutations. Standardisation of animal husbandry and treatment, 
randomisation of animal and biological material selection for investigations, and 
uniformisation of sample materials, concerning origin and mode of processing were 
emphasised in this study. 
5.1 Genetic aspects 
Low-resolution SNP genotyping of GLS001 and GLS006 mice and subsequent high-
resolution linkage analysis of GLS001 mice mapped the diabetic phenotype of both 
strains to polymorphic DNA markers on chromosome 11 at 5.9 and 7.1 Mb, 
respectively. The mouse genome database query for positional diabetes-associated 
genes revealed the glucokinase (Gck) gene as potential candidate gene for 
sequencing. Sequence analysis of Gck revealed a defined point mutation in exon 6 of 
Gck in both strains. The ENU strain GLS001 exhibited a T to G transversion at 
nucleotide position (nt) 629, leading to an amino acid exchange from methionine to 
arginine at position 210. In GLS006 mice an A to T transversion at nt 650 was 
identified, thereby resulting in an amino acid exchange from aspartic acid to valine at 
position 217. According to the respective missense mutations, the laboratory names 
GLS001 and GLS006 were replaced by the official terms Munich GckM210R and 
GckD217V mutant mouse. Mutations in the human glucokinase (GCK) gene are 
associated with 2 distinct phenotypic traits. Mutations can either cause 
hypoglycaemia (when activating glucokinase function) or hyperglycaemia (when 
impairing glucokinase function). While heterozygous inactivating mutations are 
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reported to cause maturity-onset diabetes of the young, type 2 (MODY 2), 
homozygous mutations are associated with neonatal diabetes mellitus (NDM) (Gloyn 
2003). Four M210 mutations and 1 D217 mutation have already been detected in 
human diabetic subjects, whereas base exchanges at these two positions have not 
yet been detected in other animal models so far. Referring to the missense mutation 
M210 in human subjects, the base exchanges from methionine to lysine (M210K) has 
been discovered to cause MODY 2 and NDM, whereas the mutations M210T, 
M210V, and M210I (amino acid exchange to threonine, to valine, or to isoleucine, 
respectively) have only been identified in families with MODY features. At position 
D217, only the amino acid exchange from aspartic acid to glutamic acid (D217E) has 
been reported to be associated with MODY 2 (Njolstad et al. 2001; Osbak et al. 
2009; Sagen et al. 2006; Velho et al. 1997). Various knockout mouse models for 
MODY 2 have already been generated by targeted global or tissue-specific disruption 
of Gck (Bali et al. 1995; Grupe et al. 1995; Postic et al. 2001; Postic et al. 1999; 
Terauchi et al. 1995)  (http://www.informatics.jax.org/). However, monogenic 
diseases like MODY 2 in human beings usually arise from single point mutations and 
include a broad spectrum of phenotypic outcomes depending on the position and the 
nature of the mutation. Knockout strategies which target complete ablation of the 
respective gene transcript, might fail to produce animal models that recapitulate 
human disease phenotypes. Therefore, animal models exhibiting naturally occurring 
or induced mutations represent additional useful tools to dissect specific gene 
functions (Clark et al. 1994; Oliver et al. 2007; Peltonen and McKusick 2001). A total 
number of 15 ENU-induced glucokinase mutant mouse strains have been generated 
in various ENU-driven mutagenesis projects (Fenner et al. 2009; Inoue et al. 2004; 
Toye et al. 2004) (http://www.informatics.jax.org/). In the screen for dominant 
mutations of the RIKEN mutagenesis project (RIKEN BioResouces Center), 12 of 17 
mouse strains exhibiting hyperglycaemia were identified to bear single-base pair 
substitutions in Gck (http://www.brc.riken.jp/lab/gsc/mouse/). This predominance of 
ENU-induced Gck mutations might be due to the high penetrance of Gck defects, a 
great sensitivity of the glucokinase protein to amino acid exchanges or may arise 
from the fact that Gck haploinsufficiency leads to abnormal phenotypic traits (Inoue et 
al. 2004). Another probable explanation for the plenitude of Gck mutations, identified 
in screens for hyperglycaemia in other ENU mutagenesis projects, might be founded 
in the structural properties of Gck. Exhibiting a surpassing coding sequence length 
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(1,398 bp vs. 1,137 bp median coding sequence for the mouse genome), a high exon 
number (11 exons vs. a median exon number of 6), and an above-average G+C-
content (57.3% vs. a median G+C-content of about 45%), Gck may be more 
frequently targeted by ENU-induced base exchanges than other genes for statistical 
reasons (Barbaric et al. 2007). 
The occurrence of the diabetic phenotype in both Munich GckM210R and GckD217V 
mutants remained unaltered in ensuing generations, giving proof of the heritability 
and the complete penetrance of the abnormal phenotype. Together with the linkage 
analysis carried out and the revelation of the functional consequences of the 
respective mutations, these findings indicate that the identified missense mutations in 
Gck are causative for the diabetic phenotype of both mouse strains. 
The induction of different mutations in the same gene represents an extremely 
powerful tool to address the question of gene and protein function (Justice et al. 
1999). An impressive example of an allelic series is the quaking locus. Prior to ENU 
mutagenesis, the quaking locus was defined by a single spontaneous allele, 
characterised by quaking and seizures as a result of defective CNS myelination in 
homozygous mutants. The identification of novel ENU-induced alleles indicated an 
additional involvement of quaking in embryogenesis (Justice and Bode 1988; Sidman 
et al. 1964).  
Since the causative mutations in Munich GckM210R and GckD217V mutants are located 
in a distance of only 7 amino acids to each other, the creation of an allelic series in 
these mouse strains represents an extremely valuable genetic resource for detailed 
dissection of the impact of alterations at different amino acid residues of the 
glucokinase protein on phenotypic and pathomorphologic traits.  
5.2 Functional consequences of the mutations 
5.2.1 Glucokinase activity 
The glucose phosphorylation rate by glucokinase in liver homogenate of 90-day-old 
mice was considerably reduced in heterozygous mutants of both strains, whereas the 
activity of other hexokinases and their affinity for glucose was not altered. Impairment 
of glucokinase substrate turnover rate was slightly more pronounced in Munich 
GckM210R than in GckD217V mutants (relative reduction of about 43% in M210R vs. 
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33% in D217V mutants). In homozygous GckD217V mutants, glucokinase activity and 
the affinity for glucose were severely reduced, indicating the striking impact of the 
mutation on glucokinase function when present on both alleles. Enzyme activity 
studies with recombinant M210K mutant glucokinase already revealed a reduction of 
glucokinase activity for heterozygous mutations, comparable to the reduction 
observed in Munich GckM210R mutants. The catalytic activity of the recombinant 
glucokinase, homozygous for the mutation M210K, was almost undetectable (about 
0.16% of wild-type enzyme activity), whereas the S0.5 was about 7-fold increased 
(Aguilar-Bryan and Bryan 2008; Njolstad et al. 2001; Sagen et al. 2006). The S0.5, 
reflecting the affinity of the glucokinase enzyme for its main substrate glucose, was 
unaltered in heterozygous GckD217V and was only slightly increased in GckM210R 
mutants. However, compensatory in vivo mechanisms might mask a reduced affinity 
of the mutant glucokinase to glucose in both strains. Attenuation of inhibitory effects 
of the glucokinase regulatory protein, which binds to hepatic glucokinase and 
decreases its affinity for glucose (Agius et al. 2001), is thought to represent a 
possible compensatory adaption to increase the glycolytic flux of glucose through the 
mutated glucokinase enzyme (Sturis et al. 1994; Veiga-da-Cunha et al. 1996). The 
effect of Gck haploinsufficiency on glucokinase activity has already been 
demonstrated for heterozygous global, liver- and β-cell specific Gck knockout mouse 
models, which displayed different degrees of glucokinase activity impairment. 
However, mice that lack one Gck allele either in the liver or in liver and pancreatic β-
cells exhibit a reduction of glucokinase activity by less than 50%, thereby implying 
the presence of potential compensatory mechanisms. This assumption is 
emphasised by the observation that human MODY 2 patients, especially those who 
bear a GCK mutation which is associated with severe reduction of glucokinase 
activity, exhibit a less constrained insulin secretion than expected (Sturis et al. 1994). 
Compensation might be achieved by increased transcription of the wild-type allele, 
increased translation or stability of the wild-type Gck mRNA, or by post-translational 
mechanisms (Bali et al. 1995; Grupe et al. 1995; Postic et al. 1999). Five of seven 
published ENU-induced glucokinase mutant mouse strains, which underwent 
glucokinase activity testing, exhibited a decreased glucose phosphorylating capacity, 
suggesting that diabetes-associated ENU-induced Gck mutations in mice might 
commonly affect glucokinase activity. Even if only 30% of the naturally occurring 
GCK mutations in subjects with hyperglycaemia have been characterised kinetically, 
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the majority of the analysed mutations are associated with abnormal glucokinase 
kinetics. Therefore, mutations in GCK are supposed to predominantly exert their 
functional consequences by altering glucokinase activity (Gloyn et al. 2008; Osbak et 
al. 2009). 
5.2.2 Glucokinase RNA expression 
Hepatic glucokinase mRNA is reported to be barely present in foetal or neonatal rats. 
The initial intake of carbohydrates during the suckling-weaning period, coupled with 
an increase of insulin and a decline of glucagon levels, seems to be the first stimulus 
for significant glucokinase RNA and protein expression (Bossard et al. 1993; Girard 
et al. 1992). Consequentially, relative abundance of the Gck transcript was 
appreciably low in neonatal Munich GckM210R mutant mice, independent of the 
prevailing genotype. Despite consistent low Gck mRNA levels, hepatic Gck transcript 
abundance was strikingly reduced in homozygous mutants, and was also remarkably 
decreased in heterozygous mutants as compared to wild-type littermates. Reduced 
glucokinase mRNA levels have also been observed to occur as a consequence of 
ENU-induced glucokinase mutations in two other hyperglycaemic mouse strains (M-
702 and M-475). Furthermore, glucokinase activity in these two mutant mouse strains 
was decreased to an extent, almost comparable to that in Munich GckM210R mutants. 
However, M-702 and M-475 mutants exhibited nonsense mutations, introducing 
premature stop codons. Therefore, the authors suggested that the introduction of 
premature stop codons might cause mRNA degradation by the nonsense-mediated 
mRNA decay (NMD) pathway and, consequentially, reduced glucokinase activity. 
The NMD pathway represents a quality-control mechanism to protect the organism 
from deleterious dominant-negative or gain-of-function effects, initiated by truncated 
proteins (Frischmeyer and Dietz 1999; Inoue et al. 2004). Therefore, a potential role 
of the NMD pathway in elimination of mutant mRNA of Munich GckM210R mutants, 
thereby leading to decreased Gck mRNA levels in these animals, cannot be 
excluded. However, as missense mutations in the glucokinase gene are thought to 
exert their effects predominantly by altering glucokinase activity and are supposed to 
unlikely exert dominant negative effects, a potential involvement of the NMD pathway 
might be argued (Arden et al. 2007; Gloyn et al. 2008; Takeda et al. 1993). In fact, it 
seems more likely that the reduction of Gck mRNA levels in Munich GckM210R 
mutants might represent an indirect consequence of the mutation-associated 
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reduced glucokinase activity. As hepatic Gck expression is known to be regulated 
and induced by insulin (Gregori et al. 2006; Iynedjian et al. 1989a; Nouspikel and 
Iynedjian 1992), decreased glucokinase activity and therefore, reduced insulin 
secretion are most likely to account for the downregulation of Gck in Munich GckM210R 
mutants. 
5.2.3 Glucokinase protein levels 
Western blot analysis from isolated pancreatic islets of 90-day-old heterozygous 
Munich GckM210R mutants revealed a reduction of glucokinase protein levels of about 
28% as compared to wild-type mice, even if this difference was not significant. 
Reduced glucokinase protein expression has been shown to occur in five of seven 
investigated glucokinase mutant mouse strains, derived from other ENU mutagenesis 
projects, whereby only two of these strains (M702 and M-475) exhibited coincident 
reduction of glucokinase activity and Gck expression. From a total number of four 
mutant mouse strains that bear a reduced glucokinase activity, three strains 
coincidently displayed reduced glucokinase protein levels. These findings indicate 
that in ENU-induced Gck mutant mice, reduction of glucokinase activity is often 
accompanied by diminution of glucokinase protein abundance (Inoue et al. 2004; 
Toye et al. 2004). 
5.3 Phenotypic characteristics 
5.3.1 Heterozygous mutants 
Heterozygous mutants of both strains displayed comparable, slightly elevated blood 
glucose levels already from birth. Consistent with these findings, in human MODY 2 
subjects, the diabetic phenotype is proposed to be usually present from birth even if 
often diagnosed later in life due to its mild peculiarity (Froguel et al. 1992; Murphy et 
al. 2008). Blood glucose concentrations deteriorated little until an age of 90 days, 
remaining stable thenceforth. The diabetic phenotype of Munich GckM210R and 
GckD217V mutants was mainly characterised by chronic but stable fasting 
hyperglycaemia from an age of 30 days onwards, accompanied by disturbed glucose 
tolerance. In mutants of both strains, the area under the blood glucose curve (AUC) 
during oral glucose tolerance tests was already increased at an age of 30 days. 
However, in Munich GckM210R mutants of both genders the AUC relative to wild-type 
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mice further increased with age and was significantly higher in 180-day-old male 
GckM210R than in GckD217V mutants, whereas the AUC of GckD217V mutants remained 
stable from an age of 85 days onwards. These findings suggest a trend to a more 
accelerated diabetic phenotype in GckM210R than in GckD217V mutants, which is not 
unreasonable, considering the slightly stronger diminution of glucokinase activity in 
GckM210R mutants. 
Since the glucokinase enzyme catalyses the first, rate-limiting step of glycolysis and 
functions as a glucose sensor in pancreatic β-cells, mutations that alter the enzyme's 
activity are predicted to affect insulin secretion due to direct alteration of the 
threshold for glucose-induced insulin secretion (Bedoya et al. 1986; Magnuson and 
Matschinsky 2004). Due to the genetic β-cell secretory defect, MODY 2 subjects 
usually display altered insulin secretory response to glucose, characterised by a 
lowered and right-shifted dose-response curve during intravenous glucose tolerance 
tests. Nevertheless, the first phase of insulin secretion is thought to remain preserved 
(Bell and Polonsky 2001; Byrne et al. 1994; van Haeften et al. 1991). Impairment of 
fasting insulin levels in MODY 2 subjects seems to appear occasionally but is not 
considered as a common characteristic of the MODY 2 phenotype (Froguel et al. 
1993; Velho et al. 1992). Furthermore, reflecting the β-cell function defect, the HOMA 
of baseline insulin secretion (HOMA B) is reduced in MODY 2 patients (Martin et al. 
2008; Murphy et al. 2009). Similar to human MODY 2, glucose-induced insulin 
secretion and the HOMA B were significantly reduced in heterozygous Munich 
GckM210R and GckD217V mutants. Decreased insulin secretion was first detected in 30-
day-old Munich GckM210R mutants, whereas onset of disturbed glucose-induced 
insulin secretion in GckD217V mutants was at an age of 85 days. Fasting insulin levels, 
by contrast, were only diminished in male but not female Munich GckM210R mutants, 
probably reflecting the slightly more pronounced diabetic phenotype of male mutants. 
The phenomenon of sexual dimorphism has been described for several diabetic 
rodent models (Louet et al. 2004) and also appears in human diabetes mellitus (Gale 
and Gillespie 2001). A positive impact of 17β-oestradiol has been postulated to 
account for the milder diabetic phenotype in female gender (Le May et al. 2006; 
Louet et al. 2004). In contrast, fasting insulin levels of Munich GckD217V mutants were 
only slightly and not consistently diminished, and no gender dependency was 
observable. Furthermore, recapitulating the distinct degrees of glucokinase activity 
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reduction, reduction of delta insulin secretion relative to wild-type mice was 
considerably more pronounced in Munich GckM210R than in GckD217V mutants for the 
main period of investigation. Defects of glucose-induced insulin secretion have also 
been proven to arise from other ENU-induced Gck mutations and are generic 
findings in heterozygous global and β-cell specific, but not in liver-specific Gck 
knockout mouse models (Bali et al. 1995; Grupe et al. 1995; Inoue et al. 2004; Postic 
et al. 1999). Fasting insulin levels in these mouse models were either not specified 
(Inoue et al. 2004; Toye et al. 2004) or were not significantly altered (Bali et al. 1995; 
Grupe et al. 1995; Postic et al. 1999). However, age groups for determination of 
insulin levels in Gck knockout mice were quite inhomogeneous (Postic et al. 1999), 
and fasting insulin levels were also appreciably reduced in these animals (Terauchi 
et al. 1995). 
The role of insulin resistance in long-term evolution of disorders, like monogenic 
forms of β-cell dysfunction is discussed controversially. Some authors defend the 
distinction of MODY from type 2 diabetes mellitus by the absence of characteristics 
of the metabolic syndrome (i.e. among others insulin resistance) (Argawal et al. 
2002; Murphy et al. 2008). Nevertheless, the broad opinion has been established that 
even if insulin resistance does not represent the primary genetic defect in MODY, 
impaired insulin sensitivity may contribute to chronic hyperglycaemia in some MODY 
subtypes (Hattersley and Pearson 2006; Winter 2003). Studies from 125 MODY 2 
patients and 14 unaffected first-degree relatives revealed lowered insulin sensitivity 
in some GCK-deficient probands (Clement et al. 1996). Furthermore, long-term 
follow-up studies showed that MODY 2 patients, whose glucose tolerance 
deteriorated over time, displayed a significantly decreased HOMA of insulin 
sensitivity (HOMA %S) as compared to those with impaired but stable glucose 
tolerance (Martin et al. 2008). In contrast to the HOMA B, which was markedly 
decreased in heterozygous Munich GckM210R and GckD217V mutants, the HOMA of 
insulin resistance, indicating insulin sensitivity, was unaltered in both strains and 
even appeared slightly decreased in male heterozygous GckD217V mutants. In 
contrast, heterozygous male Munich GckM210R mutants exhibited a delayed response 
to exogenous insulin from an age of 90 days onwards. Although the HOMA of beta 
cell function indices were developed to assess β-cell function in human beings (Katz 
et al. 2000; Wallace et al. 2004), a linear correlation between insulin sensitivity, 
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determined during hyperinsulinaemic euglycaemic clamp studies in insulin resistant 
mice, and the surrogate index HOMA IR has been shown (Lee et al. 2008). Thus, 
male Munich GckM210R mutants should not be considered insulin resistant, whereas 
the presence of slightly impaired insulin sensitivity might not be argued. Munich 
GckD217V mutants of both genders also displayed a less pronounced decrease of 
blood glucose levels relative from basal after intraperitoneal insulin application, but in 
contrast to male Munich GckM210R mutants, the delayed response did not occur 
consistently. Taken together with the even decreased HOMA IR, insulin sensitivity 
seemed not to be constrained in mutants of this strain, albeit mildly impaired insulin 
sensitivity can not be definitely excluded. Consistent with these findings, sensitivity to 
exogenous insulin has been reported to be normal or slightly decreased in other 
ENU-induced Gck mutants (Inoue et al. 2004). In Gck knockout mice, by contrast, 
observations concerning insulin sensitivity vary in dependence on the prevailing 
nature of Gck disruption. While enhanced insulin sensitivity was suggested for global 
Gck deficiency, mild insulin resistance was detected in mice lacking hepatic Gck. In 
these mice, additional metabolic disturbances due to the loss of liver Gck were 
suggested to lead to impaired peripheral glucose utilisation and insulin action (Grupe 
et al. 1995; Postic et al. 1999). 
5.3.2 Homozygous mutants 
Homozygous or compound7 heterozygous mutations in human GCK are known to be 
associated with low birth weight and neonatal diabetes mellitus (NDM) (Osbak et al. 
2009; Porter and Barrett 2005; Waterfield and Gloyn 2008). In contrast to the 
common findings in NDM subjects, birth weights of homozygous Munich GckM210R 
and GckD217V mutants were unaltered. However, homozygous GckM210R mutants 
exhibited marked growth retardation and barely gained weight within the first days 
post partum, whereas body weight development of homozygous GckD217V mutants 
was unaltered in the first days of life. As it has already been proven in vitro (Njolstad 
et al. 2001), homozygous M210 mutations are predicted to strikingly lower 
glucokinase activity, so that a similar reduction can be assumed for homozygous 
Munich GckM210R mutants. Therefore, the disability to secrete adequate quantities of 
insulin, which is widely known to be one of the most important growth determinants 
                                            
7 Compound heterozygous mutations are characterised by the presence of 2 different mutant alleles at 
the 2 copies of an appointed locus (Silver 1995). 
 125 
 
during early postnatal development (Avery et al. 2005), most likely accounts for the 
reduced postnatal growth in homozygous GckM210R mutants. Studies in growth 
retarded homozygous mice that lack the β-cell-specific isoform of Gck showed that 
insulin or oral antidiabetic treatment resulted in body weight gain almost comparable 
to wild-type mice (Terauchi et al. 1995). From the age of weaning - with the 
beginning of carbohydrate intake - homozygous Munich GckD217V mutants also 
exhibited delayed body weight gain as compared to heterozygous mutants and wild-
type mice. As hepatic glucokinase activity is known to dramatically increase during 
the suckling-weaning transition in rats (Walker and Holland 1965), it is not 
unreasonable to suppose that growth retardation in GckD217V mutants might initially 
manifest during the post-weaning period due to the expected higher residual activity 
of the mutant glucokinase enzyme in homozygous Munich GckD217V mutants as 
compared to Munich GckM210R mutants. Blood glucose levels of neonatal 
homozygous mutants were markedly increased, whereby homozygous Munich 
GckM210R mutants exhibited dramatic hyperglycaemia already at birth with daunting 
aggravation of the diabetic phenotype within the first days of life. Homozygous 
GckD217V mutants exhibited lower blood glucose levels and a less pronounced 
increase of blood glucose concentrations than homozygous Munich GckM210R 
mutants. The phenotypic differences between GckM210R and GckD217V mutants may 
be explained by the differences in the severity of glucokinase enzyme impairment, 
which is known to correlate with the degree of hyperglycaemia (Lowe 1998). The 
different degrees of hyperglycaemia also influenced life span. While homozygous 
GckM210R mutants showed a significantly reduced life span and died not later than at 
6 days of age, life span was not constrained in homozygous GckD217V mutants. As 
downstream products of glucose metabolism enter the mitochondrial respiratory 
chain, which uses them to generate adenosine triphosphate (ATP) (Langin 2001), the 
glucokinase enzyme exerts a crucial impact on energy metabolism in cells. 
Therefore, homozygous GckM210R mutants likely died from fatal energy deprivation 
and hyperglycaemia, rising up from presumably marginal glucokinase activity. 
Survival studies in homozygous Gck-deficient mice demonstrated a crucial effect of 
global or β-cell-specific, but not of hepatic Gck ablation on animal viability. Mice that 
lack either the β-cell-specific or both isoforms developed marked hyperglycaemia and 
growth retardation, comparable to homozygous Munich GckM210R mutants, and died 
in utero or between day 3 and 7 post partum (Bali et al. 1995; Postic et al. 2001). The 
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complete loss of hepatic Gck was neither lethal nor exerted any effect on body 
weight development and resulted only in mild hyperglycaemia (Bali et al. 1995; 
Grupe et al. 1995; Postic et al. 1999; Terauchi et al. 1995). Other ENU-induced Gck 
mutant mouse strains either exhibited similar perinatal lethality, which was thought to 
result from extreme hyperglycaemia and growth retardation, or survived at least 5 to 
12 weeks, depending on the mutation (Inoue et al. 2004; Toye et al. 2004). These 
data emphasise either strong and specific or combined effects of Gck mutations on 
glucokinase structure and/or function (exon skipping, distortion of the glucokinase 
protein, impairment of glucokinase activity, reduction of glucokinase RNA and protein 
expression (Inoue et al. 2004)) to account for the different phenotypic outcomes and 
survival rates in the affected mouse models. Even if blood glucose levels of 
homozygous Munich GckD217V mutants were strongly increased from the time point of 
weaning onwards, disturbances in glucose homeostasis deteriorated very little with 
age, and blood glucose concentrations remained considerably stable. A study in 
human NDM patients recently demonstrated the occurrence of divergent phenotypes 
due to different GCK mutations. The authors suggested that less deleterious diabetic 
phenotypes might be associated with residual glucokinase activity, high enough to 
keep β-cells viable and to marginally preserve insulin secretion (Bakri et al. 2004). 
Thus, glucokinase activity in homozygous Munich GckD217V mutants, which still owed 
16% of the wild-type enzyme activity, would be sufficient to prevent fatal 
hypoinsulinaemia and enable marginal but stable maintenance of blood glucose 
homeostasis. In contrast, the phosphorylation activity in homozygous GckM210R 
mutants, which is suggested to be almost absent (Aguilar-Bryan and Bryan 2008) 
would not be sufficient to preserve animal viability. 
5.4 Specific organ alterations 
5.4.1 Liver 
Homozygosity in Munich GckM210R mutants was not only associated with fatal 
hyperglycaemia, growth retardation, and perinatal death, but also led to hepatic 
alterations. Under normal conditions, hyperglycaemia inhibits hepatic glucose 
production and stimulates hepatic glucose uptake and glycogen synthesis by 
enhancing glucose phosphorylation rate and thereby, the flux through glucokinase 
(Postic et al. 2001; Radziuk and Pye 2001). Due to impaired hepatic glucose 
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phosphorylation capacity, livers from 4-day-old homozygous GckM210R mutants were 
almost depleted of glycogen, reflecting almost absent glycogenesis in these animals. 
With regard to the protruding role of glycogen in the energy metabolism of neonates 
(Cornblath and Schwartz 1976), an additional fatal consequence of a defective 
glucokinase function on postnatal development is emphasised. Homozygous 
GckM210R mutants also exhibited vast hepatocyte vacuolisation, and fat red staining 
revealed massive steatosis. Mice that totally lack insulin (generated by targeted 
ablation of the Insulin 1 (Ins1) and Insulin 2 (Ins2) gene) exhibited similar perinatal 
hepatic steatosis that was rescued by insulin application (Duvillie et al. 1997). Thus, 
the fatty liver phenotype in homozygous Munich GckM210R mutants most likely 
resulted from insufficient insulin secretion. Hepatic lipid accumulation may arise from 
the lack of NAD+ regeneration from downstream metabolites (pyruvate) of glycolysis 
in the tricarboxylic acid cycle (TCA or Krebs cycle). As β-oxidation of fatty acids 
requires NADH as coenzyme, inhibition of this catabolic pathway might be causative 
for steatosis, observed in homozygous Munich GckM210R mutants (Moradpour 2006). 
Glycogen deprivation and steatosis also occurred in homozygous global or β-cell-
specific Gck knockout mice, and was diagnosed in two of three ENU-induced Gck 
mutant strains that exhibited perinatal lethality. In the respective knockout models, 
steatosis was additionally accompanied by hypertriglyceridaemia and 
hypercholesterinaemia (Grupe et al. 1995; Inoue et al. 2004; Postic et al. 1999). In 
contrast to the identified liver changes of homozygous Munich GckM210R mutants and 
other mouse models of deficient glucokinase function, hepatic steatosis and 
decreased glycogen content were absent in the two homozygous M210K carriers 
(Njolstad et al. 2001). However, hypertriglyceridaemia and hypercholesterinaemia 
have been reported to occur, albeit representing a rare complication, in MODY 2 
subjects (Velho et al. 1997). Therefore, it cannot be excluded that the same 
alterations may represent common features in homozygous GCK mutation carriers, 
but have not yet been diagnosed due to the minor prevalence of GCK-NDM and the 
resulting lack of clinical studies (Edghill et al. 2008; Osbak et al. 2009; Vaxillaire et al. 
2002). 
5.4.2 Endocrine pancreas 
Although in human beings, the “glucokinase disease” MODY 2 represents a well 
known diabetic phenotype, few perceptions about the pathomorphology of this 
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putative mild disorder and the impact of glucokinase gene mutations on the integrity 
of the endocrine pancreas are existing (Zelent et al. 2005). Even though morphologic 
alterations of the endocrine pancreas are reported to arise in some MODY subtypes 
(Johnson 2007), knowledge about the specific impact of glucokinase gene mutations 
on endocrine pancreatic integrity and mass is bare. The occurrence of endocrine 
pancreas alterations in other MODY subtypes emerges from the crucial involvement 
of the affected transcription factors in elementary pathways of pancreas development 
and maintenance and their implication in β-cell differentiation and/or apoptosis 
(Johnson 2007). Even if β-cell depletion, as observable in other MODY subtypes, has 
been speculated to be absent in MODY 2 patients, particular studies about the 
influence of glucokinase aberrations on maintenance, adaption, and turnover of the 
endocrine pancreatic mass are lacking. 
Glucose has already been shown to represent a critical determinant of endocrine 
pancreas mass by influencing β-cell replication and apoptosis in a time and dose-
dependent fashion (Alonso et al. 2007; Kim et al. 2005). Therefore, GckM210R mutants 
and wild-type littermates were chosen to first undergo qualitative histological and 
quantitative stereological analysis of the pancreas at the first day post partum to 
exclude the influence of phenotypic traits such as hyperglycaemia. The total 
pancreas and β-cell volumes did not significantly differ between the respective 
genotypes, although a marginally reduced β-cell mass was identified in homozygous 
Munich GckM210R mutants. These findings indicate that the identified mutation, 
especially in heterozygous mutants, does not affect endocrine pancreas development 
and integrity, albeit, a subtle, but not decisively identifiable effect on β-cell mass in 
homozygous mutants might not be excluded. By contrast, male heterozygous 
mutants at an age of 210 days exhibited an about 30% reduced total islet and total β-
cell volume as compared to wild-type mice. Both parameters were unchanged in 
female mutants, whose β-cells are probably protected by 17β-oestradiol (Le May et 
al. 2006). Since the total β-cell volume was unaltered in neonatal heterozygous 
mutants, islet and β-cell mass reduction in adult male mutants is not a direct 
consequence of the causative mutation. Isolated β-cells (single, scattered insulin+ 
cells, endocrine cells budding from ducts and extra-islet insulin+ cell clusters (EICs) 
are considered as a parameter for new islet formation (Bonner-Weir 2001; Butler et 
al. 2003; Herbach et al. 2005; Kauri et al. 2007). Thus, a coincident reduction of the 
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total volume of isolated β-cells of male heterozygous mutants of about 30% suggests 
that reduced islet- and β-cell mass, observed in male mutants, emerge from impaired 
islet neogenesis. This assumption is supported by the absence of any apoptotic 
event in pancreatic islets of 90-day-old heterozygous Munich GckM210R mutants, as 
evinced by Western blot analysis of the inactive and active form of caspase-3. 
Nevertheless, detection and quantification of apoptosis in β-cells has already been 
reported to represent a real challenge. Although the process of β-cell destruction is 
extended over weeks or months, only few (2-7%) apoptotic β-cells are likely to be 
observable even in mouse models of severe β-cell destruction (Augstein et al. 1998; 
O'Brien et al. 1996). The difficulty in quantification of β-cell apoptosis is supposed to 
result from the nature of apoptosis kinetics. Apoptosis is an extremely rapid process, 
with only few minutes elapsing from initiation to complete disintegration of the cell 
(Butler et al. 2003). Immediate clearance of apoptotic cells by phagocytosis is also 
known to be executed in an accelerated fashion, although the time frame varies 
depending on the respective tissue (Coles et al. 1993; Platt et al. 1998; Tanaka 
2005). For this reason one might hypothesise that in case of only moderate β-cell 
destruction, apoptosis may be undetectable.  
Over the last decades there is increasing evidence that, from embryogenesis to 
adulthood, the endocrine pancreas represents a dynamic, in adult life slowly 
renewing tissue. Beta cell mass is determined by the balance between replication, 
neogenesis and apoptosis - under physiological conditions and in response to 
varying secretory demand (Ackermann and Gannon 2007; Nielsen et al. 2001). The 
factors involved in regulating β-cell mass are numerous (Ackermann and Gannon 
2007), but the potent stimulatory effect of glucose and insulin on expansion of β-cell 
mass in vivo (Bernard et al. 1999; Paris et al. 2003) and in vitro (Rabinovitch et al. 
1982; Schuppin et al. 1993) substantiates a central impact of glucose metabolism 
and insulin-signalling pathway on endocrine pancreatic mass expansion. Islet 
neogenesis and β-cell proliferation from pre-existing β-cells are reported to be the 
main mechanisms of these adaptive changes (Ackermann and Gannon 2007; 
Bouwens and Kloppel 1996; Paris et al. 2004). 
For one of these mechanisms, glucokinase has already been shown to be essential. 
Mice, haploinsufficient for pancreatic Gck, failed to increase β-cell mass in response 
to a high-fat diet, whereas wild-type controls developed compensatory β-cell 
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hyperplasia. However, in contrast to Munich GckM210R mutant mice, no reduction of β-
cell mass or islet size was detected in β-cell-specific heterozygous Gck knockout 
mice vs. wild-type mice when fed a standard chow (Terauchi et al. 2007). As the 
genetic background has a great influence on the occurrence of an aberrant 
phenotype (Andrikopoulos et al. 2005), these different observations might be 
explained by the different genetic background of the Gck mutants. Additionally, 
parameters of islet neogenesis and the influence of complete absence of β-cell 
glucokinase on the integrity of the endocrine pancreas were not investigated in these 
knockout models. 
Recent studies suggest a detrimental influence of glucokinase on endocrine 
pancreas mass dynamics by demonstrating that glucokinase is involved in 
glucotoxicity-induced β-cell death via induction of Bad dephosphorylation and Bax- 
and Bad-mediated apoptosis (Danial et al. 2003; Danial et al. 2008; Kim et al. 2005). 
Lee et al. (2009) specified the critical role of glucokinase in metabolic stress-related 
apoptosis by evincing that impairment of mitochondrial function in vitro (MIN6N8 
cells) leads to glucokinase downregulation, defective insulin secretion and apoptosis. 
These events could be blocked by either antioxidant treatment or glucokinase 
overexpression (Lee et al. 2009; Tsuruzoe et al. 1998). The coincident reduction of 
islet- and β-cell mass without altered volume fraction of β-cells in islets of male 
heterozygous Munich GckM210R mutants would imply that whole islets were destroyed 
by apoptosis. In contrast, selective β-cell destruction is considered to represent the 
final outcome in type 1 and 2 diabetes mellitus in human beings (Andre-Schmutz et 
al. 1999; Cnop et al. 2005; Yoon et al. 2003). Therefore, impaired islet neogenesis 
rather than enhanced apoptosis most likely accounts for islet and β-cell mass 
reduction in male heterozygous Munich GckM210R mutants. 
Male heterozygous Munich GckD217V mutants at an age of 550 days displayed an only 
marginal reduction of the total islet and β-cell volumes, reflecting the slightly milder 
diabetic phenotype as compared to Munich GckM210R mutants. Morphologic 
alterations of the endocrine pancreas of male homozygous mutants were more 
pronounced and mainly characterised by considerably reduced islet and β-cell mass 
and an only slightly decreased volume fraction of β-cells in the islets.  
Oxidative-stress mediated apoptosis, arising from insulin resistance and chronic 
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overstimulation of β-cells by hyperglycaemia, is considered to represent one of the 
most important contributors to β-cell loss in type 2 diabetes mellitus (Cnop et al. 
2005; Donath et al. 2005; Mandrup-Poulsen 2003; Rhodes 2005). In contrast, the 
relevance of glucotoxicity in the pathogenesis of MODY 2 is discussed 
controversially. On the one hand it has been shown that insulin sensitivity and insulin 
secretion can almost be restored by exposure of pancreatic islets, isolated from Gck-
deficient mice, to high glucose concentrations for 48-96 hours (Sreenan et al. 1998). 
On the other hand, enhanced apoptosis and downregulation of the glucokinase gene 
were observed after exposure of MIN6 cells and primary islet cells to high glucose 
concentrations for the same period (Kim et al. 2005). Nevertheless, the lack of 
detailed in vivo studies about the effect of long-term exposure to mild hyperglycaemia 
on endocrine pancreas integrity and the absence of morphometric data from Gck-
deficient mice or homozygous Gck mutants of other ENU mouse strains, impede 
definite interpretation of the morphologic alterations in Munich GckD217V mutants. 
However, as a time- and dose dependent detrimental influence of excess glucose on 
pancreatic β-cell viability was proposed (Kim et al. 2005; Robertson et al. 2003), 
increased apoptosis, arising from prolonged exposure of β-cells to elevated glucose 
levels, might be causative for the reduction of β-cell mass at least in homozygous 
Munich GckD217V mutants. 
Considering the early onset of hyperglycaemia, the severity of the diabetic phenotype 
and the stable maintenance of strikingly elevated blood glucose levels throughout 
life, islet and β-cell mass reduction was appreciably moderate in homozygous 
GckD217V mutants. Other diabetic mouse models, displaying comparable degrees of 
glycaemia developed considerably more accentuated endocrine pancreas alterations 
in a shorter period of time. Two mutations in the insulin 2 gene (Ins2), both leading to 
the loss of disulfide bonds within the insulin molecule, have been reported in mouse 
models of severe, progressive hyperglycaemia and extensive β-cell depletion: the 
Akita mouse and the Munich Ins2C95S mutant mouse. Male heterozygous Munich 
Ins2C95S mutants at an age of 180 days exhibited a strikingly reduced islet and β-cell 
volume and an 80% reduced β-cell volume fraction. The accelerated β-cell depletion 
in islets of this mouse model in opposition to the relative discrete β-cell loss in 
homozygous Munich GckD217V mutants suggests additional specific effects that 
trigger β-cell loss in Ins2 mutants. As both Ins2 mutations are predicted to induce 
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misfolding of the mutated protein, endoplasmic reticulum stress was supposed to 
major account for the β-cell loss and the progression of hyperglycaemia in both 
mouse models (Herbach et al. 2007; Wang et al. 1999; Yoshioka et al. 1997; Zuber 
et al. 2004). A current study with insulin treated male Munich Ins2C95S mutants 
stresses the additional involvement of chronic hyperglycaemia in the development of 
β-cell damage in this mouse model (personal communication Sabine Kautz and Dr. 
Nadja Herbach). Even if endoplasmic reticulum stress and components of the 
unfolded protein response are considered to play an important part in triggering β-cell 
apoptosis in diabetes mellitus (Eizirik et al. 2008; Waterfield and Gloyn 2008), 
glucokinase mutations have not been reported to induce protein misfolding in human 
beings and rodent models so far. Thus, the potential absence of endoplasmic 
reticulum stress in homozygous Munich GckD217V mutants might account for the 
considerable stable phenotype and the relatively moderate reduced islet- and β-cell 
masses. However, a possible participation of disturbed islet neogenesis, as it is 
supposed to account for endocrine mass alterations in male heterozygous Munich 
GckM210R mutants, may also play a role in Munich GckD217V mutants. Thus, further 
investigations are necessary to allocate the impact of Gck mutations and the 
associated different degrees of hyperglycaemia to the identified endocrine pancreas 
alterations. 
Taken together, glucokinase may have an important impact on the balance between 
β-cell renewal and death and, therefore, on endocrine pancreas plasticity. 
5.5 Conclusion and further prospects 
The creation of two Gck alleles in the ENU strains GLS001 (Munich GckM210R mutant 
mouse) and GLS006 (Munich GckD217V mutant mouse) and the resulting phenotypic 
similarities and differences provide the opportunity to analyse specific effects of 
distinct, but closely neighboured mutations in Gck, and to elucidate the complexity of 
the “glucokinase disease” concerning clinical and pathomorphological aspects. Both 
profoundly characterised mutant mouse strains provided unforeseen insights into the 
undiscovered pathomorphology of Gck mutations. Furthermore, this study represents 
the first report of unrestricted life span of homozygous Gck mutants. The viability of 
homozygous Munich GckD217V mutants therefore enables detailed long-term studies 
to elucidate clinical and pathomorphological aspects of human NDM. 
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Monogenic diabetes in general is supposed to be often misdiagnosed as type 1 or 
type 2 diabetes mellitus (Singh 2006). Further, the inheritance of a GCK mutation in 
human beings does not exclude the concurrent development of type 2 diabetes 
mellitus later in life, which occurs at a similar prevalence in those with GCK mutations 
as in the general population (up to 50% of the affected persons develop overt 
diabetes (Murphy et al. 2008; Olek 2006)). For this reason, even if large-scale 
population studies are lacking, the number of undiagnosed MODY 2 patients might 
be higher than estimated. A recent study with 798 human subjects at high risk for 
MODY unveiled the difficulties to distinguish GCK-mutation from non-mutation 
carriers by means of clinical diagnostic criteria alone. Further, in case of rigid 
application of the 4 screening criteria for MODY, elaborated by the European 
Molecular Genetics Quality Network (EMQN) (refer to chapter 2.6.5) (Ellard et al. 
2008), none of the participating GCK-mutation carriers would have been identified as 
MODY 2 patient (Gloyn et al. 2009). These findings emphasise the assumption that 
MODY 2 in human subjects might be often misdiagnosed or even may remain 
undiagnosed. The molecular definition of the genetic aetiology, especially in MODY 2 
subjects, allows the development of specific treatment regimes and provides the 
opportunity to reliably prevent long-term disease progression. Therefore, some 
authors emphasise the indispensability of genetic testing not only in specific risk 
populations (familiar history of diabetes, asymptomatic fasting hyperglycaemia etc.) 
(Codner et al. 2006; Osbak et al. 2009; Singh 2006). Further, small molecule 
activators of the glucokinase enzyme are not only applicable in therapy of MODY 2, 
but are also considered to represent potential therapeutics for other forms of diabetes 
mellitus (Matschinsky 2009; Sarabu and Grimsby 2005; Sarabu et al. 2007). Thus, 
both profoundly characterised Gck mutant mouse models are thought to be valuable 
to study the roles of Gck, disturbed glucose homeostasis and mild hyperglycemia in 
endocrine pancreatic mass dynamics, for the development of strategies for early 
diagnosis, and the development of potential novel therapeutics. Consequentially, 
both mouse strains represent sophisticated models for translational diabetes 
research. 
Further clarification of the specific and/or combined functional consequences of the 
respective Gck mutations in both ENU-induced mutant strains will require additional 
investigations of Gck mRNA and protein levels in both liver and pancreatic β-cells of 
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90-day-old mice to allocate the results to glucokinase activity levels. Additionally, an 
intraperitoneal glucose tolerance test should be considered to assess the first phase 
of glucose-induced insulin secretion, which is usually preserved in MODY 2 patients. 
Addressing the question of serum insulin levels in suckling mice, especially in 
homozygous mutants, represents another extremely interesting task. The absence of 
apoptosis in pancreatic islets of Munich GckM210R mutants should be further verified 
by histological methods (e.g. TdT-mediated dUTP-biotin nick end labelling; TUNEL). 
Moreover, morphometric evaluation of the endocrine pancreas from 4-day-old 
homozygous Munich GckM210R mutants, which displayed already fatal 
hyperglycaemia at this age, may be performed to examine the effect of short-term but 
extremely surpassing glucose levels on postnatal pancreas development in these 
animals. 
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6. Summary 
Several diabetic mouse strains have been generated in the Munich ENU (N-ethyl-N-
nitrosourea) mouse mutagenesis screen, representing suitable models for functional 
genome analysis in diabetes research. The aim of the present study was to identify 
the causative mutation of two of these strains (GLS001 and GLS006) and to 
characterise the resulting diabetic phenotype. For phenotypic characterisation, 
diabetic GLS001 and GLS006 mice were bred on the C3HeB/FeJ inbred genetic 
background. The causative mutation was mapped to a defined chromosomal region 
by linkage analysis. Subsequently, candidate gene sequence analysis was 
performed to identify the respective mutations. Clinical and pathomorphological 
analyses comprised regular screening of glucose homeostasis, determination of body 
and organ weights, and qualitative histological and quantitative stereological 
investigations of the pancreas. Specification of the functional consequences of the 
respective mutations was carried out with isolated pancreatic islets and liver 
homogenate from homozygous and heterozygous mutants and wild-type littermates 
by quantitative real-time PCR, Western blot analysis, and determination of 
glucokinase activity. Linkage analysis mapped the diabetic phenotype of both strains to 
a polymorphic marker on chromosome 11 at 5.9 and 7.1 Mb, respectively. Candidate 
gene sequencing of the positional glucokinase (Gck) gene disclosed a missense 
mutation in exon 6 of Gck in both strains. The ENU strain GLS001 bears a T to G 
transversion at nucleotide position 629 of Gck, leading to an amino acid exchange from 
methionine to arginine at position 210 (Munich GckM210R mutant mouse), whereas in 
GLS006 mice, an A to T transversion at nucleotide position 650 was identified, resulting 
in an amino acid exchange from aspartic acid to valine at position 217 (Munich GckD217V 
mutant mouse). Analogous mutations in human beings are associated with two 
autosomal dominant hereditary forms of diabetes mellitus. Heterozygous mutations 
are associated with maturity-onset diabetes of the young, type 2 (MODY 2), whereas 
homozygous mutations lead to neonatal diabetes mellitus (NDM). The mutations of 
both strains resulted in a significantly decreased hepatic glucokinase activity, 
whereas islet glucokinase protein abundance was unaltered in Munich GckM210R 
mutants. Further, Gck transcript abundance was appreciably decreased in neonatal 
Munich GckM210R mutants. Heterozygous mutants of both strains exhibited a MODY 
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2–like diabetic phenotype, characterised by mild, non-progressive fasting 
hyperglycaemia, a disturbed glucose tolerance, and an impaired glucose-induced 
insulin secretion. Further, male heterozygous Munich GckM210R mutants exhibited a 
delayed response to exogenous insulin, whereas insulin sensitivity was almost 
unaltered in Munich GckD217V mutants. In contrast to heterozygous mutants, 
homozygous mutants displayed strongly elevated blood glucose levels already from 
birth. Homozygous Munich GckM210R mutants showed growth retardation, liver 
steatosis, and a dramatic deterioration of hyperglycaemia within the first days post 
partum, leading to premature death within the first six days of life. In contrast, Munich 
GckD217V mutants exhibited normal postnatal development, blood glucose increase 
was less accentuated, and life span of homozygous GckD217V mutants was not 
restrained. Quantitative stereological analyses revealed a 30% reduction of islet and 
β-cell mass in male, but not female heterozygous Munich GckM210R mutants at an age 
of 210 days. The additional reduction of the total volume of isolated beta cells and 
the absence of apoptosis indicated that disturbed islet neogenesis might be 
causative for islet mass reduction in male Munich GckM210R mutants. The total islet 
and β-cell volumes were considerably decreased in 550-day-old male homozygous 
Munich GckD217V mutants, whereas these changes were only discrete in male 
heterozygous mutants. The coincident slight reduction of the volume fraction of β-
cells in the islets of homozygous mutants indicated an additional selective β-cell loss, 
most likely as a consequence of prolonged exposure to elevated blood glucose 
levels. 
Regarding the assumed number of undiagnosed MODY 2 patients and the lack of 
detailed clinical studies in human beings, these profoundly characterised diabetic 
mouse strains represent valuable models for the functional analysis of Gck. Further, 
both models enable long-term studies of relevant aspects of human MODY 2/NDM, 
the elaboration of strategies for early diagnosis, and the development of new 
treatment strategies. 
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7. Zusammenfassung 
Klinische und pathomorphologische Charakterisierung zweier diabetischer 
Mausmodelle aus dem Münchener ENU-Mausmutageneseprojekt 
Im Münchener ENU- (N-ethyl-N-nitrosoharnstoff) Mausmutageneseprojekt wurden 
mehrere diabetische Mauslinien generiert, die wertvolle Tiermodelle für die 
funktionale Genomforschung darstellen. Ziel der vorliegenden Studie war es, zwei 
dieser diabetischen Mauslinien (GLS001 und GLS006) hinsichtlich der zugrunde 
liegenden Mutationen und des daraus resultierenden diabetischen Phänotypes 
klinisch und pathomorphologisch zu untersuchen. Heterozygote Mutanten der Linien 
GLS001 und GLS006 wurden auf dem genetischen Hintergrund des Inzuchtstammes 
C3HeB/FeJ gezüchtet. Nach Eingrenzung der chromosomalen Lokalisation der 
ursächlichen Mutationen durch die Kopplungsanalyse erfolgte die Auswahl und 
Sequenzierung des Kandidatengens, die zur Identifizierung der Mutationen führte. 
Die klinische und pathomorphologische Untersuchung umfasste die regelmäßige 
Analyse Diabetes-relevanter Parameter, die Bestimmung von Körper- und 
Organgewichten, sowie qualitativ-histologische und quantitativ-stereologische 
Untersuchungen des Pankreas. Die funktionalen Auswirkungen der Mutationen 
wurden in isolierten Pankreasinseln und Leberhomogenat mittels quantitativer real-
time PCR, Westernblotanalysen, und Glucokinase-Enzymaktivitätsbestimmung 
spezifiziert. Die Kopplungsanalyse ergab bei Mutanten beider Mauslinien eine 
eindeutige Kopplung des diabetischen Phänotyps zu polymorphen DNA-Markern auf 
dem Chromosom 11 im Bereich von 5,9 beziehungsweise 7,1 Mb. Bei der 
Sequenzierung des Kandidatengens Glucokinase (Gck) wurde bei beiden Mauslinien 
eine definierte Punkmutation im Exon 6 des Gck identifiziert. Bei der ursächlichen 
Mutation der ENU-Mauslinie GLS001 handelt es sich um eine T zu G Transversion 
an Nukleotidposition 629, welche zu einem Aminosäurenaustausch von Methionin zu 
Arginin an Position 210 führt (Munich GckM210R Mutante). Die ENU-Linie GLS006 
besitzt eine A zu T Transversion an Nukleotidposition 650, die zu einem 
Aminosäurenaustausch von Asparaginsäure zu Valin an Position 217 führt (Munich 
GckD217V Mutante). Entsprechende Mutationen führen beim Menschen zu zwei 
verschiedenen, autosomal dominant vererbten Formen des Diabetes mellitus. 
Heterozygote Mutationen führen zu maturity-onset diabetes of the young, type 2 
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(MODY 2), wohingegen homozygote Mutationen mit neonatalem Diabetes mellitus 
(NDM) assoziiert sind. Die Mutationen sind bei beiden mutanten Mauslinien mit einer 
signifikanten Reduktion der Glucokinase-Enzymaktivität verbunden, wohingegen die 
Glucokinase-Proteinmenge in den Pankreasinseln von Munich GckM210R Mutanten 
unverändert war. Bei neonatalen Munich GckM210R Mutanten führt die Mutation 
darüber hinaus zu einer deutlich reduzierten Gck Transkriptabundanz. Heterozygote 
Mutanten beider Mauslinien entwickelten einen milden, dem MODY 2 des Menschen 
ähnlichen diabetischen Phänotyp, der charakterisiert ist durch konstant erhöhte 
Nüchternblutglukose, eine gestörte Glukosetoleranz und eine verminderte 
glukoseinduzierte Insulinsekretion. Außerdem zeigten männliche heterozygote 
Munich GckM210R Mutanten eine leicht verzögerte Senkung der Blutglukosewerte 
nach Insulinapplikation, wohingegen die Insulinsensitivität bei Munich GckD217V 
Mutanten nicht merklich eingeschränkt war. Homozygote Mutanten hingegen 
entwickelten einen stärker ausgeprägten diabetischen Phänotyp mit stark erhöhten 
Blutglukosewerten vom Zeitpunkt der Geburt an. Homozygote Munich GckM210R 
Mutanten zeigten Wachstumsverzögerung, Lebersteatose, eine dramatische 
Progression der Hyperglykämie und starben innerhalb der ersten sechs Lebenstage. 
Bei homozygoten Munich GckD217V Mutanten hingegen war die postnatale 
Entwicklung nicht verändert, der Anstieg der Blutglukosewerte war geringer 
ausgeprägt und die Lebensdauer war nicht eingeschränkt. Die quantitativ-
stereologische Untersuchung des Pankreas ergab eine 30%ige Reduktion der Insel- 
und Betazellmasse bei männlichen, nicht jedoch bei weiblichen heterozygoten 
Munich GckM210R Mutanten in einem Alter von 210 Tagen im Vergleich zu Wildtyp-
Kontrolltieren. Die gleichzeitige Reduktion des Gesamtvolumens der isolierten 
Betazellen und das Fehlen erhöhter Apoptoseaktivität weisen darauf hin, dass eine 
gestörte Inselneogenese ursächlich für die Reduktion des Gesamtinsel- und 
Betazellvolumens sein könnte. Bei homozygoten Munich GckD217V Mutanten in einem 
Alter von 550 Tagen war die Insel- und Betazellmasse deutlich, bei heterozygoten 
Mutanten nur geringgradig reduziert. Der leicht verminderte Volumenanteil der 
Betazellen in den Inseln bei homozygoten Mutanten weist darüber hinaus auf einen 
zusätzlichen selektiven Betazellverlust hin, der Folge der anhaltenden Exposition der 
Betazellen gegenüber erhöhten Blutglukosewerten sein könnte. 
In Anbetracht der geschätzten Dunkelziffer nicht diagnostizierter MODY 2 Patienten 
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und dem Mangel an detaillierten klinischen Studien stellen beide ausführlich 
charakterisierten Mauslinien wertvolle Modelle für funktionale Studien des Gck dar. 
Weiterhin können beide Modelle für Langzeitstudien relevanter Aspekte des humanen 
MODY 2/NDM, für die Erarbeitung von Strategien zur Früherkennung und die 
Entwicklung potenzieller neuer Therapeutika dienen. 
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9. Attachment 
9.1 Basic glucokinase enzyme kinetics and their extrapolation to studies  
Deviant from other members of the hexokinase family, the catalytic enzyme 
glucokinase exhibits profoundly unexpected structural and kinetic properties. Unlike 
other hexokinases, which follow Michaelis-Menten kinetics, the glucokinase is 
reported to exhibit sigmoidal substrate dependency. The sigmoidicity of the substrate 
saturation curve (= cooperativeness of the enzyme with a ligand) is described by the 
Hill coefficient nH (nH>1 indicates a positive cooperativity). Even displaying the kinetic 
behaviour of a monomeric enzyme, glucokinase displays a slightly positive (nH =1.7) 
cooperativeness (= strength of a substrate-enzyme interaction, depending on the 
number of subunits, already occupied by substrate molecules) with its main substrate 
glucose (Bisswanger 2008; Cornish-Bowden and Càrdenas 2004; Matschinsky 
2002). Due to exhibition of allostericity, the application of the Michaelis-Menten 
theory to determine kinetic characteristics of the glucokinase is therefore obsolete. 
Representing critical attempts to understand kinetic enzyme behaviour, the maximal 
reaction velocity (Vmax) and the the glucose level at the half-maximal activity rate (S0.5 
≙ Km in the Michaelis-Menten equation and indicates the substrate affinity of the 
respective enzyme) for the glucokinase enzyme may be determined by two distinct 
approaches (Matschinsky et al. 1998) (Fig. 9.1) 
• Extrapolation of sigmoidal glucokinase substrate-velocity curves by linear 
regression would result in kinetic constants, slightly deviant from the intrinsic 
kinetic characteristics. However, particularly in studies of crude tissue extracts 
from pancreatic islets or liver, a linear transformation of the Michaelis-Menten 
equation, approximating S0.5 or Vmax values by extrapolation, is feasible. The 
Hanes-Woolf plot (ratio of substrate concentration to reaction velocity is plotted 
against the respective substrate concentration) is predicted to be the most 
suitable plot for this purpose with the error usually being small due to genuine 
application of the substrate concentrations on the x-axis. The slope of the 
regression line indicates 1/Vmax, the y-intercept is equal to S0.5/Vmax (Matschinsky 
et al. 1998).  
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• The Hill equation, a linear transformation of the Michaelis-Menten kinetics is 
propagated to be best to illustrate glucose phosphorylation by glucokinase:  
 
SnH*VmaxV= SnH*S0.5nH
 
V = The specific substrate turnover rate at a given substrate concentration 
S = Corresponding substrate concentration 
nH = Hill coefficient 
Vmax = Maximal specific enzyme activity 
S0.5 = Respective glucose level at the half-maximal substrate turnover rate 
 
However, application of the Hill equation requires the knowledge of Vmax, which has 
to be determined by other methods, mentioned above. 
 
Cornish-Bowden diagram Hanes-Woolf plot 
  
Figure 9.1: Kinetic concepts of glucokinase and their extrapolation for kinetic studies. 
A: Direct-linear illustration (reaction velocity as a function of the substrate concentration; 
Cornish-Bowden diagram) of the substrate saturation curves of glucokinase (blue lines) and 
the high-affinity hexokinases (red line). Extrapolation of the reaction velocities of glucokinase 
by non-linear regression (hyperbolic curve (dashed blue line)) may result in misleading 
kinetic constants, as stated for the half-maximal saturation glucose concentrations (Km and 
S0.5, respectively). Due to the intrinsically sigmoidal behaviour of the glucokinase saturation 
curve (continuous line), glucose concentrations where glucokinase displays half-maximal 
saturation (S0.5) would be higher than after extrapolation (Km). While other hexokinases are 
saturated already at low glucose concentrations (low Km), glucokinase enzyme exhibits low 
glucose affinity (high Km and S0.5, respectively). B: The Hanes-Woolf plot (ratio of substrate 
A B 
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concentration to reaction velocity as a function of the respective substrate concentrations) is 
practicable to determine kinetic constants (Vmax, S0.5) of the glucokinase enzyme. However, 
due to non-linearity of the original curve (continuous line) up to a glucose concentration of 
about 8-10 mM, extrapolation of measurement data by linear regression (dashed line) would 
lead to results for Vmax and S0.5, slightly deviant from the intrinsic kinetic characteristics of the 
glucokinase enzyme. 
9.2 Low resolution mapping results 
The causative mutations in GLS001 and GLS006 mice were mapped to a defined 
chromosomal region by linkage analysis. For this purpose, the distribution of mice, 
displaying either a heterozygous (het) or the outcross (ocr = C57BL/6J) genotype 
with the respective polymorphic marker (SNP) was applied to evaluate the linkage 
(indicated by chi2 values) between the diabetic phenotype and the corresponding 
DNA marker (Table 9.1 and 9.2). 
9.2.1 GLS001 mice 
Table 9.1: Low resolution mapping results in GLS001 G2 backcross mice. 
Chromosome Locus (Mb) RefSNP 
Success 
rate Het Ocr χ
2 value P-value 
29.94 rs3706618 100.00 48 42 0.00 >0.01 
44.08 rs13459182 95.56 46 40 0.74 >0.01 
63.05 rs3688436 100.00 46 44 0.18 >0.01 
74.62 rs3090522 98.89 43 46 0.10 >0.01 
90.37 rs3684025 97.78 41 47 0.00 >0.01 
109.28 rs13476046 98.89 41 48 0.01 >0.01 
119.66 rs3672659 97.78 38 50 0.05 >0.01 
135.04 rs8250085 100.00 41 49 0.04 >0.01 
149.63 rs6264289 98.89 41 48 0.10 >0.01 
156.81 rs4222732 98.89 42 47 0.28 >0.01 
177.06 rs3702990 97.78 43 45 0.00 >0.01 
1 
189.21 rs13476297 100.00 46 44 0.00 >0.01 
13.39 rs13476352 100.00 44 46 0.18 >0.01 
37.71 rs3022883 100.00 42 48 0.00 >0.01 
57.61 rs3663027 98.89 43 46 0.01 >0.01 
71.17 rs4223216 98.89 40 49 0.55 >0.01 
102.83 rs13476672 98.89 42 47 2.53 >0.01 
118.95 rs8279353 100.00 48 42 0.18 >0.01 
131.74 rs4223511 100.00 47 43 0.04 >0.01 
2 
149.20 rs3675393 98.89 49 40 0.55 >0.01 
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10.82 rs3689058 95.56 37 49 3.77 >0.01 
30.01 rs3683804 97.78 39 49 1.64 >0.01 
43.70 rs4223943 100.00 42 48 0.71 >0.01 
54.66 rs3719338 97.78 44 44 0.41 >0.01 
70.09 rs13477178 100.00 47 43 0.04 >0.01 
79.72 rs4136771 97.78 46 42 0.41 >0.01 
103.41 rs13477302 95.56 45 41 0.05 >0.01 
113.13 rs6207837 95.56 45 41 0.05 >0.01 
132.56 rs4136518 96.67 40 47 0.93 >0.01 
150.02 rs3718378 100.00 46 44 0.18 >0.01 
3 
152.99 rs3686068 98.89 41 48 0.28 >0.01 
35.40 rs3703981 97.78 40 48 0.73 >0.01 
45.87 rs3719264 98.89 48 41 1.90 >0.01 
61.09 rs3686083 98.89 50 39 1.90 >0.01 
91.41 rs3703756 100.00 50 40 1.60 >0.01 
106.91 rs3664637 100.00 47 43 0.40 >0.01 
122.32 rs3682306 96.67 45 42 0.29 >0.01 
4 
143.67 rs13478035 100.00 46 44 0.18 >0.01 
21.18 rs3023036 97.78 44 44 0.41 >0.01 
30.47 rs3718492 100.00 47 43 0.40 >0.01 
60.37 rs3724321 98.89 49 40 1.36 >0.01 
75.65 rs4225300 97.78 47 41 1.64 >0.01 
89.33 rs3700063 95.56 46 40 2.98 >0.01 
90.80 rs3717237 100.00 48 42 2.84 >0.01 
101.81 rs8256225 98.89 50 39 4.96 >0.01 
118.75 rs4138867 98.89 53 36 8.19 <0.01 
5 
137.21 rs4225537 98.89 50 39 1.90 >0.01 
43.80 rs3703696 98.89 50 39 1.90 >0.01 
55.14 rs3688612 98.89 50 39 1.90 >0.01 
73.00 rs13478817 98.89 49 40 1.36 >0.01 
86.41 rs3656641 98.89 47 42 0.55 >0.01 
98.69 rs3702663 100.00 47 43 0.40 >0.01 
114.97 rs3720170 97.78 47 41 0.18 >0.01 
125.74 rs3701869 95.56 48 37 0.95 >0.01 
6 
139.64 rs3679077 98.89 50 39 0.91 >0.01 
8.35 rs4226424 100.00 48 42 0.00 >0.01 
27.77 rs3668793 100.00 46 44 0.18 >0.01 
37.07 rs4226613 97.78 43 45 0.00 >0.01 
53.08 rs4226645 100.00 45 45 0.04 >0.01 
67.43 rs4226725 100.00 48 42 0.18 >0.01 
77.59 rs3656285 97.78 46 42 0.05 >0.01 
7 
87.14 rs6387510 95.56 43 43 0.05 >0.01 
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102.74 rs3654133 100.00 49 41 0.40 >0.01 
130.17 rs13479566 98.89 49 40 0.55 >0.01 
9.76 rs13479604 98.89 44 45 0.10 >0.01 
30.33 rs3661862 98.89 42 47 0.10 >0.01 
46.24 rs13479741 98.89 41 48 0.28 >0.01 
54.58 rs3723574 98.89 42 47 0.10 >0.01 
75.96 rs6282879 100.00 38 52 0.71 >0.01 
94.99 rs4227350 97.78 38 50 0.41 >0.01 
107.26 rs3666037 100.00 39 51 0.40 >0.01 
8 
122.74 rs4227428 98.89 42 47 0.01 >0.01 
32.69 rs3716375 100.00 52 38 1.60 >0.01 
64.69 rs3664300 98.89 49 40 0.10 >0.01 
80.00 rs6213724 95.56 52 34 0.74 >0.01 
94.44 rs3699737 98.89 51 38 0.55 >0.01 
9 
114.04 rs3693662 97.78 44 44 0.41 >0.01 
8.30 rs4228101 98.89 44 45 0.28 >0.01 
29.03 rs3710662 98.89 46 43 1.90 >0.01 
65.70 rs3725109 100.00 43 47 0.04 >0.01 
76.58 rs13480657 100.00 42 48 0.00 >0.01 
89.25 rs3673574 100.00 41 49 0.40 >0.01 
89.40 rs4139881 100.00 41 49 0.40 >0.01 
99.23 rs4228444 100.00 42 47 0.10 >0.01 
10 
118.09 rs13480784 98.89 43 46 0.01 >0.01 
14.27 rs13480881 97.78 72 15 64.66 <0.0001 
30.00 rs3718377 98.89 65 24 44.60 <0.0001 
44.79 rs13481004 98.89 62 26 28.41 <0.0001 
59.00 rs3691800 100.00 58 32 11.38 <0.001 
76.08 rs3693943 100.00 58 32 6.40 >0.01 
94.04 rs16783394 100.00 47 43 0.04 >0.01 
11 
104.00 rs3153214 100.00 49 41 0.04 >0.01 
30.94 rs3723945 98.89 57 32 2.53 >0.01 
45.92 rs6379858 98.89 57 32 2.53 >0.01 
60.74 rs3686891 98.89 53 36 1.36 >0.01 
72.18 rs13481543 98.89 51 38 0.10 >0.01 
87.96 rs3684493 98.89 47 42 0.55 >0.01 
12 
103.43 rs6390948 100.00 44 46 0.18 >0.01 
30.26 rs6376513 98.89 43 46 0.91 >0.01 
44.56 rs6249046 98.89 47 42 0.28 >0.01 
62.21 rs3712411 98.89 42 47 1.36 >0.01 
70.66 rs4229908 97.78 41 46 0.56 >0.01 
13 
89.63 rs3709305 97.78 44 44 0.00 >0.01 
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10.72 rs4230190 98.89 50 39 0.28 >0.01 
26.12 rs3724311 97.78 48 40 0.41 >0.01 
46.05 rs3726218 98.89 47 42 0.55 >0.01 
78.28 rs3668028 97.78 43 45 0.00 >0.01 
14 
91.55 rs3688255 98.89 43 46 0.01 >0.01 
5.00 rs4230638 98.89 47 42 0.55 >0.01 
29.48 rs3656493 100.00 48 42 0.18 >0.01 
45.47 rs13482548 100.00 51 39 1.11 >0.01 
57.35 rs3702158 100.00 48 42 0.00 >0.01 
15 
79.44 rs3667621 100.00 48 42 0.00 >0.01 
10.57 rs4161352 97.78 46 42 0.05 >0.01 
27.39 rs3694564 100.00 46 44 0.00 >0.01 
46.55 rs4182798 100.00 48 42 0.18 >0.01 
54.66 rs3687272 100.00 47 43 0.04 >0.01 
74.91 rs3663889 100.00 43 47 0.40 >0.01 
16 
86.18 rs4212526 100.00 41 49 0.40 >0.01 
10.00 rs13482869 98.89 43 46 0.10 >0.01 
30.35 rs3684143 97.78 47 41 1.64 >0.01 
41.24 rs4231493 100.00 48 42 1.60 >0.01 
61.51 rs3725261 98.89 50 39 3.25 >0.01 
17 
79.55 rs2020834 98.89 54 35 4.96 >0.01 
9.43 rs3725581 100.00 52 38 0.18 >0.01 
30.29 rs3664296 96.67 50 37 0.10 >0.01 
43.72 rs13483329 98.89 48 41 0.10 >0.01 
58.98 rs3713935 100.00 46 44 0.18 >0.01 
18 
77.29 rs3705890 100.00 47 43 0.40 >0.01 
10.17 rs13483528 98.89 44 44 0.05 >0.01 
24.37 rs3717368 100.00 44 46 0.18 >0.01 
29.58 rs6238842 100.00 38 52 0.71 >0.01 19 
47.45 rs3674914 96.67 42 45 0.01 >0.01 
SNPs refer to the NCBI database (http://www.ncbi.nlm.nih.gov/) 
 
9.2.2 GLS006 mice 
Table 9.2: SNP genotyping results of GLS006 G2 backcross mice. 
Chromosome Locus (Mb) RefSNP 
Success 
rate Het Ocr χ
2-value P value 
5.11 rs13475703 93.00 45 40 0.29 >0.01 
23.48 rs13475764 97.00 46 43 1.36 >0.01 
38.09 rs13475818 96.00 46 42 1.64 >0.01 
1 
48.20 rs13475854 93.00 41 45 1.16 >0.01 
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76.19 rs3678148 96.00 43 45 1.14 >0.01 
81.73 rs30712373 96.00 46 42 1.64 >0.01 
95.16 rs13475986 95.00 46 41 0.93 >0.01 
116.68 rs13476065 98.00 43 47 0.00 >0.01 
144.12 rs30942489 100.00 42 50 0.17 >0.01 
172.66 rs33777727 98.00 39 46 1.42 >0.01 
195.08 rs13499691 96.00 41 47 0.41 >0.01 
14.32 rs13476355 96.00 35 53 1.14 >0.01 
20.21 rs27120459 97.00 28 55 2.71 >0.01 
37.00 rs13476434 96.00 39 49 0.05 >0.01 
50.65 rs13476490 95.00 38 49 0.01 >0.01 
70.83 rs13476567 96.00 44 44 0.18 >0.01 
95.61 rs3679193 96.00 47 41 0.05 >0.01 
114.23 rs27441842 96.00 48 39 0.01 >0.01 
129.49 rs27257388 96.00 48 40 0.00 >0.01 
169.33 rs13476909 93.00 47 39 0.05 >0.01 
2 
181.63 rs3691120 96.00 44 44 0.00 >0.01 
7.68 rs29657774 96.00 44 44 0.18 >0.01 
26.28 rs13477026 95.00 43 44 0.01 >0.01 
36.89 rs3151604 96.00 44 44 0.18 >0.01 
52.51 rs3685081 95.00 44 43 0.10 >0.01 
69.55 rs13477178 96.00 41 47 0.05 >0.01 
89.03 rs8259135 93.00 44 41 0.01 >0.01 
103.28 rs13477302 93.00 45 41 0.42 >0.01 
109.00 rs13477321 96.00 48 40 0.73 >0.01 
129.56 rs16799508 93.00 51 35 3.77 >0.01 
3 
142.68 rs13477460 96.00 44 44 0.18 >0.01 
10.97 rs27731305 96.00 51 37 7.68 <0.01 
22.44 rs13477603 96.00 53 35 7.68 <0.01 
35.22 rs27781503 96.00 50 38 4.55 >0.01 
62.74 rs3718270 96.00 48 40 4.55 >0.01 
86.81 rs28056583 93.00 41 45 1.16 >0.01 
101.16 rs28307021 96.00 41 47 2.23 >0.01 
133.12 rs13477989 96.00 43 45 0.41 >0.01 
4 
141.90 rs3711383 96.00 44 44 0.18 >0.01 
14.03 rs13481347 96.00 44 44 0.73 >0.01 
24.86 rs13478148 98.00 40 50 0.18 >0.01 
41.07 rs13478204 98.00 42 48 0.04 >0.01 
55.63 rs13478263 96.00 44 43 0.29 >0.01 
67.96 rs29635956 100.00 45 47 0.39 >0.01 
79.39 rs31585424 96.00 46 42 0.73 >0.01 
5 
103.34 rs13478429 97.00 43 46 0.01 >0.01 
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127.16 rs13478514 95.00 42 45 0.10 >0.01 
145.01 rs4225559 95.00 38 49 0.10 >0.01 
4.78 rs13478606 96.00 41 47 0.41 >0.01 
26.14 rs13478670 96.00 42 46 0.73 >0.01 
35.97 rs3023067 97.00 42 45 0.93 >0.01 
72.33 rs13478816 96.00 45 43 1.14 >0.01 
85.89 rs13478872 96.00 45 43 0.41 >0.01 
102.23 rs13478935 98.00 52 38 0.04 >0.01 
115.23 rs13478987 96.00 50 38 0.00 >0.01 
6 
144.45 rs13479084 100.00 47 41 0.41 >0.01 
5.23 rs13479108 93.00 35 51 2.28 >0.01 
28.11 rs13479164 96.00 41 47 2.23 >0.01 
51.83 rs16793422 96.00 39 48 0.29 >0.01 
60.70 rs13479256 93.00 40 45 0.01 >0.01 
73.17 rs16805799 96.00 44 44 0.00 >0.01 
100.08 rs4226783 96.00 48 40 0.18 >0.01 
110.34 rs13479437 96.00 48 40 0.73 >0.01 
124.03 rs13479476 93.00 48 37 0.95 >0.01 
7 
140.06 rs13479537 96.00 50 38 2.91 >0.01 
9.76 rs13479604 95.00 44 43 4.15 >0.01 
28.02 rs13479662 96.00 43 45 3.68 >0.01 
48.19 rs13479741 93.00 44 42 1.67 >0.01 
60.52 rs13479782 99.00 45 44 2.53 >0.01 
70.85 rs13479814 96.00 43 45 2.23 >0.01 
90.66 rs6264181 93.00 45 41 0.42 >0.01 
103.43 rs13479952 100.00 62 20 3.95 >0.01 
8 
116.69 rs13479998 93.00 44 42 0.19 >0.01 
13.23 rs13480073 96.00 46 42 0.18 >0.01 
37.50 rs3023207 96.00 48 40 0.00 >0.01 
57.67 rs13480217 97.00 46 43 0.10 >0.01 
80.06 rs13480299 96.00 46 42 0.73 >0.01 
96.23 rs3673055 96.00 42 45 0.01 >0.01 
9 
110.96 rs13480418 95.00 41 46 0.01 >0.01 
8.19 rs13480484 95.00 39 48 0.01 >0.01 
22.64 rs13480541 96.00 39 49 0.05 >0.01 
34.30 rs13480578 100.00 34 58 0.17 >0.01 
57.47 rs13480619 95.00 37 50 0.10 >0.01 
68.91 rs13480638 96.00 41 47 2.23 >0.01 
84.15 rs13480678 95.00 36 51 0.93 >0.01 
99.48 rs8258500 96.00 37 51 1.14 >0.01 
10 
117.84 rs13480784 97.00 39 50 0.28 >0.01 
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7.11 rs13480851 96.00 68 20 80.18 <0.0001 
21.62 rs13480905 96.00 63 25 62.23 <0.0001 
32.23 rs26822879 100.00 65 27 41.78 <0.0001 
53.99 rs26982471 100.00 55 37 12.57 <0.0001 
62.81 rs13481061 96.00 50 38 8.91 <0.001 
83.23 rs13481127 96.00 44 44 2.91 >0.01 
98.55 rs27041242 99.00 46 45 3.18 >0.01 
11 
114.33 rs27000576 96.00 43 45 2.23 >0.01 
13.15 rs13481307 96.00 48 40 1.64 >0.01 
25.78 rs13481351 96.00 48 40 1.64 >0.01 
40.56 rs13481405 93.00 47 39 5.63 >0.01 
55.74 rs13481462 100.00 51 41 5.26 >0.01 
75.04 rs8259450 96.00 46 42 4.55 >0.01 
83.44 rs6194112 96.00 45 43 3.68 >0.01 
99.32 rs13481604 99.00 45 46 2.47 >0.01 
12 
114.06 rs13459138 96.00 43 45 2.23 >0.01 
6.30 rs13481676 96.00 45 43 0.05 >0.01 
19.49 rs6345767 96.00 45 43 0.05 >0.01 
54.50 rs13481815 96.00 49 39 0.41 >0.01 
69.35 rs13481863 96.00 47 41 1.14 >0.01 
83.16 rs13481910 96.00 50 38 0.73 >0.01 
97.25 rs29566800 96.00 52 36 0.18 >0.01 
13 
111.21 rs30511458 96.00 50 38 0.18 >0.01 
22.92 rs30406796 96.00 50 37 6.08 >0.01 
46.68 rs13482161 96.00 44 44 2.91 >0.01 
59.60 rs30895903 98.00 44 46 1.60 >0.01 
88.56 rs13482292 93.00 42 44 0.74 >0.01 
105.71 rs30482696 90.00 43 39 1.22 >0.01 
14 
118.16 rs30947935 100.00 49 40 1.90 >0.01 
25.20 rs13482484 95.00 40 47 0.29 >0.01 
38.82 rs13482528 96.00 42 46 0.73 >0.01 
50.42 rs13482574 96.00 42 46 0.73 >0.01 
67.56 rs13482627 93.00 42 44 0.74 >0.01 
15 
97.72 rs16804751 97.00 48 40 2.91 >0.01 
10.87 rs4161352 96.00 36 52 1.64 >0.01 
27.44 rs4165602 95.00 40 47 0.56 >0.01 
32.19 rs4170048 93.00 45 41 0.05 >0.01 
69.80 rs4199268 96.00 50 38 0.18 >0.01 
84.14 rs4211770 97.00 49 38 0.29 >0.01 
16 
93.53 rs4220159 95.00 49 38 0.29 >0.01 
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11.59 rs33418817 95.00 51 36 0.56 >0.01 
40.94 rs33428427 95.00 51 35 0.05 >0.01 
55.31 rs29504995 96.00 50 38 1.64 >0.01 
72.72 rs13483097 96.00 47 41 2.23 >0.01 
17 
85.46 rs13483140 98.00 49 40 1.36 >0.01 
25.51 rs29827614 96.00 40 48 0.18 >0.01 
38.24 rs29823686 96.00 37 51 1.14 >0.01 
57.83 rs13483379 93.00 38 48 1.67 >0.01 
70.63 rs13483427 96.00 34 54 2.91 >0.01 
18 
86.75 rs13483484 97.00 35 53 3.68 >0.01 
13.93 rs6247194 96.00 45 43 0.41 >0.01 
26.00 rs13483576 96.00 46 42 0.73 >0.01 
43.57 rs4232188 96.00 36 51 0.10 >0.01 19 
56.34 rs6339594 96.00 38 50 0.73 >0.01 
SNPs refer to the NCBI database (http://www.ncbi.nlm.nih.gov/) 
 
9.3 Abbreviations of chemical compounds and solutions 
AgNO3 silver nitrate 
APS  ammonium persulfate 
ATP  adenosine 5'-triphosphate 
BSA  bovine serum albumine 
CaCl2 calcium chloride 
DAB  3,3’-diaminobenzidine tetrahydrochloride dehydrate 
DEPC diethylpyrocarbonate 
dNTPs deoxynucleoside triphosphate mixture 
DTT  dithiotreitol 
EDTA ethylene diamine tetraacetic acid 
EGTA ethylene glycol tetraacetic acid 
H2O2  hydrogen peroxide 
HEPES N-(2-hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid) 
KCl  potassium chloride 
KH2PO4 monopotassium phosphate 
K2HPO4 dipotassium phosphate 
NaCl  sodium chloride 
MgCl2 magnesium chloride 
MgSO4 magnesium sulphate 
NaCl/Tris sodium chloride/tris(hydroxymethyl)aminomethane 
NADP+ nicotinamide adenine dinucleotide phosphate 
NADPH reduced form of nicotinamide adenine dinucleotide phosphate 
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Na2CO3 sodium bicarbonate 
NaHCO3 sodium hydrogen carbonate 
Na2HPO4 disodium phosphate 
Na2S2O3 sodium thiosulphate 
NaOV sodium orthovanadate 
PMSF phenylmethylsulfonyl fluoride 
SDS  sodium dodecyl sulphate 
TBE buffer Tris borate EDTA buffer 
TBS  Tris buffered saline 
TBS-T Tris buffered saline with Tween 
TE buffer Tris EDTA buffer 
TEMED tetraethylethylenediamine 
Tris/HCl tris(hydroxymethyl)aminomethane/hydrochloric acid 
 
9.4 Evaluation of DNA concentrations via gel electrophoresis 
In addition to spectrophotometrical quantification (chapter 3.2.2.2 and 3.2.2.5), DNA 
amounts in purified PCR products were estimated by gel electrophoresis using EcoRI 
digested Lambda DNA as reference quantity (Fig. 9.2). In each gel electrophoresis 
0.5 and 1µg of the concentration marker Lambda DNA/EcoRI + HindIII-Marker, 3 
(MBI Fermentas, Germany) was applied. Electrophoresis was run on a 1.5% TBE 
agarose gel with a total sample volume of 12 µl (2 µl PCR product, 8 µl H2O and 2 µl 
6x DNA Loading Dye (MBI Fermentas)). 
 
 
Figure 9.2: Gel electrophoresis of purified PCR products for determination of DNA 
concentration. 1: fragment size marker (pUC mix 8; MBI Fermentas, Germany); marker 
bands represents fragment sizes of 1118, 881, 692, 501/489, 404 and 331 bp (from top to 
bottom). 2 and 4: concentration standard (Lambda DNA/EcoRI + HindIII-Marker, 3). 2: 0.5 µg 
concentration standard/lane: marker bands correspond to a concentration of 19.6, 16.3, 14.2, 
9.8, 8.6, and 5.8 ng (from top to bottom). 4: 1 µg concentration standard/lane: visible marker 
1     2                              3                             4
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bands represent concentrations of 39.2, 32.6, 28.4, 19.6, 17.2, and 11.6 ng. 3: purified PCR 
products (2 µl/lane). DNA concentrations in the amplificates were estimated by comparison 
of the respective band intensity with the intensity of the concentration standard bands. 
9.5 Principle of evaluation of real-time PCR primer efficiencies 
Amplification efficiencies of target and reference gene specific primers were 
evaluated by implementation of real-time PCR with serial diluted (range 10-3-10-9) 
PCR products. With regard to preamplification, PCR was conducted as described in 
chapter 3.2.1.2 with 1 µl cDNA (20 ng), synthesised from hepatic RNA of an adult 
C3H wild-type control animal as described in chapters 3.2.2.2 and 3.2.2.3, and the 
respective primer pairs in a total reaction volume of 20 µl. PCR Master Mix 
composition and PCR cycling conditions are described below 
Table 9.3: Master Mix and PCR conditions for evaluation primer efficiencies 
PCR Master Mix Cycling conditions 
Aqua bidest             5.25 µl 
Q-solution              4.00 µl 
10x buffer               2.00 µl 
MgCl2                   1.25 µl 
dNTPs (1 mM)           4.00 µl 
Primer sense (5 µM)       1.20 µl 
Primer antisense (5 µM)  1.20 µl 
Taq Polymerase         0.10 µl 
 
1.  Initial denaturation hot start 
2.  Denaturation       30 sec   95°C 
3.  Annealing          60 sec   45°C 
4.  Extension          30 sec   72°C 
5.  Final extension     10 min  72°C 
6.  Hold                ∞        4°C 
 
PCR product dilutions were prepared by 10 serial 1:10 dilutions (1 µl PCR product + 
45 µl RNase-free H2O (Invitrogen, Germany)), resulting in dilutions from the range of 
10-1 - 10-10 of the initial concentration. Quantitative real-time PCR was performed with 
PCR products, diluted in the range of 10-3 -10-9, as described in chapter 4.3.2. Real-
time PCR was performed each, for quantification of the target-, as well as for the 
distinct reference transcripts, and all dilutions were investigated in duplicates. After 
manual threshold setting in the exponential phase of amplification, the intercross of 
the respective amplification curves with the threshold line were determined and 
plotted against the corresponding logarithmised dilution range. Primer efficiencies 
were calculated from the slope of the resulting linear regression curves as described 
below (Figure 9.3). 
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Exemplary illustration of amplification phases during real-time PCR and 
principle of manual threshold setting 
Principle of primer efficiency calculation from real-time PCR results 
 
Figure 9.3: Principle of manual threshold setting for real-time PCR data from 
typical amplification curves (A) and evaluation of primer efficiency after real-time 
PCR implementation (B, C). A: Software generated amplification plot of ΔRn (difference 
between the normalised reporter fluorescence in the sample and in the no template 
control (NTC)) as a function of the cycle number. The threshold line represents the level 
of detection at which a reaction reaches a fluorescent intensity above the background, 
and is set manually. B: typical distribution of real-time PCR amplification curves from 
serial 1:10 diluted (dilution range 10-3 - 10-9), preamplificated PCR products. C: CTs, 
determined from B, were plotted against the respective logarithmised dilution range (3-9) 
and primer efficiencies (E) were calculated from the resulting linear regression curve, 
using the following equation: E=10-(1/slope). 
A 
B C 
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9.6 Evaluation of real-time PCR results, using the 2-ΔCT method 
Since the applied primers for amplification of the reference and target transcripts 
displayed comparable amplification efficiencies of about 0.75 ± 0.02, relative 
expression levels of the target transcripts were compared between the respective 
groups, using the 2-ΔCT method (Cohen and Kretzler 2003) (Fig. 9.4). 
Principle of calculating relative target transcript abundance from quantitative 
real-time PCR results, using the 2-ΔCT method 
 
 
2-ΔCT sample 1= 0.00552 
2-ΔCT sample 2= 0.00003 
 
 
Group wise comparison 
Figure 9.4: Hypothetical outline of relative quantification of real-time PCR results 
using the 2-ΔCT method. The target transcript abundance relative to the expression of a 
reference transcript (housekeeping gene) was compared between sample duplicate 1 (wild-
type) (A) and sample duplicate 2 (mutant) (B). The mean CT from each of the duplicate 
measurements of each sample for housekeeping- and target-sequences was calculated, as 
demonstrated for sample 1 and sample 2. Relative target gene expression levels of the 
respective RNA samples were presented as 2-ΔCT values and were compared group wise (C). 
Representing a crucial prerequisite for the reproducibility of the results, real-time PCR 
reactions of all samples, belonging to the respective groups to be compared, were run on 
identical plates, using identical Master Mixes. 
A B 
C 
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9.7  Histological staining methods 
Histological sections were prepared as described above ( refer to chapter 3.6.2), 
transferred into glass cuvettes and incubated for 1 hour in a heating cabinet (90°C, 
Memmert GmbH&Co. KG, Germany) to enable paraffin removal from the sections. 
Thereafter, tissue sections were incubated for 10 minutes in xylene (SAV, Germany) 
for final paraffin clearance, subsequently rehydrated via a descending alcohol series 
(2 x 100%, 2 x 96%, 1 x 70% ethanol), and rinsed in distilled water. Further staining 
steps depended on the respective protocols, described below: 
9.7.1 Haematoxylin and eosin (HE) staining 
1.  Mayer's haemalaun (AppliChem, Germany)  5 minutes 
2.  Rinse in running tap water 5 minutes 
3.  Dip in 1% eosin solution 2-7 times 
4.  Rinse in aqua bidest. 
5.  Dehydrate via ascending alcohol series 
6.  Xylene 
Mount under glass coverslips, using Roti® Histokitt II (Roth, Germany) 
1% eosin solution 
 Eosin G (Roth, Germany) 10 g 
 Dissolve in hot aqua bidest., then cool down 1000 ml 
 Glacial acetic acid (Merck, Germany) 1.5 ml 
Filtrated and stored at room temperature 
 
9.7.2 Perjodic acid-Schiff (PAS) staining 
1.  1% perjodic acid  10 minutes 
2.  Rinse in running tap water 10 minutes 
3.  Schiff's reagent (Roth, Germany) 30 minutes 
4.  Rinse in running tap water 5 minutes 
5.  Mayer's haemalaun 2 minutes 
6.  Rinse in running tap water 5 minutes 
7.  Differentiate in 0.5% HCl alcohol  
8.  Rinse in running tap water 5 minutes 
9.  Ascending alcohol series 
10. Xylene 
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Mount under glass coverslips, using Roti® Histokitt II (Roth, Germany) 
 
1% perjodic acid 
 Solution A: 
 Perjodic acid (Sigma, Germany) 10 g 
 Aqua bidest.  1000 ml 
 Solution B: 
 Sodium acetate (Merck, Germany) 1.6 g 
 Aqua bidest.  1000 ml 
Prepare both solutions separately, mix and store at 4°C 
 
1% HCl stock solution 
 96% ethanol 7000 ml 
 Aqua bidest.  2500 ml 
 25% HCl (Merck, Germany) 100 ml 
 
0.5 % HCl, ready-to-use 
 1% HCl stock solution 100 ml 
 70% ethanol  100ml 
 
9.7.3 Masson’s trichrome staining (modified according to Goldner and Weigert) 
1.  Weigert's iron haematoxylin 5 minutes 
2.  Rinse in running tap water 5 minutes 
3.  Differentiate in 0.5% HCl alcohol 
4.  Rinse in running tap water 15 minutes 
5.  Red colour solution 5-7 minutes 
6.  Rinse in 0.5% acetic acid 
7.  Phosphotungstic acid-orange G solution 3 minutes 
8.  Rinse in 0.5% acetic acid 
9.  Aniline blue 5 minutes 
10. Rinse in 0.5% acetic acid 
11. Ascending alcohol series 
12. Xylene 
Mount under glass coverslips, using Roti® Histokitt II (Roth, Germany) 
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Weigert's iron haematoxylin 
 Solution A:   
 Haematoxylin cryst. (Merck, Germany) 10 g 
 96% ethanol 1000 ml 
Maturation for 1 week 
 Solution B:   
 Iron (III) chloride (Honeywell Riedel-de Haën®, Germany)  11.6 g 
 Aqua bidest. 980 ml  
 Glacial acetic acid 10 ml  
Stored separately, prepared as 1:1 mixture 
 
Azophloxine solution 
 Azophloxine (CHROMA Gesellschaft Schmid GmbH&Co.,  
 Germany)  1.25 g 
 Aqua bidest.  250 ml 
 Glacial acetic acid  0.5 ml 
 
Red colour stock solutions 
 Solution A:   
 Boiling aqua dest. 1000ml 
 Acid fuchsine (Rubin S) (Merck, Germany) 10 g 
 Glacial acetic acid 10 ml 
Cool down in closed glass bottle 
 Solution B:  
 Boiling aqua bidest.  1000 ml 
 Xylidine Ponceau (Waldeck, Germany) 10 g 
 Glacial acetic acid 10 ml 
 
Red colour solution 
 Solution A  20 ml 
 Solution B 80 ml 
 Azophloxine solution 20 ml 
 
Phosphotungstic acid-orange G solution 
 Tungstophosphoric acid (Merck, Germany) 15 g 
 Orange G (Merck, Germany) 10 g 
 Aqua bidest. 
 
Aniline blue 
 Aniline blue (SERVA Feinbiochemica, Germany) 10 g 
 Aqua bidest. 1000 ml 
 Glacial acetic acid (Roth, Germany) 10 ml 
Prepare cold (4°C) 
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1% Acetic acid 
 Aqua bidest. 1000 ml 
 Glacial acetic acid 10 ml 
Ready-to-use solution prepared 1:1 with aqua bidest. 
 
9.7.4 Fat red staining 
1.  Transfer cut sections into distilled water 
2.  50% Ethanol  30 seconds 
3.  Fat red solution 5 minutes 
4.  50% Ethanol 2 seconds 
5.  Rinse in distilled water 
6.  Mayer’s haemalaun (AppliChem, Germany)   2 seconds 
7.  Rinse in distilled water 
8.  Rinse in tap water 
9.  Mount on glass slides 
10. Dry 
11. Mount under glass cover slips using Faramount Aquaeous Mounting Medium 
      Ready-to-use (DAKO, Germany) 
 
Fat red solution 
 96% ethanol 140 ml 
 Aqua bidest. 52 ml 
Boil shortly 
 Fat red 7B (Sigma, Germany) 0.5 g 
Boil shortly and stir for 30 minutes 
Filtrate before use 
 186 
 
Acknowledgements 
This study was implemented within the framework of the DFG- (Deutsche 
Forschungsgemeinschaft) supported research training group “Functional Genome 
Research in Veterinary Medicine” (GRK 1029), in the period of April 2007 until 
October 2009. 
I wish to thank Prof. Dr. Rüdiger Wanke, Prof. Dr. Bernhard Aigner, and Dr. Nadja 
Herbach for giving me the opportunity to perform this study. My deepest gratitude is 
expressed for the immense time and courtesy they spent to support this doctorate. In 
particular, I would like to express my gratitude for teaching me the molecular genetic 
and pathogenetic fundamentals of diabetes mellitus and the principles of quantitative 
stereological investigations, and for critically discussing all the particular features of 
this doctorate. I feel infinite gratitude for their incredible support and encouragement. 
I also would like to express my gratitude to Prof. Dr. Eckhard Wolf for kindly giving 
me the opportunity to work in his laboratories, for his commitment, the detailed 
discussions, and numerous helpful comments. Thanks to all co-workers at the 
Institute of Molecular Animal Breeding/Gene Center, especially to Dr. Elisabeth 
Kemter for providing not only primers but also helpful advices. Many thanks also to 
Dr. Marlon Schneider and the team of Dr. Helmut Blum. 
Of particular importance were the extremely helpful lessons about quantitative real-
time PCR implementation. Thus, I would like to gratefully thank Dr. Andreas Blutke 
(Institute of Veterinary Pathology, Ludwig Maximilian University of Munich) and Dr. 
Susanne Schwarz (Institute for Animal Physiology, Ludwig Maximilan University of 
Munich) for their generous ongoing help and endless patience. 
I show my gratitude to Prof. Dr. Martin Hrabé de Angelis for generously providing 
both mouse strains. Particular thanks to the co-workers at the Institute of 
Experimental Genetics, Helmholtz Zentrum München, especially to Dr. Matthias 
Klaften, Dr. Sybille Wagner, Dr. Birgit Rathkolb, Dr. Corinna Moerth and Mr. T. Fuchs 
for performing SNP genotyping and preliminary backcross breeding of the ENU strain 
GLS001. I am very grateful for the data and background information, they shared 
with me and would like to emphasise the protruding collaboration.  
 187 
 
Another acknowledgement goes to Prof. Dr. Bernd Kaspers for providing his 
laboratory equipment, especially for ELISA and quantitative real-time PCR 
experiments. I also wish to show my gratitude to Dr. Michaela Lohr from the Institute 
of Physiological Chemistry, Ludwig Maximilian University of Munich, for her helpful 
and dedicated tutoring in enzyme kinetics. 
I would like to thank Sabine Kautz and Marion Schuster for their great collaboration 
and assistance, for joining a memorable time and for brightening some gloomy days. 
Deepest thanks also to Lisa Pichl, not only for sedulous excellent technical 
assistance but also for teaching me all intricacies of laboratory work. Further thanks 
to all members of the GRK.  
I would like to show my special gratitude to all employees at the Institute of 
Veterinary Pathology for their help, especially to Mrs. B. Schmidt, and Mrs. M. 
O’Gorman for their support and company, and to Mrs. S. Zwirz and Mr. A. Ciolovan 
for their excellent animal management. 
The last acknowledgement is dedicated to my whole family-thank you for everything! 
 
